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Obesity is associated with dysfunctional lipoproteins, low-grade inflammation, and an 
increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). HDL 
and leukocytes play well documented roles in chronic disease development, whereas HDL-
leukocyte interactions further modify cellular cholesterol flux and inflammatory potential. 
Therefore, therapeutic strategies that alter HDL-leukocyte dynamics may have profound 
effects on obesity-related disease progression.  
 
We investigated the modulation of HDL-leukocyte dynamics by a dietary intervention known 
to favorably affect HDL metabolism and inflammation in metabolic syndrome (MetS) – a 
population at increased risk for CVD and T2DM. Thirty-seven men and women classified 
with MetS consumed a moderate carbohydrate-restricted diet in addition to either 3 whole 
eggs per day (EGG) or the equivalent amount of egg substitute (SUB) for 12 weeks. Egg 
yolks are a rich source of highly bioavailable, bioactive phospholipids and antioxidant 
carotenoids. After the 12-week intervention, all subjects increased HDL-cholesteryl 
ester/triglyceride ratios; however, whole egg intake resulted in enrichment of HDL in 
phosphatidylethanolamine and egg yolk-derived sphingomyelin species. The cholesterol- 
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accepting capacity of subject serum from macrophage foam cells was further increased by 
whole egg feeding, whereas no changes were observed from egg substitute intake.
We further assessed the effects of this intervention on peripheral blood mononuclear cell 
(PBMC) inflammation. While there were no changes in IL-1β, IL-6, and toll-like receptor 4 
(TLR4) mRNA expression throughout the intervention, TLR4 mRNA expression was 
increased by whole egg intake, positively correlating with NF-κB p65 DNA binding activity. 
However, LPS-induced IL-1β and TNFα secretion was increased from baseline to week 12 
in the SUB group only. Given these observations, we further sought to determine whether 
HDL-mediated cholesterol flux played a role in modulating PBMC inflammation. Compared 
to baseline, there was a trend toward a reduction in PBMC cholesterol content in the EGG 
group, whereas changes in PBMC cholesterol positively correlated with changes in lipid raft 
content. These observations corresponded to increases in ABCA1 and HMG-CoA reductase 
mRNA expression from whole egg intake only, in addition to a trend toward increased 
ABCA1 protein. Together, these findings suggest that HDL-leukocyte dynamics can be 
favorable modulated through diet in MetS.   
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Obesity is associated with an increased risk of developing chronic diseases, including 
cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and cancer [1]. The 
prevalence of obesity has increased over the past few decades, as now more than one-third of 
adults in the United States are obese, in addition to 17% of children and adolescents [2]. This 
trend is now similarly observed in developing countries due to increased urbanization, 
transition from traditional food patterns to energy-dense “Western diets”, and a reduction in 
physical activity [3]. As of 2008, it was estimated that obesity-related medical costs had risen 
$147 billion per year in the United States, up from $78.5 billion in 1998 [4]. Together, 
obesity has been deemed the leading cause of preventable death [5], and it has risen to 
become a global economic and health burden.  
The pathophysiology of obesity-related diseases stems from underlying metabolic 
disturbances that cause tissue stress and dysfunction. Excess nutrient intake leading to 
obesity requires adipose tissue expansion in order to accommodate the increased influx of 
nutrients, which is dependent upon insulin-mediated energy storage [6]. In adults, adipose 
expansion occurs primarily through adipocyte hypertrophy, rather than adipocyte hyperplasia 
[7]. Lipid-engorged, hypertrophic adipocytes are more prone to activation of endoplasmic 
reticulum (ER) and mitochondrial stress responses, in addition to inducing shear mechanical 
stress on the extracellular environment. Together, these factors promote the activation of 
chronic, pro-inflammatory state for as long as the cells remain stressed and engorged [6, 8].    
 Prolonged stress and inflammation within the adipose tissue can lead to adipocyte 
apoptosis and the release of chemotactic mediators such as monocyte chemoattractant 
protein-1 (MCP-1), resulting in inflammatory leukocyte infiltration [9]. While macrophages 
represent approximately 5-10% of cells in healthy adipose tissue, it has been demonstrated 
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that macrophages can represent up to 50% of all cells within hypertrophic obese adipose 
tissue [10]. Pulse-labeling studies conducted in vivo have demonstrated that the macrophages 
recruited into adipose tissue at the onset of obesity are highly pro-inflammatory, classically 
activated M1 macrophages, in contrast to resident macrophages in lean adipose, which are 
typically alternatively-activated, anti-inflammatory M2 macrophages [11-13]. Increased T 
cell infiltration is also observed in obese adipose tissue, and some evidence suggests that 
these lymphocytes may become activated in response to unique antigens generated in obese 
adipose tissue during high-fat feeding [14]. In addition, greater levels of pro-inflammatory 
TH1 cells have been observed in obese adipose, whereas levels of anti-inflammatory Treg cells 
are reduced, corresponding to greater impairments in insulin sensitivity [14, 15].  
 Inflammatory leukocytes within adipose tissue further perpetuate an inflammatory state 
through production of resistin and interleukin (IL)-1β, whereas both hypertrophic adipocytes 
and macrophages increase secretion of tumor necrosis factor α (TNFα), IL-6, and MCP-1 
[16]. Elevated levels of TNFα counteract insulin-mediated nutrient uptake, through 
inhibition of 1) glucose transporter type 4 (GLUT4) translocation to the adipocyte cell 
surface, 2) lipoprotein lipase (LPL)-mediated lipolysis of chylomicron triglycerides (TG), 3) 
peroxisome proliferator-activated receptor γ (PPARγ)-mediated TG synthesis for free fatty 
acid (FFA) adipocyte storage, and 4) perilipin-mediated lipid droplet formation [6].  
Together, these effects are associated with increased FFA mobilization from adipose into the 
circulation [17]. Hypertrophic adipocyte-derived retinol-binding protein 4 (RBP4) is also 
known to impair insulin signaling by reducing phosphatidylinositol-3 kinase (PI3K) signaling 
in muscle, while concomitantly increasing hepatic gluconeogenic enzyme expression [18, 
19].   
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 As hypertrophic adipocytes increase secretion of inflammatory mediators, production 
of adiponectin is decreased, potentially through TNFα-mediated inhibition [6]. Binding of 
adiponectin isoforms to their cognate receptors 1) induces AMP-activated protein kinase 
(AMPK)-mediated inhibition of sterol regulatory element-binding protein (SREBP)-1c-
induced lipogenesis, 2) inhibits cytosolic nuclear factor κ B (NF-κB) translocation to induce 
pro-inflammatory gene transcription, and 3) promotes PPARα and PPARγ transcriptional 
activity to increase β-oxidation and GLUT4 translocation; overall exerting anti-inflammatory 
and insulin-sensitizing effects [20]. Adipocyte-derived leptin also stimulates fatty acid 
oxidation, however, high circulating levels found in obesity are typically indicative of leptin 
resistance [21]. Therefore, hypertrophic stress prevents adequate contribution of anti-
inflammatory and insulin-sensitizing adipocyte mediators.   
 Overall, hypertrophic, inflammatory adipose loses insulin sensitivity, results in 
increased lipolysis and impaired lipid storage [6]. FFAs and TGs are mobilized to the 
circulation, leading to accumulation of their fatty acyl-CoA ester and diacylglycerol 
derivatives in the skeletal muscle, liver, and pancreatic β-cells, resulting in impaired tissue 
functioning and insulin resistance. The consequences of prolonged maintenance or worsening 
of this metabolically dysfunctional state further perpetuates dysregulation of lipid 
metabolism and immunity, thereby increasing an individual’s risk for developing a wide 
range of chronic diseases [6].  
Clinical manifestation of these underlying conditions often present as the parameters 
of metabolic syndrome (MetS), a clinical classification characterized by a clustering of three 
or more components, including central adiposity, elevated blood glucose, plasma TG, and 
blood pressure, and low plasma HDL-cholesterol (HDL-C) [22]. In addition to these 
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qualifying parameters, obesity and MetS are associated with endothelial dysfunction, 
atherogenic dyslipidemia, insulin resistance, and chronic low-grade inflammation [23]. In 
line with national obesity trends, it has been estimated that approximately 34% of adults in 
the U.S. have MetS [24]. The high prevalence of MetS is a significant public health concern, 
as classification with MetS increases an individual’s risk of CVD and T2DM by 2- and 5-
fold, respectively [22]. 
Despite the average 2- and 5-fold increased risk of CVD and T2DM [22], 
respectively, MetS classification can yield fairly diverse populations with varying degrees of 
disease risk severity due to the combinatory nature of qualifying parameters. Accordingly, 
particular combinations of MetS components within the MetS classification have been 
associated with greater risk for developing coronary heart disease (CHD) and premature 
death – including combinations that include low plasma HDL-C [25]. Independent of other 
MetS parameters, HDL-C has consistently been shown to be inversely associated with risk of 
developing CVD [26, 27]. Obesity-related diseases have also been shown to impair the 
multitude of atheroprotective function of HDL, antioxidant, anti-inflammatory, vasodilatory, 
and antithrombotic activities, in addition to the capacity of HDL to promote cholesterol 
efflux and reverse cholesterol transport (RCT). The effects of metabolic dysfunction on HDL 
hold significant implications for whole-body lipid metabolism and transport, atherosclerosis 
development, and CVD risk [28]. 
Similar trends have been observed with markers of inflammation. In men of the West 
of Scotland Coronary Prevention Study cohort, prediction of CHD and T2DM development 
over a 5-year period was strengthened by inclusion of C-reactive protein (CRP), levels of 
which were significantly higher in men with MetS [29]. CRP was additionally found to 
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predict both CHD and T2DM independent of MetS status. Ridker et al [30] reported a similar 
relationship between MetS and CRP, where CRP levels dose-dependently increased with 
greater number of MetS components, and CRP values added predictive power to the 
determination of CVD death risk. Further, peripheral blood mononuclear cells from obese 
subjects are often in a more pro-inflammatory state [31, 32], which has been associated with 
increased migration to metabolic tissues, greater vascular wall adhesion and extravasation, 
enhanced priming toward pro-inflammatory responses, and perpetuation of atherosclerosis 
and T2DM [14].  
In addition to the significant independent roles of HDL and inflammatory leukocytes 
in chronic disease progression, a relatively recent area of research has demonstrated that the 
interaction between HDL and leukocytes concomitantly modulate cellular cholesterol flux 
and inflammatory potential. Elevated levels of cellular cholesterol favor the formation of 
lipid rafts, and have been associated with increased pro-inflammatory responses in 
macrophages and T lymphocytes due to lowered cellular activation thresholds [33-35]. 
Therefore, the capacity of HDL to function as cellular lipid acceptor – in conjunction with 
the activity of anti-inflammatory HDL-associated transporters ATP-binding cassette 
transporter A 1 (ABCA1) and ATP-binding cassette transporter G 1 (ABCG1) – promotes 
maintenance of appropriately controlled leukocyte responses [36]. Together, the dynamic 
between HDL and leukocytes represents a promising therapeutic target to reduced CVD and 
T2DM risk in obesity and MetS.  
Therapeutic strategies for treating obesity and MetS often consist of modification of 
lifestyle and dietary patterns. Dietary therapies promoting weight loss and restoration of 
adipose tissue integrity are commonly prescribed to favor global improvements in metabolic 
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dysfunction [37]; however, based on recent research findings described above, the addition of 
functional foods that target HDL-leukocyte dynamics may provide further benefit. Previous 
intervention studies conducted in our laboratory have demonstrated that dietary carbohydrate 
restriction in conjunction with daily whole egg consumption promotes improvements in HDL 
profiles and inflammatory markers in obese and MetS populations [38-41]. These effects are 
thought to be attributable to the insulin sensitizing and anti-inflammatory weight loss effects 
of carbohydrate restriction, in addition to bioactive nutrients, phospholipids, and antioxidant 
carotenoids within egg yolk [42-45]. Therefore, we believe that this dietary strategy is a 
potential therapeutic candidate to favorably modulate the relationship between HDL function 
and the inflammatory potential of leukocytes in MetS – individuals at high risk for CVD and 
T2DM [22]. Within this context, this dissertation will address several important research 
questions.  
 
Research Questions 
 
Question 1: Does daily whole egg consumption during moderate carbohydrate restriction 
alter HDL lipid composition and cholesterol-accepting functions in MetS? 
 
Hypothesis 1:  We hypothesized that daily consumption of whole eggs would favorably alter 
HDL lipid composition due to habitual intake of highly bioavailable phospholipids within 
egg yolk. We further hypothesized that carbohydrate restriction would promote global 
metabolic improvements, that, in combination with HDL lipid modulation, would increase 
the cholesterol-accepting capacity of subject serum from macrophage foam cells ex vivo.   
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Question 2: Does daily whole egg consumption during moderate carbohydrate restriction 
alter the inflammatory potential of peripheral blood mononuclear cells (PBMC) in MetS? 
 
Hypothesis 2: We hypothesized that carbohydrate restriction would reduce basal 
inflammatory gene expression and NF-κB activity in PBMC, in addition to LPS-mediated 
inflammatory cytokine production due to global improvements in metabolic dysfunction and 
inflammation. We further hypothesized that daily whole egg intake would show greater 
reductions in PBMC inflammatory potential.  
 
Question 3: Does daily whole egg consumption during moderate carbohydrate restriction 
alter parameters of PBMC cholesterol flux in MetS? 
 
Hypothesis 3: We hypothesized that daily consumption of whole eggs would reduce PBMC 
cholesterol content and lipid raft formation, and that these changes would be associated with 
increased expression of HDL-associated transporters ABCA1 and ABCG1.  
 
References 
1. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz 
GA: Impact of overweight on the risk of developing common chronic diseases during 
a 10-year period. Arch Intern Med 2001, 161:1581-1586. 
2. Ogden CL, Carroll MD, Kit BK, Flegal KM: Prevalence of obesity in the United 
States, 2009-2010. NCHS Data Brief 2012:1-8. 
3. Misra A, Khurana L: Obesity and the metabolic syndrome in developing countries. J 
Clin Endocrinol Metab 2008, 93:S9-30. 
4. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W: Annual medical spending 
attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 
2009, 28:w822-831. 
  9 
5. Jia H, Lubetkin EI: Trends in quality-adjusted life-years lost contributed by smoking 
and obesity. Am J Prev Med 2010, 38:138-144. 
6. Guilherme A, Virbasius JV, Puri V, Czech MP: Adipocyte dysfunctions linking 
obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9:367-
377. 
7. Naaz A, Holsberger DR, Iwamoto GA, Nelson A, Kiyokawa H, Cooke PS: Loss of 
cyclin-dependent kinase inhibitors produces adipocyte hyperplasia and obesity. 
FASEB J 2004, 18:1925-1927. 
8. Deng J, Liu S, Zou L, Xu C, Geng B, Xu G: Lipolysis response to endoplasmic 
reticulum stress in adipose cells. J Biol Chem 2012, 287:6240-6249. 
9. Sartipy P, Loskutoff DJ: Monocyte chemoattractant protein 1 in obesity and insulin 
resistance. Proc Natl Acad Sci U S A 2003, 100:7265-7270. 
10. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel 
RL, Ferrante AW, Jr.: CCR2 modulates inflammatory and metabolic effects of high-
fat feeding. J Clin Invest 2006, 116:115-124. 
11. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose 
tissue macrophage polarization. J Clin Invest 2007, 117:175-184. 
12. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR: Increased inflammatory properties 
of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007, 
56:16-23. 
13. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, Liu-Bryan R, 
Glass CK, Neels JG, Olefsky JM: A subpopulation of macrophages infiltrates 
hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 
2 and 4 and JNK-dependent pathways. J Biol Chem 2007, 282:35279-35292. 
14. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, 
Zielenski J, Mastronardi F, et al: Normalization of obesity-associated insulin 
resistance through immunotherapy. Nat Med 2009, 15:921-929. 
15. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, 
Benoist C, Shoelson S, Mathis D: Lean, but not obese, fat is enriched for a unique 
population of regulatory T cells that affect metabolic parameters. Nat Med 2009, 
15:930-939. 
16. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulange A, Capeau J, 
Caron M: Long-term treatment with interleukin-1beta induces insulin resistance in 
murine and human adipocytes. Diabetologia 2006, 49:2162-2173. 
17. Bezaire V, Mairal A, Anesia R, Lefort C, Langin D: Chronic TNFalpha and cAMP 
pre-treatment of human adipocytes alter HSL, ATGL and perilipin to regulate basal 
and stimulated lipolysis. FEBS Lett 2009, 583:3045-3049. 
18. Norseen J, Hosooka T, Hammarstedt A, Yore MM, Kant S, Aryal P, Kiernan UA, 
Phillips DA, Maruyama H, Kraus BJ, et al: Retinol-binding protein 4 inhibits insulin 
signaling in adipocytes by inducing proinflammatory cytokines in macrophages 
through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-
independent mechanism. Mol Cell Biol 2012, 32:2010-2019. 
19. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, 
Quadro L, Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance 
in obesity and type 2 diabetes. Nature 2005, 436:356-362. 
  10
20. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K: Adiponectin and 
adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J 
Clin Invest 2006, 116:1784-1792. 
21. Scarpace PJ, Zhang Y: Leptin resistance: a prediposing factor for diet-induced 
obesity. Am J Physiol Regul Integr Comp Physiol 2009, 296:R493-500. 
22. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A: Executive 
Summary of The Third Report of The National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 
23. Huang PL: A comprehensive definition for metabolic syndrome. Dis Model Mech 
2009, 2:231-237. 
24. Ervin RB: Prevalence of metabolic syndrome among adults 20 years of age and over, 
by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl 
Health Stat Report 2009:1-7. 
25. Hong Y, Jin X, Mo J, Lin HM, Duan Y, Pu M, Wolbrette DL, Liao D: Metabolic 
syndrome, its preeminent clusters, incident coronary heart disease and all-cause 
mortality--results of prospective analysis for the Atherosclerosis Risk in Communities 
study. J Intern Med 2007, 262:113-122. 
26. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density 
lipoprotein as a protective factor against coronary heart disease. The Framingham 
Study. Am J Med 1977, 62:707-714. 
27. Asztalos BF, Tani M, Schaefer EJ: Metabolic and functional relevance of HDL 
subspecies. Curr Opin Lipidol 2011, 22:176-185. 
28. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new 
therapeutic target at the crossroads of dyslipidemia, inflammation, and 
atherosclerosis. Pharmacol Rev 2006, 58:342-374. 
29. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, 
Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and 
without C-reactive protein as a predictor of coronary heart disease and diabetes in the 
West of Scotland Coronary Prevention Study. Circulation 2003, 108:414-419. 
30. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic 
syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 
initially healthy American women. Circulation 2003, 107:391-397. 
31. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P: Circulating 
mononuclear cells in the obese are in a proinflammatory state. Circulation 2004, 
110:1564-1571. 
32. Sheu WH, Chang TM, Lee WJ, Ou HC, Wu CM, Tseng LN, Lang HF, Wu CS, Wan 
CJ, Lee IT: Effect of weight loss on proinflammatory state of mononuclear cells in 
obese women. Obesity (Silver Spring) 2008, 16:1033-1038. 
33. Surls J, Nazarov-Stoica C, Kehl M, Olsen C, Casares S, Brumeanu TD: Increased 
membrane cholesterol in lymphocytes diverts T-cells toward an inflammatory 
response. PLoS One 2012, 7:e38733. 
34. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, 
Parks JS, Edwards PA, Jamieson BD, Tontonoz P: LXR signaling couples sterol 
metabolism to proliferation in the acquired immune response. Cell 2008, 134:97-111. 
  11
35. Zhu X, Lee JY, Timmins JM, Brown JM, Boudyguina E, Mulya A, Gebre AK, 
Willingham MC, Hiltbold EM, Mishra N, et al: Increased cellular free cholesterol in 
macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of 
macrophages. J Biol Chem 2008, 283:22930-22941. 
36. Zhu X, Parks JS: New roles of HDL in inflammation and hematopoiesis. Annu Rev 
Nutr 2012, 32:161-182. 
37. Andersen CJ, Fernandez ML: Dietary strategies to reduce metabolic syndrome. 
Reviews in Endocrine and Metabolic Disorders 2013. 
38. Mutungi G, Waters D, Ratliff J, Puglisi M, Clark RM, Volek JS, Fernandez ML: Eggs 
distinctly modulate plasma carotenoid and lipoprotein subclasses in adult men 
following a carbohydrate-restricted diet. J Nutr Biochem 2010, 21:261-267. 
39. Ratliff JC, Mutungi G, Puglisi MJ, Volek JS, Fernandez ML: Eggs modulate the 
inflammatory response to carbohydrate restricted diets in overweight men. Nutr 
Metab (Lond) 2008, 5:6. 
40. Blesso CN, Andersen CJ, Barona J, Volek JS, Fernandez ML: Whole egg 
consumption improves lipoprotein profiles and insulin sensitivity to a greater extent 
than yolk-free egg substitute in individuals with metabolic syndrome. Metabolism 
2013, 62:400-410. 
41. Blesso CN, Andersen CJ, Barona J, Volk B, Volek JS, Fernandez ML: Effects of 
Carbohydrate Restriction and Dietary Cholesterol Provided by Eggs on Clinical Risk 
Factors in Metabolic Syndrome. Journal of Clinical Lipidology 2013. DOI: 
10.1016/j.jacl.2013.03.008 
42. Volek JS, Fernandez ML, Feinman RD, Phinney SD: Dietary carbohydrate restriction 
induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty 
acid partitioning, and metabolic syndrome. Prog Lipid Res 2008, 47:307-318. 
43. Forsythe CE, Phinney SD, Fernandez ML, Quann EE, Wood RJ, Bibus DM, Kraemer 
WJ, Feinman RD, Volek JS: Comparison of low fat and low carbohydrate diets on 
circulating fatty acid composition and markers of inflammation. Lipids 2008, 43:65-
77. 
44. Blesso CN, Andersen CJ, Bolling BW, Fernandez ML: Egg intake improves 
carotenoid status by increasing plasma HDL cholesterol in adults with metabolic 
syndrome. Food Funct 2013, 4:213-221. 
45. Andersen CJ, Blesso CN, Lee J, Barona J, Shah D, Thomas MJ, Fernandez ML: Egg 
Consumption Modulates HDL Lipid Composition and Increases the Cholesterol-
Accepting Capacity of Serum in Metabolic Syndrome. Lipids 2013, 48:557-567. 
 
 
 
 
 
 
  12
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Literature Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  13
Given the scope of this dissertation project, the following literature review will cover 
mechanisms underlying HDL metabolism, inflammation, the dynamics between HDL and 
leukocytes, and dietary strategies aimed at modifying these pathways within the context of 
obesity-related disease.  
 
 
Section 1 
HDL 
 
Introduction 
HDL represents a heterogeneous class of lipoprotein particles that are diverse in size, 
structure, lipid species distribution, and apolipoprotein/enzyme profiles [1, 2]. Together, 
HDL is known to protect against cardiovascular disease (CVD) by facilitating the removal of 
excess cholesterol from the body via reverse cholesterol transport (RCT), in addition to 
possessing antioxidant, anti-inflammatory, vasodilatory, antithrombotic, and 
immunoregulatory activities [2]. The following section will review the dynamics of HDL 
formation, metabolism, and functions, as well as potential therapeutic strategies to optimize 
atheroprotective HDL functions.  
HDL is the smallest class of lipoproteins, with particle diameters ranging from 5.0 to 
14.5 nm [3]. Compared to larger, more lipid-rich apolipoprotein (apo) B-containing 
lipoproteins (i.e. chylomicrons, very-low-density lipoproteins (VLDL), low-density 
lipoprotein (LDL)), HDL particles are also the most dense due to a relatively richer protein 
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content (~ 50% by weight) [1]. The primary protein component of HDL particles is apoA-I, 
which provides structural integrity to the particle [4], yet is also crucial to lipid acquisition, 
cellular cholesterol efflux, antioxidant properties, and HDL particle clearance [5, 6]. Recent 
proteomics research has identified over 100 additional HDL-associated proteins, including a 
variety of apolipoproteins, and antioxidant and antithromobtic enzymes - the distributions of 
which may further contribute to the overall function of HDL [1, 7, 8].  
The composition of HDL is dependent upon the relative “maturity” of the particle.   
Approximately 5% to 10% of HDL in healthy human plasma is in the form of small, nascent 
HDL particles [9, 10], or preβ-1 HDL, based on its electrophoretic migration pattern. Preβ 
HDL-1 circulate in a mostly lipid-free, discoidal configuration made up of two apoA-I, and ~ 
16 phospholipids (PL) that form a bilayer together with few free cholesterol (FC) molecules 
[1, 11]. Subsequent acquisition of PL, FC, and apoA-I results in the formation of more 
mature HDL particles (also termed α-HDL, based on its electrophoretic migration pattern), 
which are spherical in structure with a core of cholesteryl esters (CE) and TG surrounded by 
a PL and FC outer monolayer with 4 to 5 apoA-I [1]. αHDL represents 90% to 95% of HDL 
particles in human plasma [10]; however, constant plasma remodeling of HDL particles and 
interactions with peripheral tissues results in dynamic conversion between preβ and αHDL 
particles, as well as alterations in composition and size within preβ and αHDL subfractions 
[6].   
 
Formation of HDL  
HDL formation is initiated by the expression and secretion of apoA-I from either the liver or 
intestine as either lipid-poor, monomeric apoA-I, or as a nascent, cholesterol-poor HDL 
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particle [11]. In order to prevent rapid cubulin-mediated clearance of apoA-I by the kidneys, 
apoA-I must be 1) lipidated to form preβ-1 HDL, or 2) incorporated into pre-existing mature 
α-HDL particles [6]. Lipidation of lipid-poor apoA-I to form discoidal preβ-1 HDL particles 
requires acquisition of FC and PL via ATP-binding cassette transporter A 1 (ABCA1)-
mediated unidirectional efflux. Preβ-1 HDL particles acquire additional FC and PL via 
ABCA1- or ATP-binding cassette transporter G 1 (ABCG1)-mediated efflux, resulting in 
formation of more cholesterol-rich, spherical α-HDL particles. α-HDL particles can acquire 
further FC and PL via ABCG1- and scavenger receptor class B type I (SR-BI)-mediated 
efflux, as well as from aqueous diffusion [12, 13].  
 
Physiological determinants of plasma HDL-cholesterol levels 
It has been established that the liver-derived HDL is the primary contributor to plasma HDL-
C, and that hepatic ABCA1 plays a critical role in determining HDL-C levels [6]. Individuals 
with Tangier disease have ABCA1 gene mutations, and are known to have marked deficiency 
in HDL-C, apoA-I, and an increased risk of CVD [14, 15]. Similarly, liver-specific ABCA1-/- 
mice have an ~80% reduction in plasma HDL-C levels [8], whereas HDL-C levels in 
ABCG1-/- and SR-BI-/- mice are relatively unaffected or increased, respectively; although, the 
increases in HDL-C in SR-BI-/- mice are most likely due to decreased hepatic HDL-CE 
clearance [9]. Independent of plasma HDL-C levels, loss of SR-BI and macrophage-specific 
ABCA1 and ABCG1 results in greater development of atherosclerosis [16-18]. These 
findings demonstrate the critical role of HDL and HDL-associated transporters in 
atherosclerosis, while also supporting the notion that HDL-C levels may not truly capture 
CVD severity and risk. This concept has been further supported by the fact that multiple 
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pharmacological therapies specifically designed to increase HDL-C have failed to 
demonstrate reductions in the severity of CVD risk, progression, disease outcomes, or death 
[19, 20]. 
Atheroprotective functions of HDL  
As mentioned above, HDL exhibits atheroprotective properties beyond HDL-C levels, 
including antioxidant, anti-inflammatory, vasodilatory, antithrombotic, and 
immunoregulatory activities [2]. Together, these properties confer a wide range of biological 
activities to HDL, while also affecting the capacity of HDL to accept cellular lipids and 
participate in RCT [2]. In general, it appears that many of these atheroprotective HDL 
properties are regulated independently of circulating HDL-C levels. However, much like 
plasma HDL-C levels, many of these HDL parameters are known to be impaired in 
conditions of obesity, metabolic syndrome, and CVD, thereby resulting in the formation of 
dysfunctional HDL that may perpetuate CVD rather than protect against it. Therefore, 
therapeutic strategies to reduce CVD must strive to improve overall HDL function [21]. 
 
Antioxidant properties of HDL 
HDL is known to possess antioxidant properties which contribute to the atheroprotective 
nature of this lipoprotein class [22]. Atherosclerotic lesions contain abundant oxidized lipid 
and protein species which perpetuate plaque development and endothelial dysfunction [23]. 
Physiological environments of oxidative stress further promote the formation of oxidized 
LDL (oxLDL), which preferentially undergoes scavenger receptor-mediated uptake by 
macrophages, leading to the formation of lipid-laden foam cells – the hallmark characteristic 
of atherosclerosis [24]. OxLDL also triggers activation of pro-inflammatory, apoptotic, and 
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cytotoxic pathways to perpetuate the development and severity of coronary artery disease 
[25]. 
Antioxidant activity of HDL is predominantly related to various types of associated 
apolipoproteins and antioxidant enzymes that serve to hydrolyze and/or remove oxidized 
lipids [22]. For example, HDL-associated apolipoproteins (apo) apoA-I, apoA-II, apoA-IV, 
apoE, apoJ, and apoM are known to contribute to antioxidant activity [2, 26]. The antioxidant 
activity of both apoA-I and apoM is thought to be attributable to their ability to remove 
oxidized phospholipids from both LDL and peripheral cells – including those in the arterial 
wall – which may then be eliminated from the body through the liver [26-28]. HDL is also 
known to associate with enzymes possessing antioxidant activity, including paraoxonase 1 
(PON1), platelet-activating factor acetylhydrolase (PAF-AH), and lecithin-cholesterol 
acyltransferase (LCAT) [22, 29]. These enzymes provide antioxidant activity to HDL by 
hydrolyzing LDL-derived oxidized phospholipid species, thereby inhibiting the formation of 
oxLDL [2, 30]. HDL has also been shown to bind glutathione selenoperoxidase (GSPx), 
which further serves to protect against oxidative stress by reducing lipid hydroperoxides [31].
 Aside from antioxidant activity conferred from associated apolipoproteins and 
enzymes, HDL can prevent oxLDL formation by sequestering oxidizing transition metal ions  
[32]. HDL is also a known carrier of antioxidant nutrients, including vitamin E and 
carotenoids. However, the extent by which these nutrients contribute to the antioxidant 
activity of HDL remains unclear [22].  
HDL with defective antioxidant activities have been identified in metabolic syndrome 
(MetS) [33], type 2 diabetics [34], and healthy postmenopausal women [35] when compared 
to healthy and premenopausal women, respectively. A reduced capacity of HDL to protect 
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against LDL oxidation in these populations may be attributed to reduced activities of 
antioxidant apolipoproteins and enzymes [36].  
 
Anti-inflammatory effects of HDL 
In addition to antioxidant activity, functional HDL is known to possess anti-inflammatory 
properties. Anti-inflammatory activity of HDL typically refers to the ability of HDL to 
inhibit endothelial cell expression of adhesion molecules in response to cytokines, thereby 
reducing monocyte adhesion to the arterial wall in the initial stages of atherosclerosis 
development [2, 37]. Arterial inflammatory pathways and adhesion molecule expression can 
be activated by the same accumulation of oxidized lipids that cause oxidative stress, as 
described above [23].  
The anti-inflammatory activity of HDL is mostly attributed to the same enzymes that 
exert antioxidant activity, including HDL-associated apolipoproteins (i.e. apoA-I, apoA-II, 
apoA-IV, apoM) and oxidized lipid-hydrolyzing enzymes (PON1, PAF-AH, and LCAT) [2, 
26]. Bioactive phospholipid species carried by HDL such as sphingosine-1-phosphate (S1P) 
– carried by apoM - may also play a role in HDL’s anti-inflammatory activity, in addition to 
antiapoptotic and immunoregulatory functions [38, 39].  
Conversely, HDL can become more inflammatory during acute phase responses to 
stress, infection, or inflammation [40]. Under these conditions, HDL has been shown to have 
reduced apoA-I, PON, PAF-AH, and have be less able to prevent LDL- induced monocyte 
transmigration and monocyte chemoattractant protein-1 (MCP-1) expression in human aortic 
endothelial and smooth muscle cell co-cultures [41]. Further, HDL can acquire serum 
amyloid A (SAA) – an acute-phase pro-inflammatory protein that is known to associate with 
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HDL and displace apoA-I [42]. Similar to the acute-phase protein C-reactive protein (CRP), 
SAA has been shown to be predictive of coronary artery disease (CAD) development [43]. 
This may be due to the fact that pro-inflammatory HDL is also less able to participate in RCT 
function, as SAA increases the binding of HDL proteoglycans, thereby preventing HDL 
transport back to the liver to complete RCT [2]. 
 As with other HDL parameters, HDL inflammatory profiles do not appear to be 
related to plasma HDL-C levels [44, 45]. Similar findings have been reported in animal 
models of atherosclerosis, where atherosclerotic lesion area in cholesterol-fed rabbits 
positively correlated with SAA and inflammatory indexes for HDL and LDL, but not total 
cholesterol or HDL-C [46].  
 
Vasodilatory properties of HDL 
In addition to antioxidant and anti-inflammatory functions, HDL possesses vasodilatory 
activity by promoting the production of vasodilatory mediators, including nitric oxide (NO) 
and prostacyclin (PGI2) [2]. ApoA-I stimulates endothelial cell NO production through 
activation of nitric oxide synthase (NOS) [47], whereas HDL also induces expression of 
arachidonic acid derived-PGI2 – a potent vasorelaxer - in vascular smooth muscle cells in a 
cyclooxygenase 2 (COX-2)-dependent mechanism [48-50].  
 
Antithrombotic properties of HDL 
HDL further exhibits antithrombotic activity by inhibiting platelet aggregation [51] and 
factors that promote blood coagulation, including factors X, Va, VIIIa, and tissue factor [52, 
53]. One of the mechanisms by which HDL exerts antithrombotic activity is through 
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enrichment in cardiolipin and phosphatidylethanolamine (PE) – phospholipids with potent 
anticoagulant properties [54, 55]. PE is present on endothelial cells throughout the aorta 
under normal conditions, and is used as an essential cofactor in the protein C coagulant 
pathway. Conditions of PE deficiency or depletion increase severe risk of thrombosis, and 
are highly associated with fetal loss during pregnancy in humans and mice [56].  
 
Reverse Cholesterol Transport 
Considered to be one of the most important atheroprotective functions of HDL, RCT is the 
process of HDL-mediated lipid acquisition from peripheral cells – including arterial wall 
macrophage foam cells – for return to the liver and excretion from the body via the bile and 
feces [19]. RCT represents a diverse network of processes that encompasses 1) cellular 
cholesterol efflux from peripheral tissues to HDL, 2) intravascular remodeling of HDL 
particles through interactions with cell-surface receptors, lipid transfer proteins, lipolytic 
enzymes, and non-HDL lipoproteins, and 3) mechanisms involved in hepatic cholesterol 
uptake and HDL clearance [6, 57]. The efficiency of RCT, as well as CVD risk, is known not 
only to be dependent upon the atheroprotective quality of HDL, but also on numerous 
physiological and genetic factors that influence RCT dynamics [1, 58]. Similar to the HDL 
properties described above, RCT is thought to be impaired in individuals with metabolic 
dysfunction, although it has yet to be definitively confirmed in vivo in humans [59]. 
 
Cholesterol efflux capacity of HDL 
Cellular cholesterol efflux from peripheral tissue to HDL is considered to be the first 
step of RCT [10]. The ability and efficacy of HDL to mediate cellular cholesterol efflux is 
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often referred to as the “cholesterol efflux capacity” or “cholesterol-accepting capacity” of 
HDL. The process of cholesterol efflux is not only dependent on the presence of a functional 
lipid acceptor, but also the expression of lipid transporters. Due to the clinical relevance in 
regard to atherosclerosis development [12, 57], the focus of this section will be on the 
dynamics of HDL-mediated cholesterol efflux from macrophages.  
Macrophage FC and PL efflux to lipid-poor apoA-I/HDL occurs via aqueous 
diffusion, as well as the ABCA1-, ABCG1-, SR-BI-mediated pathways described above [60]. 
Accumulation of LDL-derived cholesterol in macrophages leads to increased formation of 
oxysterols, which are cholesterol derivatives that serve as endogenous ligands for sterol-
sensing transcription factors, liver X receptor (LXR) α and β [61, 62]. Oxysterol-induced 
activation of LXRα/β leads to LXR-retinoid X receptor (RXR) hetero-dimerization and 
transcriptional activation of ABCA1 and ABCG1, which contain LXR response elements 
(LXREs) within their promoter gene regions. Synthetic LXR agonists have been shown to 
increase HDL-C and reduce atherosclerosis; however, their success as a pharmaceutical agent 
is currently limited by their adverse ability to increase sterol regulatory element binding 
protein 1-c (SREBP-1c)-mediated hepatic lipogenesis and plasma TG levels [63].  
Despite accumulation of cellular cholesterol content, expression of ABCA1, ABCG1, 
and SR-BI has been shown to be impaired in individuals with chronic metabolic disease, 
including coronary artery disease, hypertension, and T2DM [64-67]. This may be due to the 
fact the expression of these cellular transporters can be inhibited by serum components 
known to be elevated in metabolic disease, including serum glucose, tumor necrosis factor α 
(TNFα), CRP, and oxLDL [68-72]. Fatty acids have additionally been shown to differentially 
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regulate ABCA1 and ABCG1 [73, 74], whereas weight loss can increase ABCG1- and SR-BI 
mediated efflux in obese women [75].  
As mentioned above, receptor- and aqueous diffusion-mediated FC and PL efflux 
pathways have varying specificities for different HDL subclasses; therefore the individual 
contributions of each efflux pathway is somewhat dependent upon the distribution of HDL 
particle subclasses present in plasma [76, 77]. While loss of ABCA1 results in the greatest 
arterial cholesterol accumulation and increase in atherosclerosis development in vivo, in vitro 
findings suggest that ABCG1 and SR-BI-mediated efflux pathways may also be important 
contributors when cultured in complete serum [76, 78, 79]. In addition, aqueous diffusion has 
been reported to be responsible for 30% to 35% of macrophage FC efflux in both in vitro and 
in vivo studies [80, 81].  
The cholesterol efflux capacity of HDL can further be affected by additional HDL 
characteristics, including lipid composition, associated protein and enzymes, antioxidant and 
inflammatory profiles, and disease status [2, 19]. For example, pro-inflammatory HDL is less 
able to promote efflux [82, 83], whereas PON1 can increase ABCA1-mediated HDL binding 
to promote enhanced cholesterol efflux from macrophages [84]. Enrichment of HDL in 
phospholipids – particularly phosphatidylcholine and sphingomyelin – has also been shown 
to increase the cholesterol-accepting capacity of HDL [85-87]. Compared to healthy subjects, 
cholesterol efflux is reduced in subjects with obesity [88, 89], hypertension [65], coronary 
artery disease, type 2 diabetes [90], and low HDL-C [91, 92].  
 
Intravascular remodeling of HDL particles  
A variety of proteins and enzymes are known to contribute to the intravascular 
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remodeling of HDL. In addition to the antioxidant and anti-inflammatory properties 
discussed above, LCAT plays an important role in HDL particle maturation and cholesterol 
acquisition. LCAT is a liver-derived, lipid-free or HDL-associated enzyme that is activated 
by apoA-I [93]. LCAT catalyzes the transfer of 2-acyl groups from lecithin to FC, resulting 
in the formation of HDL-CE [6, 76]. The accumulation of CE within the HDL core results in 
formation of larger, mature α-HDL particles [94]. LCAT is thought to maintain the FC 
concentration gradient between HDL and macrophages that allows for in the incorporation of 
incoming FC into HDL [13, 93-95]. Individuals with LCAT deficiency have significantly 
decreased plasma HDL-C, apoA-I, and the second most common HDL-associated 
apolipoprotein, apoA-II. In addition, levels of smaller, immature preβ-1 and α-4 HDL 
particles are increased, whereas larger, mature α-1 and α-2 levels decreased. Together, these 
data show that LCAT activity is necessary for proper HDL maturation [94].  
Another key player in intravascular HDL remodeling is cholesteryl ester transfer 
protein (CETP). CETP is a liver and adipose-derived glycoprotein that binds lipoproteins in 
the circulation, where it mediates the exchange of HDL-CE for apoB-containing lipoproteins 
(chylomicron/chylomicron remnants, VLDL, intermediate-density lipoproteins (IDL), LDL) 
–TG [96]. CETP activity is known to increase with greater apoB lipoprotein-TG content, 
resulting in HDL-CE depletion and increased HDL-TG accumulation [97]. Elevated HDL-
TG makes HDL a better substrate for hepatic lipase-mediated TG lipolysis, resulting in an 
overall reduction in HDL particle size and HDL-C levels [6]. Although elevated non-HDL-
CE levels are typically associated with increased CVD risk, CETP-mediated transfer of 
HDL-CE to apoB-containing lipoproteins still contributes to the RCT process, as these 
lipoproteins may be taken up by the liver via LDL-receptor (LDL-R), LDL-R related protein 
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(LRP)-, and SR-BI-mediated pathways for biliary cholesterol excretion [98-100], as well as 
non-bilary secretion via the transintestinal cholesterol efflux (TICE) pathway [101, 102]. In 
general, CETP activity has been regarded as pro-atherogenic. CETP-deficient patients have 
extremely high HDL-C levels and reduced CVD incidence [103]; however, while synthetic 
CETP inhibitors have been shown to increase HDL-C in humans, they have also been shown 
to increase all-cause and CVD-related mortality [104, 105]. These adverse effects have since 
been attributed to compound-specific toxicity off-target activation of the renin-angiotensin-
aldosterone system, prompting further investigation into development of safer and more 
classes of CETP inhibitors [106-108].  
As with CETP, elevated apoB-containing lipoprotein-TG content increases activity of 
lipoprotein lipase (LPL). With primary activity in adipose, skeletal muscle, and endothelial 
cell surfaces, LPL mediates lipolysis of TG within TG-rich lipoprotein (TGRL); i.e. 
chylomicron and VLDL particles, resulting in formation of CR and IDL/LDL, respectively 
[109]. LPL-mediated lipolysis of TGRL simultaneously results in the release and transfer of 
FC, PL, and apolipoproteins from TGRL to HDL, resulting in the formation of larger, more 
cholesterol- and apoA-I-rich HDL [6]. HDL-bound phospholipid transfer protein (PLTP) also 
plays a key role in HDL remodeling activity during TGRL-TG lipolysis, as it serves to 
transfer surface PL from TGRL to HDL, resulting in the formation of larger, less dense HDL 
particles [110]. Larger HDL particles observed with greater PLTP activity are also known to 
be a consequence of PLTP-mediated HDL particle fusion [111]. Lack of PLTP has been 
shown to impair ABCA1-mediated FC efflux from macrophages to lipid-free apoA-I, all 
together suggesting that PLTP plays a prominent role in HDL maturation and formation 
[112].  
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As mentioned above, CETP-mediated HDL-TG enrichment results in greater hepatic 
lipase (HL) affinity for HDL particles [6]. HL is a hepatocyte-derived enzyme with both TG 
lipase and phospholipase A1 activity.  HL has greater specificity for HDL-TG than TGRL-
TG, resulting in conversion of larger HDL to smaller HDL particles, preβ HDL, and lipid-
poor or –free apoA-I [113]. Overall, increased HL-mediated HDL particle catabolism is 
associated with lower HDL-C levels [114]. Endothelial lipase (EL) is another lipolytic 
enzyme with greater specificity for HDL-TG than TGRL-TG; however, this primarily 
endothelial cell-derived enzyme predominantly has phospholipase A1 activity. Similar to HL, 
increasing EL-mediated HDL-PL hydrolysis is associated with reduced HDL-C, apoA-I, and 
HDL particle size due to increased fractional catabolism [113].  
 
Mechanisms involved in hepatic cholesterol uptake and HDL clearance 
Following retrieval of cholesterol from peripheral tissues and subsequent 
intravascular remodeling processes, HDL may then transport CE back to the liver for biliary 
excretion, or be catabolized by the kidney or steroidogenic tissues [6, 115, 116]. Hepatic SR-
BI-mediated HDL catabolism is thought to be one of the primary mechanism by which HDL-
C is cleared from the body [117]. Although it was originally considered, recent evidence 
suggests that HDL does not play a significant role in non-biliary cholesterol excretion via the 
TICE pathway [118]. Similar to macrophage SR-BI, hepatic SR-BI preferentially binds and 
induces lipid flux from larger, more cholesterol-rich α-1 and α-2 HDL (HDL2) particles [77]. 
While SR-BI expression on macrophages contributes to lipid efflux [119], hepatocyte SR-BI 
expression allows for selective uptake of HDL lipid components, resulting in formation of 
small, dense HDL particles and shedding of lipid-free apoA-I into the circulation. Newly 
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released apoA-I must be rapidly recycled and/or relipidated through cellular efflux or HDL 
remodeling pathways in order to avoid cubulin-mediated renal catabolism and lysosomal 
degradation [6, 116]. Additional proposed mechanisms of hepatic HDL uptake have also 
been identified, including those involving scavenger receptor CD36, as well as ATP synthase 
ectopic β-chain-mediated HDL holoparticle endocytosis [120, 121]. While these pathways 
have been implicated in contributing to HDL metabolism and clearance, further 
investigations in vivo are required to determine their physiological impact on RCT and CVD 
risk.   
 
Implications for HDL-based therapies 
The evidence presented above highlights the important atheroprotective roles of HDL. Under 
optimal physiological conditions, functional HDL will possess the capacity to exert 
antioxidant, anti-inflammatory, antithrombotic, vasodilatory activities, allowing it to 
effectively serve as a lipid acceptor for cellular cholesterol [2]. As demonstrated within the 
context of atherosclerosis, the dynamic between HDL and macrophages is a critical 
determinant of disease severity [19, 64, 122]. Interestingly, recent data suggests that HDL 
may play a significant role of modulating the activity of other leukocytes – particularly in 
regard to their inflammatory potential [123-125]. Given that inflammatory leukocytes play an 
increasingly well-documented role in obesity-related disease progression [126-128], 
optimization of HDL function may confer physiological effects beyond the scope of 
atherosclerosis.  
In order to adequately assess the dynamics between HDL and leukocytes, it is 
important to first place the physiological role of inflammation into context – both in regard to 
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immunity and chronic metabolic disease. Therefore, the following section will review the 
mechanisms underlying inflammation under acute and chronic conditions.     
 
 
 
Section 2 
Inflammation 
  
 
 
Introduction 
 
      Inflammation is a normal, adaptive physiological response to pathogenic insult, including 
microbial infection and tissue injury; however the incidence of chronic low-grade, systemic 
inflammation underlying multiple highly prevalent chronic metabolic diseases warrants 
reevaluation of inflammatory processes in disease pathogenesis. Acute inflammatory 
responses are considered beneficial if executed in a local, controlled manner, as they function 
to rapidly and effectively eliminate pathogenic stimuli and return the affected tissue to a 
normal, homeostatic state through coordinated activation and resolution of pro-inflammatory 
leukocyte activity [129]. However, failure of the body to appropriately execute and resolve 
acute inflammatory responses can lead to a detrimental chronic inflammatory tissue state, 
characterized by pathological tissue remodeling, fibrosis, and impaired functioning, and due 
to persistent inflammatory cell infiltration, activation, and leukocyte-mediated tissue damage 
[130, 131]. More recently, similar adverse physiological adaptations have been observed 
within the context of obesity-related disorders, where prolonged metabolic stress and tissue 
malfunction are believed to promote the development of CVD, T2DM, insulin resistance, and 
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hepatic steatosis – all of which coincide with a chronic state of systemic, low-grade 
inflammation [132-134].  
 
The acute inflammatory response  
        Acute inflammatory responses are rapidly initiated in response to molecular alarm 
signals that are indicative of microbial invasion or tissue damage, allowing for innate 
immune cell recruitment and activation, elimination of the pathogenic stimuli, resolution of 
immune-mediated inflammation, and restoration of tissue homeostasis [135]. Infection and 
tissue injury leads to necrotic cell death, resulting in the disruption of cell membranes the 
release of cytoplasmic and nuclear components containing conserved damage-associated 
molecular patterns (DAMPs), which include DNA, nucleosomes, and high-mobility group 
box 1 protein (HMGB1) – a nuclear protein that modulates chromatin accessibility and one 
of the most well-characterized endogenous alarm signals [135-137]. Microbial pathogens 
provide similar signals termed pathogen-associated molecular patterns (PAMPs), which are 
molecular components that are conserved amongst specific classes of microorganisms, yet 
distinct from the host’s endogenous molecules (e.g. lipopolysaccharide (LPS) present in the 
cell membrane of gram negative bacteria) [138]. DAMPs and PAMPs induce leukocyte 
activation through binding of pattern recognition receptors (PRRs) such as toll-like receptors 
(TLRs) and nucleotide-binding oligomerization-domain (NOD)-like receptors (NLRs), which 
are expressed on antigen-presenting cells of the innate immune system, including patrolling 
steady-state non-classical CD14lowCD16+ monocytes, tissue-resident macrophages, and 
dendritic cells [135, 138]. Differential expression has also been reported in certain 
lymphocyte subsets [139, 140].   
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In macrophages, LPS-mediated TLR activation leads to signaling through the adaptor 
molecule myeloid differentiation primary response gene 88 (MyD88) [141], and transcription 
factors nuclear factor-κB (NF-κB) and activator protein-1 (AP-1), both of which promote the 
transcriptional activation of pro-inflammatory cytokines and chemokines, such as TNFα, and 
CXC-chemokine ligand 1 (CXCL1) and CXCL2 [135, 142, 143]. Similarly, HMGB1 has 
been shown to bind and activate receptor for advanced glycation end products (RAGE), 
TLR2, TLR4, TLR9 and interleukin 1 receptor (IL-1R), leading to the activation of NF-κB 
and greater production of TNFα, interleukin (IL)-6 and phagocyte-attracting chemokines 
such as IL-8, chemokine ligand (CCL) 3 and CCL4 [138, 144, 145].  
 
The role of NF-κB in acute inflammatory responses 
NF-κB is a family of dimeric transcription factors that serves as one of the primary 
mechanisms by which macrophages induce pro-inflammatory gene expression in response to 
cellular stress and external inflammatory stimuli [146]. As mentioned above, NF-κB plays 
important roles in both acute and chronic inflammation. Transcriptionally active NF-κB 
consists of homo- and heterodimers of NF-κB/Rel family members, including p65 (RelA), c-
Rel, RelB, p50/105, and p52/100; however, only p65, c-Rel, and RelB contain C-terminal 
transactivation domains, whereas p52 and p50 subunits rely on interactions with these factors 
to positively regulate transcription of target genes [147]. The p50-p65 dimer is the most well 
characterized, as it is the predominant NF-κB subunit pair that mediates LPS- and TNFα-
induced expression of pro-inflammatory genes [148, 149]. The majority of NF-κB dimers are 
retained in the cytoplasm of resting cells by inhibitor of κ B (IκB) proteins, which contain 
strong nuclear export signals and physically mask the nuclear localization signal (NLS) 
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regions of Rel family subunits. Activation of transcriptionally active NF-κB is therefore 
dependent upon dissociation from IκB and nuclear translocation of the NF-κB dimer [150].  
NF-κB can be activated in response to ligation of a variety cell surface immune receptors, 
including TNFα and IL-1β receptors, TLRs, NLRs, and T and B lymphocyte antigen 
receptors [148, 151, 152]. Receptor ligation triggers the activation of the trimeric IκB kinase 
(IKK) complex, containing catalytic subunits IKKα and IKKβ, as well as the regulatory 
scaffolding subunit NF-κB essential modulator (NEMO/IKKγ). Active IKK phosphorylates 
specific serine residues of IκB, resulting in dissociation from NF-κB subunits, proteosomal 
degradation of IκB, and translocation of NF-κB from the cytoplasmic compartment to the 
nucleus [146]. NF-κB dimers subsequently induce transcriptional activation of target genes 
containing NF-κB binding sites within their promoter regions, including TNFα, IL-6, MCP-
1, and COX2 [153]. Low levels of NF-κB are constitutively present in the nucleus; however, 
in non-stimulated cells, transcriptional activity is actively repressed through binding of a co-
repressor complex containing co-repressors such as nuclear receptor corepressor (NCoR), 
silencing mediator for retinoid and thyroid hormone receptor (SMRT), and histone 
deacetylase 3 (HDAC3) [149]. This basal state of active NF-κB repression allows for the 
inhibition of NF-κB by anti-inflammatory transcription factors LXR and peroxisome 
proliferator-activated receptor γ (PPARγ) in the presence of inflammatory stimuli, as 
discussed in more detail below [154].  
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Neutrophil recruitment and activation 
Dendritic cell- and monocyte/macrophage-derived cytokines and chemokines 
facilitate neutrophil activation, recruitment, and extravasation into the affected tissue, where 
neutrophils release contents from cytosolic granules containing cytotoxic reactive oxygen 
species (ROS), and antimicrobial and matrix-degrading hydrolytic enzymes [155, 156]. 
Neutrophils also release soluble complexes of IL-6 and the IL-6 receptor (IL-6R), which 
activate endothelial cells to express CCL2 and vascular cell-adhesion molecule 1 (VCAM1), 
thereby promoting the adhesion and extravasation of circulating monocytes into the affected 
tissue, where they can subsequently differentiate into macrophages in response to 
macrophage-derived granulocyte-monocyte colony-stimulating factor (GM-CSF) [157, 158]. 
Activation of monocytes/macrophages leads to rapid cyclooxygenase or lipoxygenase 
(LOX)-mediated formation of pro-inflammatory lipid mediators from membrane-derived 
arachidonic acid (AA), including prostaglandins and leukotrienes. Leukotriene B4 serves as a 
potent chemoattractant of certain T cell subsets, monocytes, and neutrophils, while also 
promoting neutrophil granule release and ROS production [159-162].  
 Together, the combined pro-inflammatory, anti-microbial, and phagocytic activity of 
neutrophils and monocytes/macrophages ultimately leads to the elimination of pathogenic 
stimuli; however, neutrophil lifespan and activity must be tightly controlled due to the 
nonspecific nature of cytotoxic neutrophil granule contents, which have the potential to cause 
excessive damage to self-tissues [156]. Accordingly, the initiation of inflammatory response 
resolution is characterized by the onset of neutrophil apoptosis and inhibition of further 
neutrophil recruitment [163]. Macrophage-derived TNFα contributes to the regulation of 
neutrophil lifespan throughout the inflammatory response, as low TNFα levels extend the 
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lifespan of relatively short-lived neutrophils, whereas excessive levels facilitate neutrophil 
apoptosis [164]. Apoptotic neutrophils release lactoferrin, lysophosphatidylcholine (LPC), 
nucleotides, and CX3CL1, which serve macrophage chemoattractants [135]. 
Monocyte/macrophage- and neutrophil-derived lipid mediators also play a critical role in 
resolution, as accumulating levels of pro-inflammatory prostaglandin E2 (PGE2) and PGD2 
gradually promote the synthesis of anti-inflammatory, pro-resolving lipoxins in a process 
termed eicosanoid class-switching [165]. Lipoxin A4 inhibits neutrophil recruitment, ROS 
production, and NF-κB activity, resulting in reduced production of pro-inflammatory 
cytokines and chemokines [166], while simultaneously promoting monocyte migration and 
macrophage phagocytosis of apoptotic neutrophils. Eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA)-derived lipid mediators, including resolvins, protectins, and 
maresins, exhibit similar anti-inflammatory and pro-resolving activity, as discussed in greater 
detail below [167]. Phagocytosis of apoptotic neutrophils further elicits anti-inflammatory 
macrophage responses by inducing increased secretion of transforming growth factor-β 
(TGF-β), IL-10, and vascular endothelial growth factor (VEGF), which serve to promote 
endothelium repair [135, 168]. Together, the coordinated efforts of innate immune cells 
allow for recognition and elimination of pathogenic insults, repair of tissue injury, and 
restoration of tissue homeostasis [167]. 
 
Chronic inflammation in metabolic disease 
 
       As opposed to acute inflammatory responses, which are triggered by specific events or 
noxious stimuli, the chronic low-grade inflammation, or “para-inflammation,” observed in 
obesity-related diseases is thought to be initiated in metabolic cells in response to excess 
nutrient overload, leading to prolonged tissue stress [129, 169]. While metabolic disturbances 
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in obesity, CVD, insulin resistance, and T2DM often span multiple metabolic organ systems 
(i.e. the liver, pancreas, and skeletal muscle), tissue stress and inflammation is thought to be 
initiated in white adipose tissue (WAT). The onset of obesity promotes excess nutrient-
induced adipocyte hypertrophy and endoplasmic reticulum (ER) stress, leading to elevated 
secretion of pro-inflammatory cytokines and leukocyte infiltration. Dysfunctional WAT also 
has a diminished capacity to store lipids, resulting in ectopic lipid deposition in non-WAT 
tissues and perpetuation of systemic insulin resistance, atherogenic dyslipidemias, and para-
inflammation [132, 169]. Clinical manifestation of these underlying conditions often present 
as the of parameters of MetS - a clinical classification characterized by a clustering of central 
adiposity, elevated blood glucose, high plasma TG, elevated blood pressure, and low plasma 
HDL-C, resulting in a 2- and 5-fold increased risk for CVD and T2DM, respectively [170].  
 
Adipose tissue dysfunction and endoplasmic reticulum (ER) stress 
 Adipose tissue is a dynamic metabolic organ that contributes to the maintenance of 
nutrient homeostasis by serving as a source of readily accessible energy stores, while also 
functioning as an endocrine organ through the secretion of hormones and adipokines.  
Insulin-dependent storage of excess nutrients is dependent upon the rapid formation of lipid 
droplets [171], which are lipid storage organelles that predominantly consist of TG and CE. 
TG and CE are synthesized within the inner leaflets of the ER membrane, forming a lipid 
droplet core that buds off surrounded by a monolayer of ER membrane-derived 
phospholipids and associated PAT-domain proteins, including perilipin, adipose 
differentiation-related protein (ADRP), and TIP47-related protein, as well as the ER 
chaperone protein BiP [172]. In obesity, prolonged intake of excessive nutrients requires 
  34
increased lipid droplet formation coupled with excessive demand for PAT protein synthesis, 
ultimately leading to ER exhaustion and an accumulation of newly synthesized unfolded and 
misfolded protein aggregates that activate the unfolded protein response (UPR) [173]. 
Accumulating protein aggregates are sensed by ER stress proteins, including PKR-like 
eukaryotic initiation factor 2α kinase (PERK), inositol-requiring enzyme 1 (IRE-1), and 
activating transcription factor 6 (ATF-6). Under normal, non-stressed conditions, BiP binds 
PERK, IRE1 and ATF6, rendering them inactive. However, increased lipid droplet formation 
limits BiP availability, leading to activation of PERK, IRE1, and ATF6 signaling [174]. IRE-
1 signaling leads to mitogen-activated protein kinase (MAPK)/c-Jun N-terminal kinase 
(JNK)-mediated activation of AP-1, whereas PERK, IRE-1, and ATF6 signaling pathways 
facilitate NF-κB activation, overall resulting in an increased production of pro-inflammatory 
cytokines and chemokines, such as TNF-α, IL-1β, IL-6, IL-8, and MCP-1 from both 
adipocytes and tissue-resident macrophages [146]. In high-fat diet-induced obese ob/ob mice, 
elevated ER stress promotes JNK-mediated serine phosphorylation of insulin receptor 
substrate-1 (IRS-1), leading to suppressed insulin receptor signaling and impaired insulin 
sensitivity. Prolonged UPR also triggers CCAAT-enhancer-binding protein (C/EBP) 
homologous protein (CHOP) and caspase-12-mediated adipocyte apoptosis, which stimulates 
leukocyte influx into adipose tissue [174]. While macrophages represent approximately ~5-
10% of cells in healthy adipose tissue, macrophages can represent up to 50% of all cells in 
obese WAT. Pulse-labeling studies conducted in vivo have demonstrated that the 
macrophages recruited into adipose tissue at the onset of obesity are highly pro-
inflammatory, classically activated M1 macrophages, in contrast to resident macrophages in 
lean adipose, which are typically alternatively-activated, anti-inflammatory M2 macrophages 
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[175-177]. Increased T cell infiltration is also observed in obese adipose tissue, and some 
evidence suggests that these lymphocytes may become activated in response to unique 
antigens generated in obese adipose tissue during high-fat feeding [126]. In addition, greater 
levels of pro-inflammatory TH1 cells have been observed in obese adipose, whereas levels of 
anti-inflammatory Treg cells are reduced, corresponding to greater impairments in insulin 
sensitivity [126, 178].  
 
Impaired nutrient storage and insulin resistance   
 The overall inflammatory state of dysfunctional obese WAT impairs the nutrient 
storage capacity of adipocytes. For example, TNFα is known to counteract insulin-mediated 
nutrient uptake through inhibition of insulin-mediated glucose transporter type 4 (GLUT4) 
translocation to the adipocyte cell surface, LPL-mediated lipolysis of chylomicron TGs for 
adipocyte storage, and perilipin-mediated lipid droplet formation. In addition, TNFα 
increases hormone sensitive lipase (HSL) activity, promoting FFA mobilization from adipose 
into the circulation [132, 179]. Elevated levels of circulating FFAs are commonly observed 
in obesity, and can be deposited in the liver, skeletal muscle, and pancreas, leading to 
impairments in tissue function, metabolic homeostasis, and increased risk of developing 
hepatic steatosis and T2DM [132, 180]. Obesity is also known to increase fat deposition in 
primary and secondary lymphoid organs, including the bone marrow, thymus, spleen and 
lymph nodes, leading to alterations in the distribution of leukocyte populations, lymphocyte 
activity, and overall immune defenses [181-185]. The lipotoxic effects of systemic lipid 
deposition contribute to the elevated levels of plasma pro-inflammatory mediators 
characteristic of obesity-related diseases, where increased levels of TNFα, IL-1β, IL-6, 
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MCP-1, and CRP are commonly observed [186]. The combination of increased lipid 
deposition and inflammatory mediators further promotes insulin resistance, as insulin 
resistant diet-induced obese ob/ob mice show greater insulin sensitivity when lacking either 
TNFα or TNF receptors [187]. TNFα receptor ligation induces JNK signaling and NF-κB 
activation, which have further been shown to contribute to insulin resistance [186]. TNFα 
signaling is also known to down-regulate peroxisome proliferator-activated receptor γ 
(PPARγ) – a ligand-activated transcription factor that counteracts insulin resistance by 
promoting adipogenesis through hyperplastic vs. hypertrophic adipocyte expansion, TG 
biosynthesis for adipocyte storage, antagonism of NF-κB, and increased expression of 
adipose-derived adiponectin, an adipokine that exerts systemic anti-inflammatory and insulin 
sensitizing effects [132, 188]. Accordingly, many of the most common and effective 
pharmacological therapies prescribed for T2DM belong to the thiazolidinedione (TZD) class 
of synthetic PPARγ ligands [189]. However, effective reversal and/or improvement of para-
inflammation and obesity-associated disease is most commonly observed with weight loss, as 
evidenced by improved resolution indices and decreased circulating levels of inflammatory 
mediators [190, 191].  
 
Role of NF-κB and AP-1 in obesity-related disease 
The role of NF-κB and AP-1 in obesity-related chronic inflammation is becoming 
increasing well characterized [169]. ER stress-activated PERK has been shown to trigger 
degradation of IκB, allowing for NF-κB-mediated expression of TNFα [192]. Similarly, AP-
1 can be activated by IRE-1 as a consequence of the UPR, leading to adipocyte dysfunction, 
macrophage activation and recruitment, and insulin resistance [174]. In liver tissue from 
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obese NASH patients, both AP-1 and NF-κB DNA binding were found to be significantly 
greater than non-obese controls, corresponding to greater insulin resistance and oxidative 
stress as measured by HOMA-IR and ferric reducing ability of plasma (FRAP), respectively 
[193]. Together, NF-κB and AP-1 serve as two of the master regulators of pro-inflammatory 
gene expression in response to ER stress, and inflammatory stimuli within the context of 
acute and chronic inflammation.   
 
Relationship between acute and chronic inflammation  
Acute inflammatory responses and para-inflammation are similar in that both are 
characterized by leukocyte activation and infiltration into affected tissues, resulting in the 
generation of pro-inflammatory mediators; however, these responses differ in the triggers of 
instigation (noxious stimuli or tissue injury vs. metabolic tissue stress), and their capacity to 
resolve inflammation and restore tissue homeostasis [167, 169]. Following successful 
elimination of the pathogenic factor, acute inflammatory responses appropriately facilitate 
resolution of inflammatory mediators, tissue repair, and return to normal, healthy tissue 
homeostasis. Conversely, the onset of para-inflammation results in a shift in homeostatic set 
points of affected tissues to perpetuate a maladaptive state with no defined marker of 
resolution [129]. Para-inflammation can also lead to impairments in acute inflammatory 
responses, as murine models of diet-induced obesity exhibit delayed resolution of 
inflammatory responses [194]. Therefore, while triggers of initiation and resolution between 
acute and chronic inflammation differ, the shared leukocyte-mediated processes and 
molecular signaling underlying acute and chronic inflammation suggests that inflammatory 
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crosstalk may occur, perhaps further complicating the pathogenesis of acute and 
inflammatory disease.   
 
Leukocyte profiles in obesity 
Similar to what is observed in metabolic tissues, leukocytes tend to reside in elevated basal 
pro-inflammatory state in obesity. In human peripheral blood mononuclear cells (PBMCs) – 
a mixed leukocyte population containing approximately 60-70% T cells, 5-15% B cells, 5-
10% natural killer cells, 0.5-2% dendritic cells, 15-30% monocyte/macrophages, and 2% 
granulocytes [195-198] – p50- and p65-DNA binding was found to be elevated in obese 
subjects when compared to normal-weight control, whereas IκBβ was significantly lower in 
the obese group. Increased NF-κB binding corresponded to increased mRNA expression of 
NF-κB target genes, including migration inhibition factor (MIF), IL-6, TNFα, and matrix 
metalloproteinase 9 (MMP9) in obese subjects, as well as significantly greater plasma FFA 
and insulin resistance, as measured by homeostasis model assessment of insulin resistance 
(HOMA-IR) [199]. Further, PBMC NF-κB-DNA binding, as well as mRNA expression of 
TNFα, IL-6, MIF, and MMP9 has been shown to decrease with 5% weight loss in non-
diabetic, obese female subjects, indicative of potential steps toward resolution of obesity-
associated para-inflammation [200]. 
Recently, elevations in the standard clinical white blood cell (WBC) measure has 
been used as a marker of leukocyte inflammation – particularly within the context of MetS. 
According to Japanese MetS criteria, WBC counts served as a positive predictor of MetS 
[201]. In addition to MetS being associated with higher white WBC counts in Japanese 
populations [202], MetS components are typically worsened in higher WBC quartiles. 
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Similarly, in an elderly (75 year old) Swedish population, WBC counts were found to be 
positively associated with parameters of MetS; however, this was more prevalent in women 
[203]. Conversely, long-term, moderate weight loss (5.4% of body weight over 3 years) has 
been shown to reduce WBC counts and serum inflammatory markers (IL-1β, IL-6, urinary 
isoprostanes) [204].  
 
Altered immunity in obesity  
Despite having an increased basal level of inflammation, obesity is associated with impaired 
immune responses, further suggesting that the elevated levels of leukocyte inflammation 
represent markers of metabolic dysfunction rather than an enhanced capacity to clear 
infection and mount organized immune responses. Both high-fat diet-fed and ob/ob obese 
mice experience increased mortality in response to Staphylcoccus aureus-induced sepsis, 
corresponding to several impaired innate immune functions [205]. Diet-induced obesity has 
been shown to impair memory CD8+ T cell responses to influenza virus infection, resulting 
in increased mortality, viral titers in lung, and worsened lung pathology [183]. These adverse 
effects were associated with an obesity-induced failure to maintain influenza-specific CBD8+ 
memory T cells, suggesting that obesity may reduce vaccine efficacy [183]. Obesity has 
additionally been associated with impaired T cell-mediated immune surveillance by 
promoting reductions in thymopoiesis and constriction of T cell receptor (TCR) diversity 
[206]. As mentioned above, the reduction in certain lymphocyte subsets may coincide with 
concomitant increases in T cell that respond to antigens unique to dysfunctional adipose, as 
well as lymphocytes that favor metabolic tissue infiltration and pro-inflammatory responses 
[126, 178]. In the National Health and Nutrition Examination Survey (NHANES) 2005-2006 
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cohort, obesity was associated with an increased prevalence of allergic disease in children, 
primarily driven by allergic sensitization to food [207]. These findings suggest that obesity 
impairs normal immune functioning, which may further perpetuate metabolic disease 
complications.  
 
The role of inflammatory leukocytes in perpetuating obesity-related disease 
Evidence for the role of pro-inflammatory leukocytes in perpetuating obesity-related 
metabolic dysfunction has been documented on both animal and human models. Winer et al. 
[126] demonstrated that the incidence of murine insulin resistance could be regulated through 
CD4+ T cell-based immunotherapy. Inflammatory monocytes and macrophages have 
additionally been associated with physiological complications in metabolic tissues – 
particularly in adipose and the arterial wall within the context of atherosclerosis. Certain 
subsets of “inflammatory” CD16+ monocytes have been shown to be more likely to interact 
with activated endothelium, extratravasate into the arterial wall, and differentiate into 
macrophages [208, 209]. CD14+/CD16+ monocytes have been associated with 
hypercholesterolemia, as well as an increased incidence of CHD [127, 128]. Further, 
polarization of classically activated pro-inflammatory M1 or alternatively activated anti-
inflammatory M2 macrophage subsets has been shown to affect atherosclerosis and adipose 
tissue dynamics [175, 210], a process which is further regulated by T cells [211].  Together, 
these findings demonstrate that obesity promotes a state of positive feedback between 
inflammatory leukocytes and adverse metabolic outcomes.  
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Exogenous and endogenous factors linking acute and chronic inflammatory responses 
As described above, mechanisms underlying the activation of acute inflammatory responses 
overlap with pathways of obesity-related chronic inflammation. A variety of exogenous and 
endogenous factors similarly play a role in both acute and chronic inflammation, and may 
further perpetuate the dysregulated relationship between the two in obesity. Keeping the 
scope of this dissertation in mind, the following section will review the roles of LPS, fatty 
acids, and cholesterol in inflammation.   
 
The role of lipopolysaccharide (LPS) in inflammation 
LPS is immunostimulatory glycolipid located on the outer membrane of Gram-negative 
bacteria that activates innate immune responses via PRRs such as TLRs [135, 212]. LPS 
consists of an amphipathic lipid A component that serves as the conserved molecular pattern 
element, in addition to core hydrophilic polysaccharides and O-antigen [212]. As described 
above, LPS-mediated TLR activation leads to the initiation of pro-inflammatory signaling 
cascades, thereby promoting the transcriptional activation of pro-inflammatory cytokines and 
chemokines via transcription factors such as NF-κB and AP-1 [135, 142, 143]. Control of 
LPS-induced inflammatory responses is essential to prevent adverse physiological 
consequences, including organ dysfunction and failure, hypotension, and septic shock [213].   
 While the role of LPS in acute inflammation and infection has been well elucidated, 
recent research has demonstrated an increasingly significant role for LPS in obesity-related 
chronic inflammation [214, 215]. Aside from direct bacterial infection, LPS exposure can 
occur via the consumption of LPS-containing foods, as well as the presence of LPS-
containing microbiota in the gut. Both exogenous and endogenous LPS has been shown to 
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contribute to plasma LPS levels, as gut- or diet-derived LPS is known to be absorbed into 
intestinal capillaries, then transported into circulation by lipoproteins [216-218]. Since 
obesity is associated with increased energy intake and adverse shifts in microbiota 
populations [219], it is plausible to expect that LPS plays a role in obesity-related 
inflammation.   
Recent research findings have further corroborated this concept. In an observational 
study conducted in 201 healthy men, plasma LPS concentrations were found to be positively 
correlated with dietary fat and energy intake [220]. In C57B6/J mice, 4 weeks of high-fat 
feeding increased plasma LPS concentrations 2- to 3-fold, while also increasing the 
proportion of LPS-containing gut microbiota. Subcutaneous infusion of LPS further induced 
insulin resistance, adipose tissue inflammation, and hepatic lipid deposition [216]. 
Correspondingly, circulating levels of LPS have been shown to be elevated in T2DM patients 
when compared to healthy controls, whereas LPS has additionally been shown to activate 
inflammatory pathways in human adipose tissue ex vivo [214]. Interestingly, 10-wk 
rosiglitazone treatment reduced LPS levels, along with glucose and insulin. Fasting insulin 
positively correlated with serum endotoxin levels in non-diabetic subjects [214]. 
Lipopolysaccharide-binding protein (LBP) - an indirect measure of LPS and systemic 
inflammation - is associated with many factors of obesity and MetS, including abdominal 
obesity, low HDL-C, and elevated levels of serum cytokines and liver enzymes (IL-6, IL-8, 
alanine aminotransferase (ALT), aspartate aminotransferase (AST) [215]. Together, these 
findings support the detrimental role of LPS in obesity-related inflammation and metabolic 
dysfunction. 
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The role of fatty acids in inflammation 
Fatty acids are well known to influence both pro- and anti-inflammatory activity through a 
variety of cellular mechanisms. Fatty acids are key components of cell membrane 
phospholipids, and due to their variability in structure and functionality, alterations in 
membrane fatty acid composition can influence the physical properties of membranes in 
terms of fluidity and lipid raft structure, as well as the availability of fatty acids to be used as 
precursors for the generation of bioactive lipid mediators, and ligands for lipid-sensing 
transcription factors [221, 222]. The ability of fatty acids to differentially modulate 
inflammatory responses has significant implications for both dietary recommendations and 
within the context of chronic inflammation underlying metabolic disease [223]. Immune cell 
fatty acid membrane composition highly correlates with dietary intake, usually in a dose-
dependent manner, whereas obesity is associated with excess amounts of adipose-derived 
plasma FFAs, resulting in exposure of body tissues to greater concentrations of fatty acids, 
while also resulting in lipid deposition in non-adipose tissues [132, 221]. Together, fatty 
acids predominantly exert pro- and anti-inflammatory effects by 1) serving as precursors to 
immunoregulatory eicosanoids and lipid mediators, 2) through activation of TLR4-mediated 
activation of NF-κB and AP-1-mediated pro-inflammatory gene expression, and 3) by acting 
as ligands for PPARs, which are able to suppress pro-inflammatory gene expression via 
SUMOlyation-dependent transpression of NF-κB and AP-1 [154, 224, 225].  
 
Immunoregulatory properties of fatty acid derived-lipid mediators 
      Omega-3 (ω-3) and omega-6 (ω-6) PUFAs serve as essential dietary precursors to 
eicosanoids, which are potent bioactive lipid mediators involved in both the propagation and 
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resolution of inflammatory responses [167, 225]. Human leukocytes are typically rich in the 
ω-6 PUFA arachidonic acid (AA), representing ~ 20% of membrane phospholipid fatty acid 
content [221]. AA is therefore the predominant substrate for eicosanoid synthesis, giving rise 
to multiple lipid mediators with variable inflammatory properties, including prostaglandins 
(PGs), thromboxanes (TX), leukotrienes (LTs), and lipoxins (LXs). Whereas LXs exhibit 
anti-inflammatory and pro-resolving activity, PGs, TXs, and LXs are most commonly 
associated with pro-inflammatory responses, with PGE2 and LTB4 being two of the most well 
characterized subclasses.  In response to a wide variety of physical, chemical, hormonal, and 
inflammatory stimuli [226], AA is released from cell membrane phospholipids via hydrolysis 
by phospholipases such as phospholipase A2, allowing for COX-1 and COX-2-mediated 
formation of PG and TX precursors, as well as 5-LOX- mediated formation of LT precursors 
[221]. LTB4 binds G protein-coupled transmembrane receptors BLT1 and BLT2, inducing 
signaling to promote potent chemotaxis of certain T cell subsets, monocytes, and neutrophils, 
in addition to neutrophil granule release and ROS production [159-162]. Four E type 
prostanoid (EP1, -2, -3, -4) receptor subtypes
 
have been characterized that bind PGE2, each 
triggering the activation of different intracellular signaling pathways [226]. Although PGE2 is 
known to induce macrophage and dendritic activation and inflammatory mediator expression, 
it has also been shown to decrease expression of TNFα, IFNγ, IL-1β, and MCP-1 in LPS-
stimulated macrophages, suggesting that variation in EP receptor ligation may affect the pro-
inflammatory activity traditionally associated with this eicosanoid [226-230]. In addition, 
accumulating levels of PGE2 and PGD2 in macrophages gradually promote the synthesis of 
anti-inflammatory, pro-resolving lipoxins in a process termed eicosanoid class-switching 
[165]. LXA4 activates the LXA4 receptor (ALX), a G-protein coupled receptor, whose 
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signaling has been shown to block components of the p38 MAPK pathway and attenuate NF-
κB activation, resulting in reduced production of pro-inflammatory cytokines and 
chemokines [166]. ALX may also be activated by 15-epi-LXA4, an “aspirin-triggered 
lipoxin,” contributing to this common, non-steroidal drug’s anti-inflammatory benefits [231]. 
Aspirin (acetyl-salicyclic acid) induces acetylation of the COX2 active site, thereby altering 
its enzymatic activity to switch from PG precursor production, to that of 15-HpETE – a 
substrate for 5-lipoxygenase-mediated 15-epi-LXA4 formation [131]. Together, LXA4 –ALX 
signaling in known to reduce neutrophil recruitment and degranulation, while
 
promoting 
monocyte/macrophage migration and phagocytosis of apoptotic leukocytes and lymphocytes, 
overall promoting the resolution of inflammatory responses [131, 232].  
 ω-3 PUFAs also serve as precursors to anti-inflammatory, pro-resolving lipid 
mediators, including resolvins, protectins, and maresins. COX-2 and cytochrome P450 
mediate the formation of EPA-derived E series Resolvin E1 (RvE1) and E2 (RvE2), whereas 
formation of DHA-derived D series resolvins (RvD1-4) is dependent upon LOX activity 
[131]. RvE1 and D series resolvins bind the G-protein coupled receptors CMKLR1 and 
GPR32/ALX, respectively, resulting in suppression of dendritic cell and macrophage 
inflammatory cytokine production, reduced neutrophil recruitment, and stimulation of 
macrophage phagocytosis [131, 233]. RvE1 is also known to displace LTB4 by binding its 
receptor, BLT1, resulting in a dampening of LTB4-mediated pro-inflammatory activity [234]. 
Intraperitoneal injection of RvE1 into ob/ob mice was shown to improve markers of high-fat 
diet-induced hepatic steatosis and insulin resistance, as evidenced by reduced hepatic lipid 
accumulation, as well as increased mRNA expression of adiponectin, GLUT4, IRS-1, and 
PPARγ in WAT [235]. DHA can also give rise to 15-LOX-generated protectin D1, or 12-
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LOX-generated maresin 1, both of which share similar anti-inflammatory and pro-resolving 
effects of lipoxins and resolvins [236, 237]. 
 
Modulation of gene expression by fatty acids 
      In addition to serving as precursors to immunomodulatory eicosanoids, a variety of fatty 
acids and fatty acid derivatives have been shown to differentially modulate pro-inflammatory 
gene expression through 1) activation of TLR4-mediated NF-κB and AP-1, and 2) 
SUMOlyation-dependent transrepression of NF-κB and AP-1 by PPARγ [154, 224, 225]. A 
medium-chain saturated fatty acid (SFA) component of LPS, lauric acid, has been shown to 
trigger TLR4 signaling in RAW 264.7 macrophages, corresponding to increased NF-κB 
activation and COX-2 expression [238]. Myristic (14:0), palmitic (16:0), and stearic (18:0) 
SFAs have also been shown to induce IL-6 expression in macrophages, whereas unsaturated 
fatty acids (UFAs) have no effect [224]. Originally believed to directly ligate TLR4, recent 
findings suggest that SFAs indirectly trigger TLR4 signaling through modulation of the cell 
surface receptor orientation and spacing within lipid raft structures [239, 240]. The ability of 
SFA to modulate TLR4 has potentially significant implications within the context of obesity 
and T2DM, where increased levels of circulating FFAs and para-inflammation are commonly 
observed [129, 132, 180]. In mice, in vivo lipid infusion and high-fat diet feeding resulted in 
TLR4-dependent increases in NF-κB-DNA binding and TNF-α, IL-6, and MCP-1 mRNA 
expression in adipose, corresponding to greater impairments in skeletal muscle and WAT 
glucose sensitivity [224]. LPL-mediated lipolysis of TGRLs results in the release of FFA 
fractions that promote increased TNF-α and intracellular adhesion molecule (ICAM) 
expression, as well as elevated ROS production in human aortic endothelial cells (HAECs) 
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[241]. Treatment of LPS-stimulated human monocyte/macrophages with physiological 
concentrations of SFAs resulted in greater IL-6 and IL-8 mRNA and protein expression, 
which was at least partially attributable to SFA metabolism to ceramide, and activation of 
protein kinase C (PKC)-ζ and MAPKs Erk, JNK, and p38 [242]. Further, in human U937 
monocyte-derived macrophages, treatment of the SFAs palmitic and lauric acid resulted in 
significantly greater increases in the pro-atherogenic and lymphocyte migration inducing 
chemokine IP-10 mRNA, whereas UFAs oleic acid, EPA, linoleic acid, and AA had no 
effect. Palmitic acid also led to increased mRNA expression of COX-2, IL-8, MCP-1, and 
MIG, as well as greater NK-κB DNA binding activity when compared to untreated control 
cells [243]. 
 In contrast to pro-inflammatory transcriptional responses induced by SFAs, a variety 
of UFAs and UFA derivatives have been shown to inhibit pro-inflammatory gene expression 
by promoting PPARγ-mediated transpression of NF-κB and AP-1 [154]. Multiple ω3- and 
ω6-PUFAs and PUFA derivatives serve as ligands for PPARα, -β/δ, and -γ, which are 
members of the nuclear receptor superfamily of transcription factors that serve well-
characterized roles as master regulators of metabolic processes [244]. Upon ligand binding, 
PPARs heterodimerize with RXRs, allowing for PPAR-RXR binding to PPAR response 
elements (PPRE) within promoter regions of target genes, including those involved in 
mitochondrial and peroxisomal fatty acid β-oxidation in the liver (PPARα), fatty acid 
oxidation in skeletal muscle (PPARβ/δ), and activation of WAT fatty acid synthesis, storage, 
glucose homeostasis, and adipogenesis (PPARγ) [132, 244]. While anti-inflammatory roles 
for all PPAR subtypes have been reported, the most well-characterized is that of PPARγ, 
predominantly due to its ability to inhibit NF-κB- and AP-1-mediated pro-inflammatory gene 
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transcription via SUMOlyation-dependent transrepression, similar to that of LXR [154]. 
PPARγ is predominantly expressed in adipose tissue, adrenal gland, and spleen, and its 
expression is rapidly induced upon differentiation of human monocytes to macrophages [245, 
246]. In macrophages, endogenous PPARγ ligands include essential fatty acid metabolites 
such as 15-deoxy-∆12,14-prostaglandinJ2 (15d-PGJ2), and oxidized fatty acids 9-HODE and 
13-HODE, which are often found as components of oxidized LDL particles [244]. In 
addition, the insulin-sensitizing TZD class of antidiabetic drugs act as potent synthetic 
activators of PPARγ [189]. Upon ligand binding, PPARγ undergoes allosteric reconfiguration 
to reveal specific lysine residues that are targets for conjugation with SUMO1, which is 
dependent upon the activity of SUMO E3 ligase protein inhibitor of activated signal 
transducer and activator of transcription 1 (PIAS1). SUMOlyated PPARγ binds NCoR and 
SMRT-containing corepressor complexes on NF-kB and AP-1, preventing their dissociation, 
recruitment of coactivator complex, and transcriptional activation of target genes [154, 247]. 
Accordingly, PPARγ activation is known to suppress expression of TNFα, IL-15, MCP-1, 
vascular cell adhesion molecule 1 (VCAM1), and inducible nitric oxide synthase (iNOS) in 
LPS-stimulated macrophages in an NCoR-dependent transrepression [154]. In addition, 
recent findings have demonstrated that PPARγ activation primes primary human monocytes 
toward differentiation of alternatively activated M2 macrophages, which predominantly 
produce anti-inflammatory IL-4 and IL-13 cytokines over IFNγ and IL-1β [248]. PPARγ is 
also known to positively regulate transcriptional activation of PPRE-containing LXRα, 
resulting in greater ABCA1 activity and the addition LXR-mediated transrepression of pro-
inflammatory gene expression [249, 250]. Activation of PPARγ in endothelial and vascular 
smooth muscle cells has also been shown to result in inhibition of NF-κB phosphorylation 
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and transcriptional activity [251, 252]. Lastly, PPARγ activation in adipose tissue is 
associated with reduced adipocyte hypertrophy, leukocyte infiltration, pro-inflammatory 
cytokine secretion, circulating free fatty acids levels, and overall improvements in insulin 
sensitivity and adipose dysfunction [169, 253-255].  
 Together, fatty acid-rich lipid membranes serve as vital sources of potential 
immunomodulatory lipids with varying capacities to promote pro- and anti-inflammatory 
activity through a variety of mechanisms. The presence of elevated FFAs in obesity-related 
diseases, as well as the ability to shift fatty acid-mediated inflammatory activity through diet 
suggest that modulation of fatty acid consumption and endogenous metabolism may serve as 
a mechanism to modulate para-inflammation underlying chronic metabolic disease [221].         
 
The role of leukocyte cholesterol content in inflammation  
In addition to LPS and fatty acids, an additional factor linking acute and chronic 
inflammation is the regulation of leukocyte cholesterol flux. This is predominantly due to the 
fact that cholesterol serves as an essential structural component of lipid rafts, which are 
dynamic cholesterol-rich microdomains within the exoplasmic leaflets of the phospholipid 
bilayer of plasma membranes where transmembrane proteins and receptors reside – including 
PRRs such TLR4 [256]. Elevated levels of cellular cholesterol favor the formation of lipid 
rafts, and have been associated with increased pro-inflammatory responses in macrophages 
and T lymphocytes due to lowered cellular activation thresholds [124, 257, 258]. Given the 
significant role of these cell types in immunity and chronic disease, these findings have 
important implications for the physiological consequences of obesity.  
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 In line with its traditional atheroprotective role as an acceptor of lipids from arterial 
wall macrophage foam cells and peripheral tissues, a novel role for HDL has emerged in the 
regulation of leukocyte inflammatory potential via the modulation of cholesterol flux. The 
significance of this pathway has further been supported by the immunomodulatory functions 
of HDL-associated transporters, including ABCA1 and ABCG1 [123, 125, 258, 259]. This 
relationship may further uncover a dysfunctional HDL-leukocyte dynamic within the context 
of obesity and MetS – conditions associated with atherogenic dyslipidemia, chronic 
inflammation, and altered immunity [183, 260]. Therefore, the following section will review 
the evidence thus far elucidating the role of HDL-leukocyte interactions in relation to cellular 
inflammatory potential and cholesterol flux.   
   
Section 3 
HDL-leukocyte dynamics 
 
 
The role of cholesterol in hematopoiesis and leukocyte dynamics 
Cellular cholesterol availability and handling is also known to play a role in hematopoiesis, 
particularly in regards to maintenance of hematopoietic stem cells (HSC) and multipotent 
progenitor (MPP) populations [261]. Cholesterol is an essential component of cellular plasma 
membranes, and can be derived from either lipoprotein uptake or local synthesis, whereas 
cholesterol export mechanisms are known to maintain appropriate cellular cholesterol 
balance [262]. LXRα and LXRβ function as oxysterol-sensitive, ligand-activated 
transcription factors, which heterodimerize with RXR to increase expression of ABCA1 and 
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ABCG1, which serve to facilitate cholesterol efflux leukocytes to HDL. Mice lacking 
ABCA1 and ABCG1 display leukocytosis, a myeloproliferative disorder characterized by 
elevated leukocyte numbers – particularly monocytes. Abca1-/-Abcg1-/- mice have elevated 
levels of bone marrow leukocyte progenitors, and circulating monocytes and neutrophils in 
blood, which is attributable to increased cell proliferation due to hyper-responsiveness to 
hematopoietic growth factors IL-3 and GM-CSF [261]. Cell-surface IL-3 and GM-CSF 
receptors are integrated into cholesterol- and glycoprotein-rich lipid rafts within the cellular 
plasma membrane, which allow for enhanced receptor oligomerization and signaling, 
resulting in rapid HSC and progenitor proliferation in response to growth factor signaling 
[262, 263]. High cholesterol-feeding and low plasma HDL contributes to excess 
accumulation of cellular cholesterol, resulting in greater lipid raft formation, and greater 
responsiveness to proliferative cues, whereas elevated HDL levels have been shown to 
suppress HSC and MPP proliferation [123, 261, 262, 264]. Greater expression of genes 
involved in cholesterol metabolism has been observed in more primitive progenitors, 
corresponding to greater proliferative capacity, whereas expression of these genes decreases 
with subsequent differentiation [265-267]. In addition, leukocytes derived from acute 
myeloid leukemia patients display altered cholesterol metabolism, in that they take up more 
LDL, fail to repress cholesterol synthesis, and may have impaired cholesterol efflux, all 
together promoting greater proliferation and cell survival [267]. Overall, these findings 
suggest that disruptions in cellular cholesterol metabolism may favor expansion of myeloid 
lineage cells.       
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Role of ABCA1 and ABCG1 in leukocyte inflammation 
Leukocyte-specific ABCA1 and ABCG1 play important roles in atherosclerosis, 
inflammation, and immunity, as recent data suggests that ABCA1- and ABCG1-mediated 
redistribution of cellular lipids to HDL modulates cellular membrane and lipid raft 
composition in a manner that diminishes inflammatory potential of leukocytes [123, 257]. In 
addition to near depletion of plasma HDL-C levels, global deletion of ABCA1 resulted in 
accumulation of macrophage CE in Ldlr-/- mice, in addition to increased expression of 
scavenger receptors and chemotactic responses in vitro [268]. Further, Abca1-/-Ldlr-/- 
additionally exhibited exacerbated LPS-induced endotoxemia. Interestingly, increases in 
circulating inflammatory markers (MCP-1, IL-1β, macrophage colony-stimulating factor (m-
CSF)) were observed without increases in total WBC, or specific leukocyte subsets 
(lymphocytes, monocytes, neutrophils, eosinophils, or basophils) when compared to Ldlr-/- 
mice, suggesting an increased inflammatory potential of leukocytes without inducing 
hyperproliferation [268].   
Macrophage-specific ABCA1 deletion leads to impaired lipid efflux to apoA-I, in 
addition to increased membrane free cholesterol and lipid raft content when compared to WT 
macrophages [258]. Further, ABCA1-/- macrophages displayed greater expression of pro-
inflammatory cytokines (IL-6, IL-12p40, TNFα) in response to LPS, which was in part 
dependent upon TLR4/CD14-associated adaptor protein MyD88 signaling and NF-κB and 
MAPK pathways [258]. No changes were observed in plasma lipids, corresponding to other 
studies that show macrophage-specific ABCA1 has little impact on plasma HDL-C levels 
[269, 270]. Interestingly, increased free cholesterol accumulation in ABCA1-/- macrophages 
did not appear to induce ER stress despite greater inflammatory potential pathways [258].  
  53
As indicated above, much of the anti-inflammatory effects of ABCA1 and ABCG1 
appear to be due to alterations in plasma membrane lipid raft content. ABCA1 expression 
leads to significant redistribution of cholesterol and sphingomyelin from lipid rafts to non-
raft regions of cell membranes through its ATPase-related function [271]. ABCA1-mediated 
reductions in lipid raft content have been shown to increase ADAM17-mediated cleavage of 
TNF and TNF receptors, which may result in reduced TNFα signaling [272]. Lipid raft 
structure also affects TLR signaling, as TLR4 and MyD88/TRIF-mediated inflammatory 
gene expression was significantly increased in peritoneal macrophages isolated from 
ABCA1-/-, ABCG1-/-, and ABCA1-/-ABCG1-/- mice [259]. Loss of ABCG1 in CD4 T cells 
additionally increases total lipid raft content, resulting in enhanced TCR-mediated 
hyperproliferation [123]. ApoA-I-ABCA1 interactions have also been shown to trigger 
JAK2-mediated activation of STAT3, which can suppress LPS-induced pro-inflammatory 
gene expression of TNFα and IL-6 in macrophages [273, 274]. Interestingly, comparative 
analysis of mouse monocyte subsets revealed that ABCA1 expression is lower in 
inflammatory Ly6Chi blood monocyte populations, which yield greater pro-inflammatory 
activity in response to LPS and IFNγ when compared to Ly6Clo monocytes [275].  
 
The role of ABCA1 and ABCG1 in immunity 
The roles of ABCA1 and ABCG1 in modulating leukocyte activity have important 
implications for immunity. Myeloid cell-specific knockout of ABCA1 protected C57BL/6 
mice against Listeria monocytogenes infection, as characterized by reductions in liver 
damage, inflammation, and lipid accumulation when compared to wild type mice [276]. 
Further, deletion of ABCA1 increased LPS-induced macrophage chemotaxis (in vitro) and 
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migration in vivo, which corresponded to findings of increased hepatic 
monocyte/macrophage infiltration to clear infection more efficiently. Interestingly, Listeria 
monocytogenes infection in vitro caused reductions in ABCA1 protein in wild type 
macrophages, in addition to LXR target genes related to lipid metabolism, including ABCG1 
and apoE. (ABCA1 mRNA was not affected). These findings suggest that L. monocytogenes 
reduces ABCA1 as a compensatory mechanism to increase cellular free cholesterol and lipid 
raft content to increase cellular inflammatory potential to clear infection [276]. However, 
these findings differ from Kaplan et al. [277], who found that LPS increased ABCA1 mRNA 
and protein expression, whereas LPS had no effect on ABCG1 in THP-1 cells. In vivo, mice 
injected with LPS dose-dependently increased hepatic ABCA1 expression, whereas ABCG1 
and cholesterol 7α-hydroxylase (Cyp7α1) was reduced. Regulation of LPS-induced ABCA1 
expression appeared to be LXR-independent [277]. Similar findings were reported by 
Thompson et al. [278], where LPS induced ABCA1 protein and mRNA expression, whereas 
both LPS and the LXR-agonist T0901317 stimulated ABCA1-mediated efflux of cell-surface 
LPS as a potential mechanism to restore cellular homeostasis [278].  
 
The role of HDL in immunity 
Given that the anti-inflammatory properties of ABCA1 and ABCG1 are in part attributable to 
their capacity to efflux cellular cholesterol and LPS [123, 258, 278], their immunoregulatory 
activities are additionally dependent upon the presence of an extracellular lipid acceptor – or 
HDL [261]. As described in previous sections, HDL possesses various anti-inflammatory and 
immunoregulatory activities by serving as a carrier for oxidized lipid-neutralizing enzymes 
and bioactive lipid species [279]. In addition to these functions, HDL may alter inflammatory 
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responses through neutralization of LPS. This function is not exclusive to HDL, as other 
lipoproteins (including chylomicrons, VLDL, LDL) are capable of binding the bioactive lipid 
A portion of LPS within their phospholipid-rich surfaces, thereby preventing it from 
interacting with receptors molecules on LPS-responsive cells [280, 281]; however, LPS 
appears to preferentially bind to HDL in plasma [281, 282]. Lipoproteins serve an important 
function in expulsion of LPS from the body – which can occur via hepatic uptake and 
secretion into bile [280, 283] – as the turnover rates of LPS-bound lipoproteins are faster than 
the rates of dissociation of LPS from lipoproteins [284].  
Some studies suggest that the binding of LPS to HDL has profound effects in 
protecting against endotoxin-induced inflammation and shock. In C57BL6/CBA mice, 
Levine et al. [284] found that doubling the plasma HDL level by human ApoA-I transgenic 
expression or infusion of reconstituted HDL resulted in a 3- to 4-fold increase in survival 
from a lethal dose of LPS [284]. Lipoprotein-bound LPS has additionally been shown to lose 
its bioactivity in septic patients [281]. The LPS-neutralizing properties of HDL may be 
particularly important in obesity and MetS, where blood LPS levels are often found to be 
elevated, and may perpetuate metabolic dysfunction and inflammation [214, 216]. However, 
the low levels and dysfunctional nature of HDL – in addition to reduced expression levels of 
ABCA1 and ABCG1 – in these populations may fail to effectively sequester LPS, thereby 
further exacerbating disease progression.  
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Section 4 
The potential role of diet in modulating HDL-leukocyte 
dynamics 
 
 
Introduction 
 
Given the significant independent and interrelated roles of HDL function and leukocyte 
inflammation in obesity-related disease progression, modulation of HDL-leukocyte dynamics 
appears to be a novel and promising therapeutic target. While dietary therapies that promote 
weight loss are commonly prescribed to favor global improvements in metabolic dysfunction, 
the addition of functional foods that target specific physiological pathways may provide 
further benefit [279, 285]. Previous intervention studies conducted in our laboratory have 
demonstrated that dietary carbohydrate-restriction in conjunction with daily egg consumption 
promotes improvements in HDL profiles and inflammatory markers [286-290]. Therefore, 
we believe that this dietary strategy is a potential therapeutic candidate to favorably modulate 
the relationship between HDL function and the inflammatory potential of leukocytes.  
 
Carbohydrate restriction  
Carbohydrate-restricted diets (CRD), or consumption of approximately < 35% of 
kilocalories from carbohydrate sources [291], have been proven to be one of the most 
effective dietary strategies to promote weight loss and improve clinical parameters of MetS 
[292]. CRD have further been shown to effectively improve HDL profiles, elevated markers 
of inflammation, insulin resistance, and endothelial dysfunction.   
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Carbohydrate restriction and lipid metabolism 
Carbohydrate restriction induces a metabolic state that favors increases in plasma 
HDL-C and atheroprotective large, CE-rich HDL particles. Due to the body’s limited 
capacity to store carbohydrates in excess of oxidative metabolism, excess energy from CHO 
sources promotes hepatic de novo lipogenesis [293]. Greater glucose and insulin responses 
following CHO consumption results in the activation of 1) carbohydrate response element 
binding protein (ChREBP) and 2) SREBP-1c, respectively, resulting in transcriptional 
activation of numerous lipogenic genes, including acyl CoA carboxylase (ACC) and fatty 
acid synthase (FAS) [294, 295]. Increased hepatic lipogenesis results in increased packaging 
and secretion of large, TG-rich VLDL particles, which serve as preferred substrates for 
CETP-mediated transfer of CE from large (α-1) HDL particles to TGRL in exchange for TG, 
resulting in decreased HDL-C [291, 296, 297].  
By reducing dietary carbohydrate substrate, CRD have been shown to decrease de 
novo lipogenesis [298], plasma TG, as well as decrease total number of VLDL particles 
measured by nuclear magnetic resonance (NMR), with greater decreases observed in large 
and medium-sized VLDL. Although changes in CETP activity are typically not observed, 
CRD have been shown to increase plasma HDL-C concentrations and LCAT activity, 
corresponding to increases in large atheroprotecive HDL particles, with decreases in 
medium-sized, potentially pro-atherogenic HDL particles [289, 293, 299, 300]. Therefore, 
based on these findings, it appears that CRD-induced increases in HDL-C are most likely the 
indirect result of decreasing TGRL-TG, resulting in modulation of HDL remodeling to favor 
the formation of larger, more cholesterol-rich HDL particles.    
  58
Some evidence from animal studies suggests that the beneficial effects of CRD on 
MetS parameters may occur at the expense of the liver. In a hereditary hypertriglyceridemic 
rat model of MetS, high-sucrose feeding promoted VLDL secretion, down-regulated FFA 
oxidation, and increased de novo FFA synthesis from glucose, whereas the reverse was 
observed with high-fat feeding [301]. These changes corresponded to greater plasma TG and 
FFA in the sucrose group, as well as increased liver TG deposition in both fed and fasting 
states in the high-fat-fed animals [301]. While these data suggest that more data may be 
needed to properly assess the apparent benefits of carbohydrate-restriction in obesity and 
MetS, human studies suggest that carbohydrate restriction may benefit hepatic steatosis and 
MetS [302-304]. Further, carbohydrate-restriction was shown to be more effective in 
reducing liver TG than calorie restriction (-55% vs. -28%) in non-alcoholic fatty liver disease 
(NAFLD) subjects, despite similar weight loss between groups [305]. Additionally, a 12-
week hypocaloric CRD (12% carbohydrate, 59% fat, 28% protein) increased postprandial 
flow-mediated dilation (FMD) when compared to a hypocaloric low-fat diet (56% 
carbohydrate, 24% fat, 20% protein) in overweight men with moderate hypertriglyceridemia 
[306], thereby suggesting that CRD improve endothelial function.  
 
Carbohydrate restriction and inflammation 
In addition to improving parameters of HDL metabolism, CRD have also proven to an 
effective dietary strategy to reduce markers of inflammation in obese and MetS populations 
[190, 290]. In overweight men, carbohydrate-restriction (17% of energy from carbohydrates) 
effectively reduced plasma MCP-1 over the course of 12 weeks. When compared to a low-fat 
diet, a very-low carbohydrate diet (12% of energy from carbohydrate) was more effective at 
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reducing plasma levels of TNFα, IL-6, IL-8, MCP-1, E-selectin, ICAM-1, and plasminogen-
activator inhibitor-1 (PAI-1) in overweight men and women. Further, the CRD reduced 
serum SFA in both TG and CE fractions [190], which may further contribute to anti-
inflammatory effects. In MetS subjects of the Functional Genomics and Nutrition 
(FUNGENUT) cohort, a 12-week diet of high postprandial insulin response up-regulated 
genes related to tissues stress, and cytokine/chemokine-related signaling in subcutaneous 
adipose tissue, whereas a 12-week diet consisting of low postprandial insulin response foods 
down-regulated expression of genes related to insulin signaling and apoptosis [307]. 
Together, these findings suggest that CRD are effective therapeutic strategies for mitigating 
obesity-related inflammation in high-risk population such as MetS.  
 
Eggs 
In addition to the beneficial changes in HDL and inflammation from carbohydrate restriction 
described above, daily consumption of whole eggs has similarly been shown to confer benefit 
to HDL profiles and plasma inflammatory markers [286-290]. Eggs contain numerous 
bioactive components, including phospholipids, antioxidant carotenoids, and cholesterol 
[288, 308]. Together, the combination of these nutrients appears to have the capacity to 
modulate HDL metabolism and inflammation.  
 
Effects of egg intake on HDL metabolism and reverse cholesterol transport  
Many therapeutic strategies aimed at reducing cardiovascular disease risk have 
targeted RCT – one the primary mechanism by which HDL protects against atherosclerosis 
development [116]. Numerous studies have investigated the effects of egg intake on various 
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parameters of RCT [286, 289, 309-311]. Egg consumption has consistently been shown to 
increase plasma HDL-C – particularly in conjunction with carbohydrate restriction [286, 
289]. In addition to increased HDL-C, egg intake promotes greater increases in the number of 
large CE-rich HDL particles and LCAT activity when compared to intake of yolk-free egg 
substitute, while simultaneously decreasing number of medium-sized HDL particles [289, 
312, 313]. Together, findings from these studies suggest that whole egg intake favorably 
promotes HDL function and RCT, and may therefore reduce the risk and severity of 
atherosclerosis.    
The initial step of RCT involves the efflux of cellular cholesterol to HDL [19]. In 
healthy men, consumption of 2 eggs per day during a 24-day National Cholesterol Education 
Program (NCEP) Step I diet (<30% fat, <10% saturated fat) increased cholesterol efflux from 
Fu5AH cells to subject serum when compared to an egg-free diet. Conversely, egg intake had 
no effect on cholesterol efflux during consumption of an oleic acid-rich diet (22% of energy) 
[309]. Further, the effects of egg intake appear to be a result of habitual consumption, as a 
single-dose egg meal does not appear to affect postprandial cholesterol efflux in healthy men 
[310]. Murine macrophage-like J774 cells incubated with postprandial serum following 
consumption of 1, 2, or 4 eggs had no effect on cellular total, free, or esterified cholesterol. 
However, cellular free cholesterol was slightly higher when comparing all egg groups 
combined to the 0-egg meal [310].  
Egg intake has additionally been shown to alter the activity of proteins involved in 
HDL metabolism and RCT, including LCAT and CETP. Intake of 3 eggs per day during 
carbohydrate restriction has been shown to increase LCAT activity in overweight men [289], 
as well as men and women with metabolic syndrome [286]. While it remains controversial as 
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to whether increased LCAT activity is beneficial, some studies suggest that LCAT promotes 
RCT and reduces atherosclerosis [314]. In addition, CETP activity was shown to be 6% 
higher in healthy male subjects following a 24-day diet of 4 eggs when compared to intake of 
0, 1, or 2 eggs per day (combined) [310]. Although high CETP activity has been implicated 
development of atherosclerosis due to the transfer of HDL-cholesterol to apoB-containing 
lipoproteins, CETP has also been shown to be important for macrophage RCT and HDL-
derived cholesterol excretion in human and animal models [315, 316].  
Egg feeding has additionally been shown to promote sterol excretion – potentially due 
to a combination of decreased absorption and increased RCT [311]. In Sprague-Dawley rats, 
egg-enriched diets increased fecal neutral sterol and bile acid concentrations, as well as 
hepatic mRNA expression of LDL-receptor, cholesterol 7α-hydroxylase, and LCAT when 
compared to egg-free control. Further, egg feeding blunted increases in plasma total and 
LDL-cholesterol, as well as liver triglyceride and cholesterol levels that were observed in a 
pure cholesterol-fed group, while also promoting greater increases in plasma HDL-C. These 
observations corresponded to decreased apoB and increased apoA-I [311]. Overall, findings 
from the studies presented above suggest that egg intake favorably promotes RCT, and may 
therefore reduce cardiovascular disease risk.     
 
Egg intake and leukocyte cholesterol  
Egg intake has similarly been shown to modulate leukocyte mRNA expression of LDL-R and 
3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG CoA Red) – the rate-limiting enzyme of 
cholesterol synthesis. Mononuclear cell HMG CoA Red activity was reduced within 2 hours 
of consuming 4 hard boiled eggs (~1g cholesterol) in healthy men, whereas depletion of 
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circulating cholesterol levels by plasmapheresis led to a two-fold increase in activity in 
monocytes [317]. Further, daily intake of whole eggs during carbohydrate restriction reduced 
HMG CoA Red and LDL-R mRNA expression in overweight men, whereas subjects 
consuming yolk-free egg substitute during carbohydrate restriction displayed increases in the 
expression of both genes [318]. These findings indicate that both carbohydrate restriction and 
egg intake are capable of modulating leukocyte cholesterol flux.  
 
Eggs and Inflammation  
Eggs contain a number of dietary factors with the potential to promote pro- and anti-
inflammatory pathways. Egg white-derived hen egg lysozyme has been shown to reduce 
intestinal inflammation in an experimental model of colitis [319], whereas egg yolk serves as 
a rich, bioavailable source of antioxidant carotenoids lutein and zeaxanthin [320]. Eggs are 
also a good source of bioactive phospholipids – particularly phosphatidylcholine (PC) [321, 
322]. While PC is known to have anti-inflammatory properties [323-325], PC has also been 
shown to promote gut microflora-mediated production of trimethylamine-N-oxide (TMAO) – 
a PC metabolite associated with an increased risk of adverse cardiovascular events [326]. 
Egg yolk is also a rich source of cholesterol, which can be cytotoxic in high doses [327]; 
however, adverse effects of dietary cholesterol are largely dependent on intestinal cholesterol 
absorption. Intestinal cholesterol absorption is highly variable amongst individuals, both 
within and between populations of different health statuses. While intestinal cholesterol 
absorption can range from 15% to 85% in healthy individuals [289, 328], obese [329] T2DM 
[330] and metabolic syndrome [331] subjects tend to have lower rates of fractional 
cholesterol absorption compared to healthy controls. Decreased capacity to absorb 
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cholesterol is often coupled with increased endogenous cholesterol synthesis, which most 
likely contributes to the dyslipidemias observed in these populations [332]. 
Multiple studies have demonstrated that habitual egg consumption can alter markers 
of inflammation, with effects varying across populations and metabolic disease status. In a 
subset of older adult (over 60 years old) taking cholesterol-lowering medication, 
consumption of 2 or 4 eggs per day for 4 weeks did not alter CRP [333] - an acute phase 
protein that is a strong predictor of cardiovascular disease risk [43]. However, in overweight 
men consuming an ad libitum carbohydrate-restricted diet for 12 weeks, the addition of three 
eggs per day resulted in decreases in plasma CRP [290]. Beneficial reductions in CRP were 
not observed in overweight men consuming an equivalent amount of yolk-free egg substitute, 
although pro-inflammatory MCP-1 was reduced in this group. Both egg and egg substitute 
groups displayed increases in adiponectin – an adipose-derived protein with anti-
inflammatory and insulin-sensitizing properties [334]; however, changes in the whole egg 
group (+21%) were greater than those in the egg substitute group (+7%). Daily consumption 
of whole egg and egg substitute during carbohydrate restriction had no effect on plasma 
levels of other inflammatory markers in this population, including pro-inflammatory soluble 
vascular cell adhesion molecule 1 (sVCAM-1), soluble intracellular adhesion molecule 1 
(sICAM-1), TNFα, and IL-8 [290]. These data suggest that whole egg and egg white intake 
during carbohydrate restriction promotes reductions in systemic inflammation, with whole 
egg intake conferring slightly greater benefit.  
 Egg consumption has similarly led to improvements in circulating plasma 
inflammatory markers in men and women classified with metabolic syndrome [287]. While 
consuming a moderate carbohydrate-restricted diet, the addition of 3 eggs per day led to 
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decreases in TNFα and serum amyloid A (SAA), whereas no changes in these compounds 
were observed in MetS subjects consuming a yolk-free egg substitute. Differing from the 
results observed in overweight men, no changes in CRP or adiponectin were observed in 
either egg group in the MetS population, nor were changes observed in sVCAM-1, sICAM-1, 
IL-6 or anti-inflammatory IL-10 [287].   
 While numerous studies have demonstrated beneficial effects of eggs on markers of 
inflammation, additional evidence suggests that degree of insulin sensitivity is an important 
factor in determining the response to egg feeding. Tannock et al. [335] found that 
consumption of 4 eggs per day for 4 weeks increased CRP and SAA in lean insulin-sensitive 
subjects following an American Heart Association–NCEP step 1 diet, whereas no changes in 
these inflammatory markers were observed in lean or obese insulin resistant subjects. These 
observations may be due to the fact that lean and obese insulin resistant patients have a 
diminished capacity to absorb dietary cholesterol [336, 337], which may promote tissue 
inflammation if compensatory mechanisms to mitigate cholesterol-mediated cytotoxicity are 
inadequate [338].   
Egg intake may also increase inflammatory gene expression in PBMCs by promoting 
cellular cholesterol loading, which can enhance leukocyte-mediated inflammatory responses 
[124]. The relationship between cellular cholesterol flux and inflammatory potential may 
have profound effects on both atherosclerosis development and immunity [124, 259]. 
Evidence for the role of dietary cholesterol in leukocyte-mediated inflammation and 
immunity has been demonstrated by Perez-Guzman et al. [339], where individuals 
consuming 800 mg cholesterol/day increased the sterilization rate of sputum cultures in 
pulmonary tuberculosis patients. However, in populations with impaired immunity, such as 
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those who are obese [183], egg intake during carbohydrate-restriction may rectify 
dysregulated HDL-leukocyte dynamics, as this intervention favors global metabolic 
improvements and reduction in factors that negatively regulate anti-inflammatory ABCA1 
and ABCG1 expression, such as TNFα and CRP [287, 292]. Taken together, the extent by 
which egg intake influences leukocyte inflammation in relation to immune response and 
metabolic disease outcomes remains to be determined.  
 
Conclusions 
The data presented in this review highlights a significant role for HDL function and 
leukocyte inflammation in pathogenesis of obesity-related disease. These findings further 
support the potential for dietary modulation of HDL-leukocyte dynamics, which hold 
significant implications for the therapeutic role of diet in ameliorating chronic disease risk 
and progression.   
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Chapter 3 
Intervention Study Overview 
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Introduction 
Based on the evidence presented in the previous chapter, it is reasonable to predict that diet 
can exert effects on the dynamics between leukocyte inflammation, cholesterol flux, and 
HDL function. The relationship between diet and these physiological processes may be 
particularly relevant for individuals at high risk for metabolic disease and immune 
dysfunction, such as those classified with MetS. Based on results from previously conducted 
intervention studies in our laboratory [1-5], we hypothesize that egg intake during 
carbohydrate restriction may modulate these parameters in MetS.  
Therefore, in order to assess the specific aims outlined in the introduction, the 
following intervention was performed as described below. This intervention was similarly 
designed to assess the clinical outcomes and implications on parameters of MetS, lipoprotein 
sizes, insulin resistance, and carotenoid status. The findings from these objectives have 
recently been published [4-6].  
 
Experimental Design 
 
Subject recruitment  
Subjects were recruited from the University of Connecticut population and surrounding 
communities, with the goal of recruiting 40 men (n = 20) and women (n = 20). Inclusion 
criteria was defined as I) being between the age of 30-70 years old, and II) classification with 
MetS as defined by the NCEP:ATPIII criteria [7]. MetS parameters are presented in Table 
3.1. Individuals were excluded from participation if they had a personal history of diabetes, 
stroke, cancer, liver, renal, or heart disease, endocrine disorder, or any known inborn errors 
of metabolism; if they were pregnant or lactating; if they had experienced weight loss of 
>10% of body weight in preceding 12 weeks; if they were taking any glucose-lowering 
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prescriptions or supplements; if they had fasting TG > 500 mg/dL, fasting glucose > 126 
mg/dL, resting BP > 140/90 mmHg; or an allergy to eggs. Eligibility for participation was 
determined following a fasted screening session, in which MetS parameters will be assessed.  
 
Table 3.1 NCEP:ATP III criteria for MetS  
 
MetS Parameters 
Waist circumference  
 Men ≥ 102 cm 
 Women ≥ 88 cm 
Fasting triglycerides  
  ≥ 150 mg/dL 
Fasting HDL-C  
 Men  ≤ 40 mg/dL 
 Women ≤ 50 mg/dL 
Fasting glucose  
  ≥ 100 mg/dL 
Resting blood pressure  
 Systolic ≥ 130 mmHg 
 Diastolic ≥ 85 mmHg 
 or  
 Taking blood pressure medication 
 
Dietary Intervention 
We conducted a 12-week, parallel, single-blind intervention study in which subjects were 
instructed to follow a CR diet (25-30% of total calories), in addition to consuming either 3 
whole eggs/day (EGG group) or the equivalent amount of egg yolk-free egg substitute (SUB 
group). An overview of the study intervention is depicted in Figure 3.1. EGG and SUB 
group assignment was determined randomly, and subjects were matched based on gender, 
age, and BMI following qualification for the study by screening. Subjects were not informed 
of their egg group assignment throughout the intervention; therefore, subjects were asked to 
refrain from eating any other egg products outside of what was provided to them during the 
study. Both whole egg and egg substitute products were commercially available, liquid egg  
  
Figure 3.1 Overview of study intervention
products (Sysco). Subjects were provided with egg products on a bi
containers. Ingredients in the whole egg product included: whole eggs, citric acid (to 
preserve color), and 0.15% water (added as
substitute product included: egg whites (99%), less than 1% vegetable gums (xanthan and 
guar gum) and β-carotene to provide color. The nutrient composition of both egg products is 
provided in Table 3.2. In addition to the dietary prescription, subjects were asked to maintain 
all medication, supplement, and exercise doses and regimens. 
Table 3.2 Egg product nutrient composition
 
Nutrient  
Energy, kcal  
Carbohydrates, g  
Protein, g  
Total fat, g  
Saturated fat, g  
Cholesterol, g  
 
1Nutrient composition is representative of a daily serving of each egg product (1/2 cup). 
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-weekly basis in coded 
 a carrier for citric acid). Ingredients for the egg 
 
1 
Whole egg (EGG)  Egg substitute (SUB)
186  60
0  2 
16  14
12  0 
4  0 
534  0 
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Baseline characteristics 
As described above, subjects were randomly assigned to either the EGG or SUB group on the 
basis of gender, age, and BMI. Additional baseline characteristics are presented in Table 3.3. 
No significant differences were observed between EGG and SUB groups in any parameter.  
Table 3.3 Baseline characteristics of study subjects 
 
 EGG  SUB  P value 
Gender, n      
 Men  7  5  - 
Women 13  12  - 
Age, y 50.6 ± 8.5  50.9 ± 8.3  0.894 
Body weight, kg 87.3 ± 20.2  85.6 ± 16.2  0.765 
Body mass index (BMI), kg/m2 30.4 ± 5.5  30.6 ± 5.1  0.926 
Waist circumference, cm      
 Total  105.0 ± 11.7  102.9 ± 11.7  0.599 
 Men  113.1 ± 9.6  104.9 ± 17.5  0.320 
Women 100.6 ± 10.6  102.1 ± 9.3  0.715 
Blood pressure      
 Systolic, mmHg 119.3 ± 14.3  117.9 ± 15.2  0.773 
 Diastolic, mmHg 80.5 ± 9.7  81.1 ± 9.9  0.836 
 Taking BP medication, n 4  5   
Total cholesterol, mg/dL 192.4 ± 30.4  200.5 ± 38.5  0.477 
LDL-C, mg/dL 114.2 ± 29.1  122.0 ± 35.1  0.468 
HDL-C, mg/dL      
 Total 49.9 ± 14.3  50.1 ± 13.8  0.981 
 Men  38.0 ± 5.0  36.4 ± 9.8  0.781 
 Women 56.4 ± 13.5  55.8 ± 11.0  0.899 
Triglycerides, mg/dL 140.9 ± 58.0  142.4 ± 63.5  0.938 
Glucose, mg/dL  96.8 ± 14.5  97.5 ± 12.0  0.871 
HOMA-IR 2.3 ± 2.2  1.7 ± 1.0  0.242 
CRP, mg/L  0.35 ± 0.35  0.49 ± 0.60  0.374 
Total cholesterol, HDL-C, triglycerides, and glucose were measured by Cobas c 111 analyzer by 
enzymatic assay as described by Blesso et al [4]. HOMA-IR was calculated using insulin values 
measured by ELISA [4]. P value represents independent t-test comparisons between EGG vs. SUB 
groups.   
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Dietary compliance 
Subjects were asked to complete 5-day diet records at baseline, week 6, and week 12 of the 
intervention to assess dietary intake and compliance. Subjects received personalized dietary 
guidelines based on estimated energy expenditure, in addition to bi-weekly diet counseling 
and weigh-ins. Egg product compliance was assessed by return of empty egg containers 
provided in the previous dispersement, as well as by a daily egg compliance questionnaire. 
Daily average nutrient intakes for each group are presented in Table 3.4 and Figure 3.2. 
While all subjects experienced similar changes in macronutrient intake, differences were 
observed between groups in intake of egg yolk-derived nutrients cholesterol and choline. 
 
Summary of clinical outcomes 
In addition to the objectives outlined by this dissertation, this intervention was previously 
implemented to determine the effects of egg intake during moderate carbohydrate restriction 
on the clinical parameters of MetS, in addition to atherogenic lipoprotein profiles and 
carotenoid status. Notably, when compared to egg substitute intake, whole egg consumption 
induced more favorable effects on plasma HDL-C, lipoprotein size profiles, plasma 
inflammatory markers, insulin resistance and plasma and lipoprotein carotenoids, despite 
similar degrees of weight loss (~4% of body weight). Therefore, the findings presented in the 
subsequent chapters are within the context of these previously reported observations [4-6]. 
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Table 3.4 Average daily nutrient intake  
 
 Baseline  Week 6  Week 12  P value 
Energy, kcal/day        
 EGG 1943 ± 520a  1597 ± 341b  1537 ± 419b  < 0.0001 
SUB 2121 ± 310a  1603 ± 670b  1560 ± 566b   
Carbohydrate, % en        
 EGG 42.7 ± 6.3a  30.4 ± 8.1b  27.6 ± 10.1b  < 0.0001 
 SUB 38.8 ± 8.2a  28.0 ± 7.3b  29.1 ± 9.1b   
Fat, % en        
 EGG 37.3 ± 5.9a  44.1 ± 7.0b  46.0 ± 8.2b  < 0.0001 
 SUB 40.2 ± 6.8a  45.1 ± 7.7ab  45.4 ± 6.7b   
Protein, % en        
 EGG 17.3 ± 3.0a  22.7 ± 4.9b  23.2 ± 4.1b  < 0.0001 
 SUB 17.3. ± 3.1a  25.7 ± 5.0b  24.0 ± 4.2b   
Cholesterol, mg/day        
 EGG 359.9 ± 177.7a  692.6 ± 103.9b#  740.8 ± 139.7b#  < 0.001 
 SUB 344.9 ± 133.1a  219.9 ± 123.1b  213.4 ± 83.3b   
Choline, mg/day         
 EGG 332.1 ± 127.4a  503.8 ± 90.7b#  505.5 ± 113.3b#  < 0.05 
 SUB 350.1 ± 90.3a  278.2 ± 120.4ab  247.8 ± 99.9b   
Dietary data was collected from 5-day diet records collected at each time point, then analyzed by 
Nutrition Data System for Research (NDSR). All data are presented as mean ± SD. EGG: n = 19; 
SUB: n = 17. P values represent significance for time effects for all subjects determined by two-way 
repeated measures ANOVA. Different subscripts within each row represents differences between 
means as determined by post-hoc multiple comparisons with Bonferroni correction (P < 0.05). 
#Indicates significant time point differences between EGG and SUB group (P < 0.001).   
 
 
Figure 3.2 Average daily macronutrient intake 
 
 
CHO FAT PTN
0
50
100
150
200
250
Week 0
Week 6
Week 12
***
g/
da
y
Changes in total grams of dietary 
carbohydrate (CHO), fat (FAT) and 
protein (PTN) throughout the 
intervention. Data from all subjects 
are presented together. ***P < 
0.0001 represented significance 
changes over time as determined by 
repeated measures ANOVA. 
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Abstract  
We recently demonstrated that daily whole egg consumption during moderate carbohydrate 
restriction leads to greater increases in plasma HDL-cholesterol (HDL-C) and improvements 
in HDL profiles in metabolic syndrome (MetS) when compared to intake of a yolk-free egg 
substitute. We further investigated the effects of this intervention on HDL composition and 
function, hypothesizing that the phospholipid species present in egg yolk modulate HDL 
lipid composition to increase the cholesterol-accepting capacity of subject serum. Men and 
women classified with MetS were randomly assigned to consume either 3 whole eggs (EGG, 
n = 20) per day or the equivalent amount of egg substitute (SUB, n = 17) throughout a 12-
week moderate carbohydrate-restricted (25-30% of energy) diet. Relative to other HDL 
lipids, HDL-cholesteryl ester (CE) content increased in all subjects, with greater increases in 
the SUB group. Further, HDL-triglyceride (TG) content was reduced in EGG group subjects 
with normal baseline plasma HDL-C, resulting in increases in HDL-CE/TG ratios in both 
groups. Phospholipid analysis by mass spectrometry revealed that HDL became enriched in 
phosphatidylethanolamine in the EGG group, and that EGG group HDL better reflected 
sphingomyelin species present in the whole egg product at week 12 compared to baseline. 
Further, macrophage cholesterol efflux to EGG subject serum increased from baseline to 
week 12, whereas no changes were observed in the SUB group. Together, these findings 
suggest that daily egg consumption promotes favorable shifts in HDL lipid composition and 
function beyond increasing plasma HDL-C in MetS.  
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Introduction 
HDL is a key cardioprotective biomarker in obesity-related metabolic diseases, including 
cardiovascular disease (CVD) and metabolic syndrome (MetS) [1]. The primary mechanism 
by which HDL promotes cardiovascular health is thought to be through mediating the 
acquisition of lipids from macrophage foam cells within the arterial wall for participation in 
reverse cholesterol transport (RCT) [2], while antithrombotic, anti-inflammatory, and 
antioxidant properties of HDL confer further protection against atherosclerosis [3]. It is well 
recognized, however, that HDL function is impaired under inflammatory conditions 
associated with obesity, and that standard clinical measures of steady-state plasma HDL-
cholesterol (HDL-C) often fail to capture the true atheroprotective - or even atherogenic - 
potential of circulating HDL particles [3, 4]. Therefore, therapeutic strategies aimed at 
enhancing HDL-mediated cardioprotection should target mechanisms that go beyond simply 
increasing HDL-C, and rather improve the quality of HDL as a lipid acceptor [5, 6]. 
The capacity of HDL to facilitate cellular cholesterol efflux is differentially affected 
by the diverse, heterogeneous nature of HDL size and structure, as well as protein and lipid 
composition [6]. While various HDL components and pathways have been targeted, 
modulation of HDL lipid composition – particularly the HDL-phospholipid (HDL-PL) 
fraction – is an emerging and promising approach to improving HDL function [7, 8]. In the 
majority of circulating HDL, phospholipids represent ~ 45-50% of total lipids [9], with 
predominant phospholipid classes including phosphatidylcholine (PC; ~80%), sphingomyelin 
(SM; ~10%), phosphatidylethanolamine (PE; ~3%), lysophosphatidylcholine (LysoPC; ~1-
2%) and phosphatidylinositol (PI; ~1-2%) [10, 11].  
  101
Total HDL-PL, as well as the distribution of HDL phospholipid classes, has been 
related to CVD risk and severity [12, 13], and can differentially affect the lipid-accepting 
capacity of HDL [8, 14]. Greater enrichment of HDL in phospholipids – such as PC and SM 
– has also been associated with a greater lipid-accepting capacity of HDL and/or human 
serum; however, the extent by which different phospholipid classes can promote efflux may 
be variable across cellular models and efflux pathways mediated by ATP-binding cassette 
transporter A I (ABCA1), ATP-binding cassette transporter G I (ABCG1), scavenger 
receptor B I (SR-BI), or aqueous diffusion [7, 8, 15].  
Dietary intake of phospholipids derived from soy, safflower, dairy, marine, and egg 
sources are known to favorably modulate plasma lipid levels in both humans and animal 
models [16-20]; however, few studies have investigated how intake of phospholipid-rich 
foods or supplements affect the relative distribution HDL-PL classes or lipid-accepting 
functions. Dietary phospholipids are known to be highly bioavailable (>90%), can be 
partially absorbed intact in the intestine, and are preferentially incorporated into HDL 
following ingestion [21, 22]. Of all food sources to favorably modulate HDL-PL distribution 
and particle function, eggs represent one of the most promising candidates, since egg yolk is 
one of the richest dietary sources of PC, PE, and SM [23, 24]. Previous studies in our 
laboratory have demonstrated that consumption of 3 eggs per day as part of a carbohydrate-
restricted diet improves atherogenic lipoprotein profiles and increases plasma HDL-C in 
overweight men [25] and men and women with MetS [26, 27] to a greater extent when 
compared to intake of a yolk-free egg substitute. In MetS, beneficial changes from whole egg 
intake included greater increases in large HDL particles, HDL and LDL diameters, and 
lecithin–cholesterol acyltransferase (LCAT) activity, as well as greater reductions in 
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atherogenic large and medium VLDL particles when compared to the intake of egg substitute 
[26]. These findings are significant since individuals with MetS can have dysfunctional HDL 
[28] and a 2-fold increased risk of developing CVD [29]. Therefore, the aim of this study was 
to determine whether improvements in HDL profiles from egg intake correspond to changes 
in HDL lipid composition and the cholesterol-accepting capacity of HDL. We hypothesized 
that daily consumption of phospholipid-rich egg yolk for 12 weeks would modulate HDL-PL 
distribution to reflect egg-derived phospholipid species, corresponding to greater cholesterol 
efflux to subject serum.   
 
Materials and Methods 
Study design and subjects 
Experimental design and subject characteristics have previously been described [26, 27]. 
Briefly, 37 subjects (25 women; 12 men) classified with MetS were recruited to participate in 
a 12-week parallel, randomized, single-blind diet intervention. Eligibility for participation 
was dependent upon subjects falling within the age range of 30-70 years old, meeting the 
National Cholesterol Education Program Adult Treatment Panel III (NCEP:ATP III) revised 
criteria for MetS [30], and having no clinical diagnosis of chronic/metabolic disease [26, 27]. 
During the 12-week study, subjects were instructed to follow an ad libitum moderate 
carbohydrate-restricted diet (25-30% of energy from carbohydrates) in addition to consuming 
either 3 whole eggs (EGG group) or the equivalent amount of egg yolk-free egg substitute 
(SUB group) each day. The egg substitute product consisted of egg whites (99%), <1% 
xanthan and guar gums, beta-carotene for color, and provided 0 mg of cholesterol, whereas 
the daily serving of whole egg contained 534 mg of cholesterol. Dietary analysis and nutrient 
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composition of both egg products have been reported in greater detail elsewhere [26, 27]. 
This study was approved by the University of Connecticut Institutional Review Board; 
Protocol #: H10-173.   
 
Plasma and serum collection  
Fasting plasma and serum samples were collected at baseline and week 12. Plasma was 
obtained following blood collection into EDTA-coated tubes and centrifugation at 2200 x g 
for 20 minutes at 4°C. A preservative cocktail (1 ml/L sodium azide, 1 ml/L 
phenylmethylsulfonyl fluoride, and 5 mL/L aprotinin) was added to plasma prior to storage. 
Serum was obtained following collection of blood into anticoagulant-free tubes and 
processed under sterile conditions. Both plasma and serum were aliquoted and stored at -80° 
C until analysis.  
 
Plasma lipids and body weight  
Fasting plasma HDL-C, total cholesterol (TC) and triacylglycerides (TG) were measured by 
enzymatic methods using a Cobas c 111 clinical analyzer (Roche Diagnostics, Indianapolis, 
IN), as previously described [26]. LDL-C was estimated by the Friedewald equation [31]. 
Body weight was assessed biweekly from baseline to week 12.   
 
Isolation of LDL and HDL subfractions from plasma 
LDL (d = 1.019-1.063 g/mL) and HDL subfractions (d =1.063-1.21 g/mL) were isolated 
from EGG (n = 19) and SUB (n = 15) subject plasma at baseline and week 12 by sequential 
ultracentrifugation as previously described [27]. Plasma yields from 3 subjects were not 
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adequate to perform isolation. Plasma density was first adjusted to 1.019 g/mL with KBr and 
centrifuged at 42,000 rpm for 19 hours to remove VLDL and IDL fractions (d < 1.019 g/mL) 
using an Optima LE-80K ultracentrifuge. The remaining plasma fractions was sequentially 
adjusted to appropriate densities to isolate LDL (d = 1.019-1.063 g/mL) and HDL (d =1.063-
1.21 g/mL) with KBr, then layered beneath corresponding KBr-based density solutions [32] 
in Quickseal tubes (Beckman Coulter). LDL and HDL subfractions were isolated by 
centrifugation for 3 hours at 60,000 rpm in a vertical vTi-65 rotor. LDL was used for 
acetylation experiments described below, whereas HDL was then dialyzed for 24 hours 
(0.9% NaCl, 0.01% Na2EDTA, pH 7.4), aliquoted, and stored at -80° C for further analysis 
of lipid components. 
 
Analysis of HDL lipid components  
Phospholipid (PL), free cholesterol (FC) (Wako Chemicals, Richmond, VA), TC and TAG 
(Pointe Scientific, Canton, MI) content of HDL subfractions (d = 1.063-1.21) was determined 
by commercially available reagent kits according to the manufacturer’s instructions. 
Cholesteryl ester (CE) content was calculated as (TC - FC) x 1.67.  
 
Analysis of HDL and egg product phospholipid classes and associated species  
Quantification of PC, LysoPC, PE, PI, and SM species in HDL samples and egg products 
was performed as described by Sorci-Thomas et al. [33]. Briefly, egg product and HDL lipids 
were extracted by the Bligh-Dyer method [34] containing internal standards, evaporated 
under an argon stream, and dissolved in chloroform/methanol (2:1). Lipid extracts were 
injected onto a 3.9 x 200 mm Waters µPorasil column (10 µm particle size) and analyzed by 
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tandem mass spectrometry utilizing a Finnigan TSQ Quantum Discovery Max mass 
spectrometer (MS/MS). Data for each phospholipid class in egg products are presented mg/g 
of egg protein or mole-percent (mol%) of total phospholipids. Data for HDL phospholipid 
classes are presented as mol%. Percent homology of phospholipid molecular species for the 
EGG group was calculated as: [HDL molecular species (nmol) identified in both HDL and 
egg product/Total HDL molecular species (nmol)] x 100. Phospholipid species homology of 
the SUB group was similarly calculated by identifying the percentage of total HDL species 
(nmol) that were identified in the egg substitute product. 
 
LDL Acetylation  
LDL was isolated from combined fasting plasma samples from two healthy donors by 
sequential ultracentrifugation, as described previously [27]. Following isolation, LDL was 
dialyzed (0.15 M NaCl) for 24 hours at 4°C. Protein content was measured by bicinchoninic 
acid (BCA) assay (Thermo Scientific) modified to contain 0.2% sodium dodecyl sulfate 
(SDS) as recommended by the manufacturer for measurement of lipoprotein samples. The 
LDL sample was added in equal parts to a saturated sodium acetate solution with continuous 
stirring in an ice water bath while protected from light. Acetic anhydride was then slowly 
added over 1 hour (1.5 µl/mg LDL protein). The acetylated-LDL (acLDL) solution was 
dialyzed (0.15M NaCl, 0.3 mM EDTA, pH 7.4) for 24 hours at 4°C then filter-sterilized for 
use in cholesterol efflux assays.  
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Cholesterol efflux assays  
RAW 264.7 macrophages were used to conduct cholesterol efflux assays for a subset of 
subjects. 24 hours after seeding on 12-well plates, cells were loaded with 100 µg/ml acLDL 
and 0.5 µCi [1,2-3H(N)]cholesterol (American Radiolabeled Chemicals, Inc., St. Louis, MO) 
for 24 hrs. Cells were then washed and treated with 10 µM T0901317 for 24 hours to 
stimulate liver X receptor (LXR)-mediated expression of lipid transporters, ABCA1 and 
ABCG1. Efflux media was then added containing 20% subject serum and 0.2% BSA in 
RPMI, with each serum sample ran in triplicate. Efflux was performed for 3 hours at 37°C, 
followed by collection of cell media and cell lysates. Cell lysates were obtained by washing 
cells with 0.1 N NaOH and collection of the supernatant. Aliquots of cell media and lysates 
were added to liquid scintillation cocktail and radioactivity was measured with a Beckman 
LS 6500 Scintillation Counter (Beckman Coulter Inc., Indianapolis, IN). Percent cholesterol 
efflux was calculated as [(3H-cholesterol radioactivity in media) x 100] / [(3H-cholesterol 
radioactivity in media) + (3H-cholesterol radioactivity in cell lysate)].   
 
Statistical analysis  
All statistical analyses were performed using SPSS version 18. Repeated measures ANOVA 
was used to test the overall effects of the intervention between EGG vs. SUB groups (the 
between-subjects factor) and over time (the within-subjects factor). Paired t tests were used 
to test differences between baseline vs. week 12 values within EGG or SUB groups. 
Independent t tests were used to compare the differences in absolute or percent change in 
variables between groups. Bivariate Pearson correlations were used to determine 
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relationships between parameters. Data are reported as mean ± SD unless noted otherwise. P 
< 0.05 was considered significant.  
 
Results 
 
Egg product phospholipid analysis  
Whole egg and yolk-free egg substitute products were analyzed by mass spectrometry to 
identify the predominant phospholipid classes and associated molecular species (Table 1). 
The relative distribution of phospholipid classes was similar between the two egg products, 
with PC representing the most abundant phospholipid class, followed by PE, and smaller 
amounts of SM, LysoPC, and PI. As expected, the whole egg product provided significantly 
greater amounts of phospholipid within each class, since the majority of egg phospholipids 
are found in the yolk [23]. Additionally, a greater number of molecular species within each 
class – with the exception of SM – were identified in the whole egg product. Percent 
similarity of molecular species detected within each phospholipid class (i.e. species 
homology) between whole egg and egg substitute products ranged from 62.5 – 100%.   
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Table 4.1 Phospholipid composition of whole egg and egg substitute products 
 
Total phospholipids and individual phospholipid classes are reported as mg/daily serving (1/2 cup) of 
whole egg or egg substitute products. Values in parentheses represent the contribution of each 
phospholipid class to total phospholipids, reported as mole percent (mol%). The total number of 
individual molecular species identified within each phospholipid class is shown for both egg 
products. Species homology represents the (%) similarity of individual molecular species within each 
phospholipid class between whole egg and egg substitute products. 
 
Baseline characteristics and changes in body weight  
As described in Chapter 3, there were no differences in plasma TC, LDL-C, HDL-C, weight, 
BMI, age, or the additional MetS parameters between EGG and SUB groups at baseline 
(Table 3.3) [26, 27]. As expected with moderate carbohydrate restriction, subjects in both 
groups significantly decreased body weight over the course of the 12-week intervention, with 
no differences between groups (EGG: -3.6 ± 2.6 kg vs. SUB: -3.4 ± 2.3 kg; P = 0.78).  
 
Plasma HDL-C classification and response  
Changes in plasma lipids and lipoprotein particle profiles were briefly described in Chapter 3 
and have been reported elsewhere [26, 27]. Upon admission into the study, 55% of EGG 
Nutrient 
 
Whole Egg 
 Egg 
Substitute 
 Species 
homology (%) 
   
Total phospholipids (mg/serving) 
 
413.6  18.9   
Molecular species (#) 
 
65  57  82.1 
  
PC (mg/serving) 
 
308.8 (72.1%)  14.3 (73.2%) 
 
 
 
      Molecular species (#) 
 
21  19 82.0 
  
PE (mg/serving) 
 
86.1 (20.5%)  3.4 (17.9%)   
 
      Molecular species (#) 
 
19  17  89.5 
 
SM (mg/serving) 
 
10.4 (2.6%)  0.6 (3.3%)   
 
      Molecular species (#) 
 
5  5  100.0 
  
LysoPC (mg/serving) 
 
8.2 (2.9%)  0.3 (2.6%)   
 
      Molecular species (#) 
 
7  6  62.5 
  
PI (mg/serving) 
 
9.4 (1.9%)  0.7 (3.0%)   
 
      Molecular species (#) 
 
13  10  69.2 
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subjects met the MetS criteria for low plasma HDL-C (men: < 40 mg/dL; women: < 
50mg/dL), similar to 53% of SUB subjects enrolled. While no changes were observed in 
either TC or LDL-C throughout the 12-week intervention, plasma HDL-C increased in all 
subjects, with greater increases in the EGG group (+19.1%) when compared to the SUB 
group (+ 9.9%) (P < 0.05) (Figure 4.1) [26, 27]. Interestingly, the difference in HDL-C 
response between groups was primarily driven by subjects who entered the study with 
normal HDL-C levels (EGG (n = 9): +11.56 ± 8.0 mg/dL vs. SUB (n = 8): + 4.0 ± 3.5 
mg/dL; P = 0.026), rather than those with low baseline HDL-C (EGG (n = 11): +6.1 ± 6.3 
mg/dL vs. SUB (n = 9): +5.3 ± 6.9 mg/dL; P = 0.79). By the end of the intervention, only 
15% of subjects in the EGG group still met the MetS criteria for low plasma HDL-C, 
compared to 23.5% of SUB subjects.   
 
Figure 4.1 Effects of egg intake and carbohydrate restriction on plasma HDL-C 
 
 
Plasma HDL-C was measured at baseline, week 6, and week 12 of the intervention. **P < 0.01, 
repeated measures ANOVA (time effect). *P < 0.05, independent t test.    
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HDL lipid composition 
HDL subfractions (d = 1.063-1.21) were analyzed to assess whether egg feeding could 
impact the relative distribution of HDL lipid fractions (Table 4.2). While there were no 
changes in HDL-FC or -PL content from baseline to week 12, HDL became relatively more 
enriched in CE in all subjects, with slightly greater increases in the SUB group. Reductions 
in HDL-TG (P = 0.078) and HDL-PL (P = 0.082) content from baseline to week 12 were 
observed in EGG and SUB groups, respectively, although these changes failed to reach 
statistical significance. Interestingly, however, comparison of subjects with normal baseline 
HDL-C revealed that HDL-TG content was reduced in the EGG group only (EGG: -2.2 ± 
2.4% vs. SUB: 0.0 ± 0.9%; P = 0.03). Together, these changes led to increases in HDL-
CE/TG ratios in all subjects, whereas the slightly greater increases in the EGG group failed to 
reach significance when compared to the changes in the SUB group (P = 0.071). Baseline 
plasma HDL-C levels and gender did not appear to have an effect on changes in HDL lipid 
composition in either EGG or SUB group.  
 
Distribution of HDL phospholipid classes  
HDL subfractions (d =1.063-1.21) were further analyzed by mass spectrometry to identify 
the distribution of predominant PL classes (Table 4.3). While the relative distribution of 
HDL-PC, –LysoPC, –PI, or –SM did not change throughout the intervention, enrichment of 
HDL in PE was observed in the EGG group only (EGG: +40.8 ± 16.3% vs. SUB: -3.6 ± 
25.5%; P = 0.026). Interestingly, changes in HDL-PE content were positively associated with 
increases in plasma HDL-C (r = 0.74; P = 0.038), and negatively associated with changes in 
HDL-TAG content (r = -0.833; P = 0.010).  
  111
 
 
 
 Ta
bl
e 
4.
2 
 
Ef
fe
ct
s 
o
f e
gg
 
fe
ed
in
g 
o
n
 
H
D
L 
lip
id
 
co
m
po
sit
io
n
 
du
ri
n
g 
m
o
de
ra
te
 
ca
rb
o
hy
dr
at
e 
re
st
ri
ct
io
n
 
 
 
 
EG
G
 
 
SU
B
 
 
P 
v
a
lu
e 
B
a
se
lin
e 
W
ee
k 
12
 
C
ha
n
ge
 
 
B
a
se
lin
e 
W
ee
k 
12
 
C
ha
n
ge
 
 
Ti
m
e 
Ti
m
e 
x
 
G
ro
u
p 
CE
,
 
m
a
ss
%
 
40
.
4 
±
 
3.
4a
 
41
.
3 
±
 
4.
2a
 
+
 
1.
00
 
 
40
.
7 
±
 
3.
4a
 
42
.
1 
±
 
2.
2b
 
+
 
1.
40
 
 
0.
03
7 
0.
72
 
FC
,
 
m
a
ss
%
 
5.
1 
±
 
1.
5 
5.
6 
±
 
1.
3 
+
 
0.
51
 
 
5.
6 
±
 
1.
0 
5.
5 
±
 
1.
0 
−
 
0.
13
 
 
0.
36
 
0.
13
 
PL
,
 
m
a
ss
%
 
46
.
0 
±
 
3.
8 
45
.
4 
±
 
4.
2 
−
 
0.
60
 
 
45
.
0 
±
 
3.
8 
 
43
.
9 
±
 
3.
6 
 
−
 
1.
16
 
 
0.
14
 
0.
64
 
TA
G
,
 
m
a
ss
%
 
8.
5 
±
 
2.
7 
7.
6 
±
 
2.
4 
−
 
0.
91
 
 
8.
6 
±
 
2.
7 
8.
5 
±
 
2.
7 
−
 
0.
11
 
 
0.
11
 
0.
21
 
CE
/T
G
,
 
 
m
a
ss
 
ra
tio
 
5.
5 
±
 
2.
9 
6.
1 
±
 
2.
6 
+
 
0.
6 
 
5.
2 
±
 
1.
8 
5.
4 
±
 
1.
7 
+
0.
2 
 
0.
04
8 
0.
32
 
 In
di
v
id
u
al
 
lip
id
 
co
m
po
n
en
ts
 
o
f 
H
D
L 
su
bf
ra
ct
io
n
s 
(d 
=
 
1.
06
3−
1.
21
) f
ro
m
 
EG
G
 
(n 
=
 
19
) a
n
d 
SU
B
 
(n 
=
 
15
) g
ro
u
ps
 
ar
e 
pr
es
en
te
d 
as
 
pe
rc
en
t o
f t
o
ta
l H
D
L 
lip
id
 
m
as
s 
(m
as
s%
). C
E/
TG
 
ra
tio
s 
ar
e 
pr
es
en
te
d 
as
 
m
as
s 
ra
tio
s.
 
D
at
a 
ar
e 
re
po
rt
ed
 
as
 
m
ea
n
 
±
 
SD
.
 
D
iff
er
en
t l
et
te
rs
 
w
ith
in
 
th
e 
sa
m
e 
ro
w
 
in
di
ca
te
 
sig
n
ifi
ca
n
tly
 
di
ffe
re
n
t m
ea
n
 
v
al
u
es
 
(P
 
<
 
0.
05
). 
 
  112
 
Ta
bl
e 
4.
3 
Ef
fe
ct
s o
f e
gg
 
fe
ed
in
g 
on
 
H
D
L-
PL
 
cl
a
ss
 
di
st
ri
bu
tio
n
 
du
ri
n
g 
m
od
er
a
te
 
ca
rb
o
hy
dr
a
te
 
re
st
ri
ct
io
n
 
 
 
          
Ph
o
sp
ho
lip
id
 
cl
as
se
s 
id
en
tif
ie
d 
in
 
H
D
L 
su
bf
ra
ct
io
n
s 
(d 
=
 
1.
06
3−
1.
21
) f
ro
m
 
EG
G
 
(n 
=
 
4) 
a
n
d 
SU
B
 
(n 
=
 
4) 
gr
o
u
ps
 
ar
e 
pr
es
en
te
d 
as
 
pe
rc
en
t o
f t
o
ta
l H
D
L-
PL
 
(m
o
l%
). D
at
a 
ar
e 
re
po
rt
ed
 
as
 
m
ea
n
 
±
 
SD
.
 
D
iff
er
en
t l
et
te
rs
 
w
ith
in
 
th
e 
sa
m
e 
ro
w
 
in
di
ca
te
 
sig
n
ifi
ca
n
tly
 
di
ffe
re
n
t m
ea
n
 
v
al
u
es
 
(P
 
<
 
0.
05
). *
P 
<
 
0.
05
; i
n
de
pe
n
de
n
t t
 
te
st
 
co
m
pa
rin
g 
ch
an
ge
s 
in
 
%
H
D
L-
Pt
dE
tn
 
fro
m
 
ba
se
lin
e 
an
d 
w
ee
k 
12
 
be
tw
ee
n
 
EG
G
 
v
s.
 
SU
B
.
 
 
 
 
 
 
m
o
l%
 
EG
G
 
 
SU
B
 
 
P 
v
a
lu
e 
Ba
se
lin
e 
W
ee
k 
12
 
C
ha
n
ge
 
 
Ba
se
lin
e 
W
ee
k 
12
 
C
ha
n
ge
 
 
Ti
m
e 
Ti
m
e 
x
 
G
ro
u
p 
PC
 
79
.
1 
±
 
3.
4 
76
.
1 
±
 
4.
3 
−
 
3.
0 
 
78
.
6 
±
 
1.
4 
77
.
3 
±
 
2.
8 
−
 
1.
3 
 
0.
07
0 
0.
40
 
PE
 
3.
1 
±
 
0.
9a
 
4.
3 
±
 
1.
0b
 
+
 
1.
2*
 
 
3.
2 
±
 
0.
4a
 
3.
1 
±
 
0.
7a
 
−
 
0.
2 
 
0.
08
5 
0.
03
1 
SM
 
11
.
8 
±
 
1.
4 
13
.
5 
±
 
3.
6 
+
 
1.
7 
 
12
.
1 
±
 
0.
4 
 
12
.
5 
±
 
0.
6 
+
 
0.
5 
 
0.
28
 
0.
54
 
Ly
so
PC
 
3.
2 
±
 
2.
3 
3.
9 
±
 
1.
7 
+
 
0.
7 
 
3.
7 
±
 
1.
7 
4.
4 
±
 
2.
1 
+
 
0.
7 
 
0.
15
 
1.
00
 
PI
 
2.
9 
±
 
0.
5 
2.
3 
±
 
0.
6 
−
 
0.
5 
 
2.
3 
±
 
0.
4 
2.
7 
±
 
0.
7 
+
 
0.
5 
 
0.
87
 
0.
10
 
  113
Phospholipid species homology between HDL and egg products  
We further aimed to identify whether HDL subfractions became relatively more enriched in 
phospholipid molecular species present in the egg products throughout the intervention. In 
calculating the homology between HDL and egg product phospholipids, we found that 
molecular species identified in egg products represented an average 85%, 84%, 95%, and 
90% of total HDL species of PC, PE, LysoPC, and PI classes, respectively. This trend 
remained constant from baseline to week 12. The primary differences between PC and PE 
from egg and human HDL were the concentrations of 1-O-alkyl- or –alk-1-enyl species. On 
average, human HDL contained 3-fold more 1-O-alkyl- or –alk-1-enyl-phosphocholine and 
9-fold more 1-O-alkyl- or –alk-1-enyl-phosphoethanolamine (data not shown). In contrast, 
the SM species identified in whole egg and egg substitute products represented only 23.2% 
and 24.5% of HDL-SM species in EGG and SUB groups at baseline, respectively. By the end 
of the 12-week intervention, HDL subfractions from the EGG group shared greater SM 
species homology with the whole egg product (Figure 4.2), whereas no changes in homology 
between SUB group HDL and the egg substitute product were observed. Further, changes in 
SM species homology were positively correlated with changes in HDL-C (r = 0.80, P = 
0.017). Increases in SM species homology in the EGG group were due to increases in the 
appearance of egg product SM species in HDL subfractions rather than non-specific 
reductions in non-egg product-derived SM species (data not shown). These findings suggest 
that EGG-derived SM species may be incorporated into HDL in a manner that can 
significantly alter HDL phospholipid species distribution.  
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Figure 4.2 SM species homology between egg products and HDL 
                             
Percent homology of SM species in HDL and egg products. SM species homology represents the 
percentage of total HDL-SM species (nmol) that were similarly identified in the whole egg (EGG 
group) or egg substitute (SUB group) products. N = 4 per group; data are represented as mean ± 
SEM. *P < 0.05; NS: non-significant.   
 
 
Cholesterol efflux  
Cholesterol efflux to subject serum was measured to assess whether changes in HDL lipid 
composition from egg feeding affected the cholesterol-accepting capacity of HDL. While no 
changes in cholesterol efflux were observed in the SUB group, cholesterol efflux 
significantly increased in the EGG group (+2.4%) from baseline to week 12 (Figure 4.3). 
There was a trend toward a positive association between changes in cholesterol efflux and 
changes in SM homology between HDL and egg product SM species (r = 0.69; P = 0.060), 
as well as a trend toward a negative correlation between changes in cholesterol efflux and 
changes in fasting plasma glucose (reported in [26])(r = − 0.69; P = 0.060). No correlations 
were found between changes in cholesterol efflux and any other HDL lipids.  
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Figure 4.3 Effects of egg intake on the cholesterol-accepting capacity of serum 
                          
Percent cholesterol efflux from macrophage foam cells to subject serum. Cholesterol efflux was 
performed over a 3-hour period to assess the total cholesterol-accepting capacity of serum obtained 
from EGG (n = 4) and SUB (n = 4) subjects. Data are represented as mean ± SEM. *P < 0.05; NS: 
non-significant.   
 
Discussion 
While previous studies have found that egg consumption increases HDL-C and improves 
HDL particle profiles [25-27, 35], it has yet to be determined whether these changes 
correspond to alterations in HDL composition or HDL function. Since eggs are a rich source 
of dietary phospholipids which known to exert plasma lipid-modulating effects, we 
hypothesized that daily egg consumption may additionally alter HDL lipid composition and 
PL class distribution to improve the ability of HDL to function as a lipid acceptor in MetS - 
individuals often characterized with low HDL-C, dysfunctional HDL [6], and an overall 2-
fold increased risk of developing CVD [29]. Compared to intake of a yolk-free egg 
substitute, consumption of 3 eggs per day for 12 weeks resulted in greater enrichment of 
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HDL in CE, PE, and SM species present in whole eggs, as well as greater cholesterol efflux 
from cholesterol-loaded macrophages to subject serum. These changes correspond to 
previously reported improvements in HDL particle profiles in this population, along with 
beneficial effects on additional markers of atherogenic dyslipidemia and insulin resistance 
[26]. To our knowledge, this is the first study to demonstrate that increases in HDL-C from 
egg consumption during carbohydrate restriction correspond to modulation of HDL lipid 
composition and increase in the overall lipid-accepting capacity of serum in MetS.   
The classification of MetS by the NCEP:ATP III criteria is diverse in nature due to 
the requirement of any 3 or more qualifying parameters [29], thereby creating a spectrum of 
MetS severity. Severity of MetS may be related to the degree of metabolic disturbances that 
affect lipoprotein metabolism, including insulin resistance and low-grade systemic 
inflammation [1]. Prospective cohort studies have further demonstrated that individuals who 
meet a greater number of MetS parameters have an increased risk of CVD [36] – particularly 
when low plasma HDL-C is one of the factors [37]. In this population, over half of the 
subjects randomized to each group had low plasma HDL-C levels. While we have observed 
greater increases in HDL-C from whole egg feeding in previous studies [18, 26, 27], it is 
interesting to note that the greater HDL-C response to whole egg feeding in MetS was driven 
by subjects who began the intervention with normal HDL-C levels. As we did not identify 
any differences in HDL lipid composition between subjects with low and normal baseline 
plasma HDL-C levels, this observation may be reflective of a greater responsiveness to the 
intervention in subjects falling within the healthier end of the MetS spectrum, as 7 out of 8 
EGG group subjects with normal baseline HDL-C met only 3 MetS parameters, whereas 
EGG group subjects with low baseline HDL-C more commonly met 3, 4, and 5 MetS 
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parameters (data not shown). Although the pattern of MetS parameters between subjects with 
low and normal baseline HDL-C were similarly observed in the SUB group, these factors did 
not appear to impact the overall reduced HDL-C response in the SUB group when compared 
to the EGG group [26, 27]. While it is important to note that the dietary cholesterol provided 
by whole eggs may play a role in HDL-C responses [18], the overall pattern of plasma lipid 
changes in the EGG group (i.e. increases in HDL-C without adversely affecting TC or LDL-
C levels [26, 27]) is similar to findings reported from dietary phospholipid supplementation 
studies, suggesting that the yolk-derived phospholipids are responsible for the observed 
effects [16, 17]. This concept is further supported by the fact that egg PC and SM has been 
shown to decrease lymphatic absorption of cholesterol [64, 65]. Although further 
investigation is warranted, it is reasonable to hypothesize that phospholipid-rich foods other 
than egg may confer benefits to HDL lipid composition and function similar to those 
observed in the current study.  
HDL lipid composition has been shown to be an important factor in determining HDL 
function, metabolism, and CVD risk beyond plasma HDL-C levels. Individuals with low 
HDL-C [38] and MetS [39] often have greater enrichment in HDL-TG and reduction in 
HDL-CE and HDL-PL. Enrichment of HDL in TG has been associated with greater 
cholesteryl ester transfer protein (CETP) activity [40], enhanced clearance of apoA-I from 
circulation [41], and impaired LCAT-mediated esterification of free cholesterol and HepG2 
cell uptake of HDL-CE [42]. Conversely, CE enrichment of HDL promotes greater SR-BI-
mediated HDL-CE uptake [43], and is indicative of larger, more buoyant HDL particles that 
often correlate with reduced risk of CVD [44]. We observed relative increases in HDL-CE 
content in all subjects, concurrent with the previously described increases in HDL particle 
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size in this population [26]. Although there were slightly greater relative increases in HDL-
CE in the SUB group, this is most likely reflective of greater non-significant reductions in 
HDL-FC and HDL-PL compared to the EGG group. Interestingly, whole egg feeding led to 
greater reductions in HDL-TG content in subjects who entered the study with normal plasma 
HDL-C levels, further suggesting that these subjects were metabolically healthier and more 
responsive to the dietary intervention. HDL-CE/TG ratios increased all subjects, suggesting 
an overall improvement in HDL lipid composition regardless of group assignment, as would 
be expected due to the hypotriglyceridemic effects of carbohydrate-restricted diets [45].  
Although changes in total HDL-PL were not found as we hypothesized, we did 
observe changes in the distribution of HDL phospholipids classes and SM species, including 
an increase in relative HDL-PE content and SM species homology to the whole egg product 
in the EGG group only. Alterations in HDL-PE content may affect the cholesterol-accepting 
capacity of patient serum, as well as pathways of HDL metabolism and the anti-thrombotic 
properties of HDL [6, 8, 46]. In hypercholesterolemic men with exceptionally high plasma 
HDL-C (>1.75 mmol/L, or 68 mg/dL), HDL was found to be enriched in PE, yet HDL-PE 
content was negatively correlated with cholesterol efflux from rat Fu5AH hepatoma cells [8]. 
Conversely, the relationship between HDL-PE and cholesterol efflux was positive in men 
with normal HDL (1.10 to < 1.50 mmol/L, or 43 - 58 mg/dl), although this pattern did not 
reach statistical significance. Our findings suggest that greater HDL-PE content may be 
associated with greater cholesterol efflux in a macrophage cell model in men and women 
with MetS – a population predominantly with low plasma HDL-C.  
Enrichment in HDL with specific phospholipids may also confer atheroprotective 
benefits beyond that of modulating cholesterol efflux capacity. PE is also known to promote 
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activated protein C-mediated anticoagulant activity [46]; therefore, PE-enriched HDL may 
exert greater antithrombotic activity [6, 47]. Oxidation of HDL has also been shown to 
promote depletion of PE [48], suggesting that enrichment of HDL in PE may be indicative of 
a less oxidized HDL profile.  
In addition to increases in HDL-PE content, we observed that daily whole egg 
consumption for 12 weeks led to the enrichment of HDL in SM species present in the egg 
product, potentially reflecting egg-derived SM that became incorporated into HDL. Egg yolk 
serves as a uniquely rich and highly bioavailable (>90%) source of dietary phospholipids, 
which can be absorbed partially intact in the intestine and have been shown to be 
preferentially incorporated into HDL particles following ingestion [21, 22]. Further, in 
various animal models, feeding of natural PC and synthetic dimyristoylphosphatidylcholine 
(DMPC) has been shown to increase jejunal apoA-I synthesis [49, 50], which may promote 
intestinal secretion of HDL - a process which is thought to contribute ~30% of total 
circulating HDL [51, 52]. Further, the presence of egg SM has been shown to lower 
lymphatic absorption of other phospholipids (PC, PE, lysoPC, and PI), without affecting SM 
absorption [66]. This finding may explain the increase in % SM species homology from 
baseline to week 12 observed in the EGG group. Together, these concepts suggest that 
consumption of egg-derived phospholipids may serve as a relatively direct mechanism to 
modulate HDL lipid composition and intestinal HDL production.  
We further demonstrated that cholesterol efflux to subject serum increased from 
baseline to week 12 in the EGG group only (+2.4%). Due to the variability in experimental 
methodology for efflux assays and the relatively recent application of this approach to 
assessing CVD risk in response to therapeutic intervention, it is yet to be determined how the 
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observed changes in efflux affect long-term CVD risk and development. However, through 
implementation of statistical modeling that adjusted for standard cardiovascular disease risk 
factors, Khera et al. [5] found that coronary artery disease (CAD) risk (as measured by 
carotid intima-media thickness) was reduced by 30% for every 1-SD increase in cholesterol 
efflux capacity. These findings suggest that CAD risk could be significantly reduced with 
relatively small increases in cholesterol efflux. Following this logic, we believe that the 
+2.4% (or +0.5 SD) increase in efflux observed in the EGG group is a clinically relevant 
improvement in CVD status.   
The increases in cholesterol efflux associated with whole egg consumption may be 
attributed to an increased lipid-accepting capacity of HDL, as well as changes in other serum 
components. Various factors related to MetS have been associated with impaired cellular 
cholesterol efflux, including hypertension [53], overweight/obesity [54], low HDL-C [55], 
elevated blood glucose [56], and markers of inflammation [57]; however, it remains unclear 
whether cholesterol efflux is impaired in MetS. Conflicting results may be due to variability 
of different cellular efflux models [15], as well as the innate diversity of MetS populations in 
regard to qualifying parameters [58]. Cholesterol and phospholipid efflux from fibroblasts to 
subject plasma was shown to be similar between healthy individuals and those classified as 
non-diabetic MetS [59, 60]; however, fibroblasts express minimal SR-BI – a pathway that is 
more responsive to shifts in HDL-PL, larger HDL particles, and a greater contributor to total 
efflux in macrophages [61, 62]. Although few clinical trials have examined the effects of diet 
on cholesterol efflux, weight loss has been shown to increase cholesterol efflux to plasma via 
SR-BI- and ABCG1-mediated pathways, whereas ABCA1-mediated cholesterol efflux was 
reduced – presumably due to a reduction in more nascent preβ HDL [63]. These findings 
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corresponded to increases in the larger HDL2 subfractions, which additionally become more 
phospholipid rich [63]. Cholesterol efflux was also increased in MetS subjects following a 
12-week treatment of insulin-sensitizing drug pioglitazone [5]. Accordingly, we observed a 
trend toward a negative correlation between changes in fasting plasma glucose and 
cholesterol efflux, suggesting that improvements in insulin resistance promote greater efflux 
in MetS.  
In summary, we have demonstrated that increases in HDL-C from daily whole egg 
intake during moderate carbohydrate restriction coincide with clinically relevant changes in 
HDL lipid composition and the lipid-accepting capacity of subject serum in MetS. Further, it 
appears that changes in HDL-C and lipid composition in response to egg feeding vary within 
the MetS classification, whereas subjects with normal plasma HDL-C levels at baseline 
displayed more favorable increases in HDL-C and a reduction in HDL-TG content. Similar to 
the changes in cholesterol efflux, these observations may be related to variation in insulin 
sensitivity within this MetS population. Overall, these findings indicate that eggs may serve 
as a functional food to promote beneficial shifts in HDL composition, metabolism, and 
function in MetS.  
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Egg intake during carbohydrate restriction alters the 
inflammatory potential of peripheral blood mononuclear cells 
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Abstract 
Leukocyte inflammation under basal, unstimulated conditions has been linked to adverse 
metabolic outcomes in relation to CVD and T2DM. Therefore, it is important to address this 
issue in populations at high risk of chronic metabolic disease, such as individuals with 
metabolic syndrome (MetS). We set out to determine whether egg intake during 
carbohydrate-restriction – an intervention that has previously been shown to reduce plasma 
inflammatory markers – could effectively reduce the inflammatory potential of peripheral 
blood mononuclear cells (PBMCs) in MetS. Thirty-seven men and women classified with 
MetS consumed a moderate carbohydrate-restricted diet (25-30% of energy) for 12 weeks, in 
addition to consuming either 3 whole eggs per day (EGG group) or the equivalent amount of 
yolk-free egg substitute (SUB group). PBMCs were isolated at baseline and week 12 of the 
intervention. Body weight was reduced by an average ~4% in all subjects from baseline to 
week 12 of the intervention. While there were no changes in PBMC mRNA expression of IL-
1β, IL-6, and TLR4 throughout the intervention, contrary to our expectations, TLR4 mRNA 
expression was increased in the EGG group only. Changes in TLR4 mRNA expression 
positively correlated with changes in NF-κB p65 subunit DNA binding activity, in addition 
to changes in dietary cholesterol and choline intake. However, upon stimulation with LPS, 
PBMC TNFα and IL-1β production increased from baseline to week 12 in the SUB group, 
whereas no changes were observed in the EGG group. Together, these findings suggest that 
daily whole egg consumption during carbohydrate restriction does not increase the 
inflammatory potential of PBMC in response to LPS, despite increases in TLR4 expression. 
Conversely, moderate carbohydrate-restriction and egg substitute intake increases LPS-
induced inflammatory responsiveness in the MetS.  
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Introduction  
Chronic, low-grade inflammation is commonly associated with obesity-related metabolic 
diseases, and is often indicative of organ stress and insufficient resolution of inflammatory 
immune responses [1-3]. Elevated levels of plasma inflammatory markers have been reported 
in CVD, T2DM, and MetS [4, 5]. These cytokines, chemokines, adhesion molecules, and 
acute phase proteins may be derived from metabolically stressed adipose tissue, liver, and 
skeletal muscle, in addition to activated leukocytes [1-3].   
 Recent focus has been turned to the role of leukocytes in contributing to metabolic 
disease progression [6, 7], as well as how obesity can affect basic leukocyte properties and 
function and immunity [8]. Multiple studies have demonstrated that factors related to obesity 
increase the basal inflammatory profile of lymphocytes [9], in addition to promoting greater 
pro-inflammatory responses upon stimulation and activation [10, 11]. The consequences of 
these actions can include altered monocyte and lymphocyte migration and adhesion patterns, 
impaired immunity, prolonged systemic inflammation, and greater difficulty in resolving 
acute inflammatory responses. These changes have further been linked to greater progression 
of atherosclerosis, arterial dysfunction, adipose tissue inflammation and dysfunction, and 
insulin resistance [7, 10, 11]. Therefore, it is important that therapeutic intervention strategies 
targeting markers of chronic low-grade inflammation similarly address dysregulated 
leukocyte signaling.  
Dietary and lifestyle therapies that promote weight loss and improved diet quality 
have been shown to effectively ameliorate markers of systemic inflammation, including 
inflammatory cytokines and acute phase proteins such as TNFα, CRP and lipoprotein-
associated SAA [12-14]. Moderate weight loss (~5% of body weight) has additionally been 
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shown to reduce inflammatory gene expression and NF-κB DNA binding activity in PBMC 
from obese women [9].  
It has previously been established that carbohydrate restriction effectively reduces 
plasma inflammatory markers in overweight populations [14]. We have further demonstrated 
that daily intake of whole eggs during carbohydrate restriction reduces CRP in overweight 
men [13], as well as TNFα and SAA in men and women with MetS [12] – individuals at 
increased risk for developing CVD and T2DM [15]. Eggs contain various anti-inflammatory 
factors, including the antioxidant carotenoids lutein and zeaxanthin, as well as various 
bioactive phospholipid species [16, 17]. Therefore we sought to determine whether whole 
egg intake during carbohydrate restriction could further modulate inflammatory properties of 
PBMC in MetS, as PBMC subsets (predominantly lymphocytes and monocytes) play 
important roles in the progression of CVD and T2DM [7, 18-20].   
 
Materials and Methods 
 
Study Design 
Men and women (n = 37) classified with MetS according to the NCEP:ATP III criteria [15] 
were recruited to participate in a 12-wk moderate carbohydrate-restricted (25-30% of total 
energy) diet intervention. Subjects were randomly assigned to consume either 3 whole eggs 
per day (EGG group) or the equivalent amount of yolk-free egg substitute (SUB group). 
Details of this intervention are described in Chapter 3.   
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Dietary analysis                      
Dietary intake of was determined by analysis of 5-day food records collected at baseline, 
week 6, and week 12 of the intervention. Nutrient analysis was performed using Nutrition 
Data Systems for Research (NDSR).   
 
Sample collection 
Fasting blood samples were collected at baseline and week 12 of the intervention for 
isolation of PBMC and serum for cell culture assays. All samples were processed under 
sterile conditions. Serum was aliquoted and stored at -80°C.  
 
Peripheral blood mononuclear cell isolation 
Fasting blood (50ml) was collected into EDTA vacutainer tubes, diluted with PBS, and 
layered over Ficoll Paque (GE Healthcare) according to the manufacturer’s instructions. 
Samples were centrifuged at 400 x g for 35 minutes using a Beckman Coulter centrifuge with 
swing bucket rotors allowing for separation of the buffy coat. The buffy coats were collected, 
washed twice with PBS, and resuspended in RPMI. Aliquots of freshly isolated PBMCs were 
taken for collection of nuclear extracts and RNA extraction as described below. Remaining 
cells were diluted 1:1 with cryopreservation media (RPMI containing 20% FBS, 10% 
DMSO) and frozen at a controlled rate in CoolCell containers (BioCision) at -80°C for at 
least 24 hrs. PBMC samples were then transferred to liquid nitrogen for long-term storage.  
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Quantitative real-time RT-PCR  
PBMC mRNA expression of inflammatory genes was determined by quantitative real-time 
RT-PCR (qRT-PCR) [21, 22]. RNA from freshly isolated PBMCs was extracted using 
TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 1 µg 
of RNA was treated with DNase I (Promega, Madison, WI) and reverse transcribed by 
MMLV reverse transcriptase (Promega, Madison, WI) using a Bio-Rad C1000 Thermal 
Cycler (Bio-Rad Laboratories). qRT-PCR analysis was performed using the Sybr Green 
procedure and a Bio-Rad CFX96 system (Bio-Rad Laboratories). Primer sequences were 
designed according to the GenBank database, and are presented in Table 5.1. Expression of 
mRNA values was calculated using the threshold cycle (Ct) value. Relative expression levels 
of each target gene were calculated using the comparative 2-∆∆Ct method following 
normalization to 18S rRNA expression [21-23].  
 
 
Table 5.1 Quantitative real-time RT-PCR primer sequences 
 
Gene Forward Primer Reverse Primer 
IL-1β 5’-ACGATGCACCTGTACGATCACT-3’ 5’-CACCAAGCTTTTTTGCTGTGAGT-3’ 
IL-6 5’-GCTGCAGGCACAGAACCA-3’ 5’-GCTGCGCAGAATGAGATGAG-3’ 
TLR4 5’-GCAGGTGCTGGATTTATC-3’ 5’-GTAGAGAGGTGGCTTAGG-3’ 
TNFα 5’-GGGACCTCTCTCTAATCA-3’ 5’-CTACAACATGGGCTACAG-3’ 
18S RNA 5’-CGGCTACCACATCCAAGGAA-3’ 5’-GCTGGAATTACCGCGGCT-3’ 
 
 
 
 
NF-κB p65 DNA binding activity 
Nuclear fractions were collected from freshly isolated PBMCs using the Nuclear Extraction 
kit (Active Motif, Carlsbad, CA) following the manufacturer’s instructions [22, 24]. Nuclear 
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fractions were stored at -80°C until analysis. Total nuclear protein was determined by BCA 
assay (Thermo Scientific), then used to determine the DNA binding activity of the NF-κB 
p65 subunit using the TransAM® NFκB p65 Kit (Active Motif, Carlsbad, CA) according to 
the manufacturer’s instructions. Briefly, PBMC nuclear extracts were added to the 96-
stripwell ELISA plate. Each well was coated in multiple copies of immobilized specific 
double-stranded oligonucleotides, which allow for binding of activated NF-κB. NF-κB p65 
binding was then detected by addition of a primary NF-κB antibody, followed by a 
horseradish peroxidase-conjugated secondary antibody. Following color development, p65 
DNA binding activity was quantified spectrophotemetrically at 450 nm with a reference 
wavelength of 655nm. Data are presented as the spectrophotometric reading at optical 
density (OD) 450 nm.  
 
PBMC stimulation assays 
Inflammatory responses to LPS were assessed in a subset of subject PBMCs (EGG: n = 5; 
SUB: n = 5). 2 x 106 PBMCs were plated in 12-well plates, then treated with or without 500 
ng lipopolysaccharide (LPS) per well for 6 hrs in serum-free media. Media was collected, 
then assayed for TNFα (BD Bioscience), IL-1β, and IL-10 (Abcam) by ELISA.   
 
Statistical analysis 
All statistical analyses were performed using SPSS version 18. Repeated measures ANOVA 
was used to test the overall effects of the intervention between EGG vs. SUB groups (the 
between-subjects factor) and over time (the within-subjects factor). Paired t tests were used 
to test differences between baseline vs. week 12 values within EGG or SUB groups. 
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Independent t tests were used to compare the differences in absolute or percent change in 
variables between groups. Bivariate Pearson correlations were used to determine 
relationships between parameters. Data are reported as mean ± SEM unless noted otherwise. 
P < 0.05 was considered significant.  
 
Results 
 
Moderate carbohydrate restriction reduces body weight regardless of egg group assignment  
As described in previous chapters, all subjects adhered to the moderate carbohydrate dietary 
prescription, thus increasing percent of daily energy coming from fat and protein sources, 
while reducing percent of energy from carbohydrates (Figure 5.1 A). While no differences in 
macronutrient intake between groups was observed, the EGG group increased daily intake of 
egg yolk nutrients, including dietary cholesterol and choline intake throughout the 12-week 
intervention (Figure 5.1 B). Conversely, the SUB group reduced daily dietary intake of 
cholesterol and choline. Regardless of group assignment, subjects in both EGG and SUB 
groups experienced an average ~4% reduction in body weight by the end of the intervention 
(Figure 5.1 C). 
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Figure 5.1 Moderate carbohydrate restriction reduces body weight regardless of egg 
product assignment 
 
 
Moderate carbohydrate restriction reduces body weight regardless of daily whole egg or egg 
substitute intake. A) Macronutrient intake as % of daily energy. Data from both EGG and SUB 
groups are combined, as there were no statistical differences in macronutrient intake between groups. 
B) Average daily intake of dietary cholesterol and choline in EGG (yellow bars) and SUB (orange 
bars) groups. C) Changes in body weight throughout the intervention. All data are presented as mean 
± SEM. *P < 0.05, **P < 0.01, ***P < 0.0001 (time effect) and +++P < 0.0001 (group effect) as 
determined by repeated measures ANOVA. ###P < 0.001, paired t test comparing baseline to week 12 
in each group. P = 0.6 represents independent t test comparing the difference between changes in % 
weight loss between EGG and SUB groups.  
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Inflammatory gene expression 
Pro-inflammatory gene expression in PBMCs is known to be elevated in conditions of 
obesity and metabolic dysfunction, and reduced by weight loss [9]. Therefore, we sought to 
determine whether our dietary intervention could modulate inflammatory PBMC gene 
expression. Interestingly, although we did not observe changes in IL-6, IL-1β, or TNFα 
mRNA expression in either group, TLR4 mRNA expression increased from baseline to week 
12 in the EGG group only (Figure 5.2 A). Correspondingly, changes in TLR4 mRNA 
expression positively correlated with changes in % dietary fat (r = 0.649, P < 0.0001), as well 
as with changes in daily dietary intake of cholesterol (r = 0.433; P = 0.012) and choline (r = 
0.394; P = 0.026) (Figure 5.2 B) – nutrients that are abundant in egg yolk.  
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Figure 5.2 Egg intake during moderate carbohydrate restriction is associated with 
increased PBMC mRNA expression of TLR4  
 
 
Changes in pro-inflammatory gene expression from egg intake. A) All data are expression as mean ± 
SEM. mRNA expression was determined by qRT-PCR, with data normalized to 18S rRNA. P values 
represent paired t tests between baseline and week 12 for each respective group. B) Pearson 
correlation representing the relationship between changes in PBMC TLR4 mRNA expression and 
changes in dietary fat (as % of total energy), cholesterol, and choline from baseline to week 12 of the 
intervention.  
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NF-κB p65 DNA binding activity 
Increased PBMC NF-κB activity has been implicated in the increased pro-inflammatory gene 
expression observed in obese individuals, while it has also been shown to be decreased by 
weight loss [9]. Therefore, we assessed the DNA binding activity of the active NF-κB 
subunit p65 in response to our dietary intervention. Changes from baseline to week 12 did 
not reach significance in either EGG or SUB group (Figure 5.3 A), nor did the difference in 
changes between groups (P =0.085) (Figure 5.3 B). However, changes in NF-κB p65 DNA 
binding activity positively correlated with changes in TLR4 mRNA expression (r = 0.394; P 
= 0.026), as well as with changes in daily dietary choline intake (r = 0.442; P = 0.035) 
(Figure 5.3 C).    
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Figure 5.3 Increased PBMC TLR4 mRNA expression is from egg intake is associated 
with NF-κB activity 
 
 
                                              
Effects of egg intake on NF-κB p65 DNA binding activity. NF-κB p65 DNA binding activity was 
assessed in nuclear extracts obtained from freshly isolated PBMCs. A) NF-κB p65 DNA binding 
activity at baseline and week 12 of the intervention in EGG and SUB groups. B) Changes in NF-κB 
p65 DNA binding activity in EGG and SUB group subject PBMCs. C) Pearson correlation between 
changes in NF-κB p65 DNA binding activity and changes in PBMC TLR4 mRNA expression and 
dietary choline.  
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weight and composition. Therefore, we sought to determine whether our dietary treatment 
had an effect on responsiveness of PBMCs to inflammatory stimuli. PBMCs were cultured 
and assessed for their capacity to secrete pro-inflammatory IL-1β and TNFα, or anti-
inflammatory IL10, either under basal conditions or in response to LPS.    
Under basal, non-stimulated conditions, no significant changes in PBMC IL-1β or 
TNFα production from baseline to week 12 were observed in either group (Figure 5.4 A). 
This may be in part due to a large variability in subject response and a relatively small subset 
sample size. However, a weak trend for reduced IL-1β was observed over time in the SUB 
group (P = 0.086), as well as for TNFα when all subjects were combined (P = 0.089) 
(Figure 5.4 A). IL-10 levels were below the range of assay detection for the majority of 
subjects under resting conditions (data not shown).  
Conversely, surprising group differences were detected upon stimulation with LPS. 
While no changes in IL-1β or TNFα were observed in the EGG group, LPS-induced PBMC 
production of IL-1β and TNFα were increased from baseline to week 12 in the SUB group 
(Figure 5.4 A). Changes in both IL-1β and TNFα were significantly greater in the SUB 
group when compared to the EGG group (Figure 5.4 B). Changes in IL-10 from baseline to 
week 12 failed to reach significance in wither group, although a weak trend suggested an 
increase overall when all subjects were combined (P = 0.087). Changes between EGG and 
SUB groups were not statistically different (P = 0.245) (Figure 5.4 C).   
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Figure 5.4 Egg substitute intake during carbohydrate restriction increases PBMC 
inflammatory responsiveness to LPS  
 
 
 
 
Effects of egg intake during carbohydrate restriction on LPS-induced cytokine secretion. A) PBMC 
TNFα and IL-1β secretion with or without stimulation with LPS. B) Changes in LPS-induced TNFα 
and IL-1β secretion from baseline to week 12. C) LPS-induced PBMC IL-10 secretion. IL-10 was 
generally non-detectable under non-stimulated conditions. All data are represented as mean ± SEM. 
EGG: n = 5, SUB: n = 5.   
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Discussion 
Elevated levels of basal leukocyte inflammation have been demonstrated in obesity and 
metabolic syndrome [9, 25], and have been implicated in leukocyte-driven progression of 
metabolic disease [6, 7]. Therefore, dietary strategies represent a promising strategy to 
mitigate inappropriate activation of pro-inflammatory leukocyte responses in order to prevent 
adverse metabolic disease outcomes.  
In this study, we demonstrate that, contrary to our original hypothesis, mRNA 
expression of TLR4 is increased by daily intake egg intake during moderate carbohydrate 
restriction, correlating with NF-κB p65 DNA binding activity. However, these changes did 
not correspond with alterations in inflammatory PBMC responsive to LPS, whereas LPS-
induced PBMC TNFα and IL-1β secretion was increased in by moderate carbohydrate 
restriction and egg substitute intake. Together, these findings further exemplify a novel role 
for dietary egg consumption and carbohydrate restriction in modulating the inflammatory 
potential of leukocytes.  
Previous studies [9] have reported reductions in inflammatory gene expression in 
PBMCs following moderate weight loss. This phenomenon is thought to be indicative of 
global improvements in metabolic tissue stress and function, thereby reducing the presence 
of pathogenic factors capable of activating leukocytes, while also promoting the resolution of 
inflammatory responses. However, despite moderate weight loss and decreases in plasma 
TNFα and SAA from whole egg consumption in this population [12], we did not observe 
reductions in PBMC mRNA expression of TNFα, IL-1β, or IL-6 from baseline to week 12. 
Conversely, we observed significant increases in TLR4 mRNA expression in subjects 
consuming whole eggs.  
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TLR4 is a member of the TLR family of pattern recognition receptors that recognizes 
exogenous and endogenous ligands, including Gram-negative bacteria-derived LPS and fatty 
acids [26]. Elevated expression of TLR4 may be particularly influential in obesity-related 
disease, as obesity has been associated with increased intake of dietary fatty acids, increased 
gut permeability and serum levels of LPS, as well as elevated levels of circulating FFA 
capable of activating TLR4 signaling [26, 27]. Increased TLR4 activity has been associated 
with high-fat feeding, elevated cellular cholesterol levels, and activation of NF-κB 
transcriptional activity, corresponding to the correlations observed in this study [27-30].  
Despite the role of TLR4 in obesity, our study is limited in that only mRNA levels of 
TLR4 were measured. While various inflammatory factors differentially regulate TLR4 
mRNA expression, functional activity of this receptor is further regulated at the level of 
protein translation, cell surface localization, accessory molecule availability and expression, 
and plasma membrane composition [27]. Interestingly, omega-3 fatty acids have been shown 
to inhibit LPS- or SFA-induced TLR4 activation by altering plasma membrane lipid raft 
composition, thereby preventing assembly of TLR4 homodimers and signaling component 
complexes within lipid rafts to allow for subsequent inflammatory signal transduction [31]. 
Similar impairments in TLR4 signaling have been demonstrated via depletion of cellular 
cholesterol – an important structural component of lipid rafts [29, 30]. Further, TLR4 
expression can also promote different types of cellular signaling depending on the cell type in 
which it is expressed. This is an important consideration with regard to the present study, 
since PBMCs consist of mixed leukocyte population containing approximately 60-70% T 
cells, 5-15% B cells, 5-10% natural killer cells, 0.5-2% dendritic cells, 15-30% 
monocyte/macrophages, and 2% granulocytes [32-35]. For example, TLR4 protein is 
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expressed intracellularly in naïve human CD4+ T cells, whereas cell surface TLR4 expression 
is found in activated CD4+ T cells [36]. Cell surface expression of TLR4 is associated with 
increased anti-inflammatory Treg cell activation, as well as an enhancement of Treg cell-
mediated suppressive functions [37]. Therefore, simply observing changes in TLR4 mRNA 
expression does not necessarily signify changes in cellular inflammatory potential without 
further analyzing surface protein expression or plasma membrane and lipid raft composition, 
and additional measures of inflammatory potential.  
 Correspondingly, the fact that TLR4 mRNA expression does not necessarily translate 
to increased cellular inflammatory responses was further exemplified by our findings from 
PBMC stimulation assays. Despite increased mRNA expression of TLR4 that correlated NF-
κB p65 DNA binding activity, daily whole egg intake for 12 weeks rendered PBMCs less 
responsive to LPS-induced cytokine secretion when compared to responses from egg 
substitute consumption. These findings suggest that 1) a component of the egg substitute 
product (in conjunction with carbohydrate restriction) was inducing greater inflammatory 
responses that were only observed upon LPS stimulation of PBMC (and not under basal 
conditions or in plasma); and/or 2) a component of the egg product was blunting increased 
PBMC responsiveness to LPS induced by carbohydrate restriction.  
One possible explanation could be that whole eggs provide dietary oxidized 
phospholipids (OxPL) that impair responsiveness of PBMCs to LPS. Compared to other 
dietary phospholipid sources, egg-derived phospholipids have been shown to more 
susceptible to copper- and pH-induced oxidation due to its relatively higher content of long-
chain PUFAs [38]. Generation of oxidized phospholipid metabolites by gut microflora has 
also been reported in response to egg feeding [39]. Although OxPL have been linked to pro-
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inflammatory responses and atherosclerosis in some cases [40, 41], the oxidized 
phospholipid 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (Ox-PAPC) and 
associated phospholipid oxidation products have been shown to inhibit LPS-mediated TLR4 
activation [42, 43]. OxPL species have been shown to inhibit LPS-induced inflammatory 
signaling in macrophages, endothelial cells, and smooth muscle cells through alteration of 
lipid raft and caveolar processing and through competitive interaction with TLR accessory 
proteins, such as MD-2, CD14, and LPS-binding protein [42-44]. Together, the presence of 
OxPL inhibits LPS-induced membrane translocation of LPS receptor complexes that are 
required for signaling and propagation of pro-inflammatory cytokine production [42, 43]. 
The capacity of OxPL to inhibit bacterial pathogen-induced inflammatory signaling is 
thought to serve as an endogenous feedback mechanism to potentiate oxidative damage and 
promote resolution of tissue inflammation [44, 45]. Although we did not assess the effects of 
this intervention on oxidized species in serum, PBMCs, or lipoproteins, we did observe 
significant changes in HDL phospholipid composition from egg intake (see Chapter 4), 
suggesting the possibility of incorporating egg yolk-derived OxPL into blood components if 
present in the whole egg product. 
 Another explanation for the differential PBMC responses to LPS between EGG and 
SUB groups could be that PBMCs from the SUB group were more primed toward pro-
inflammatory responses due to the relatively greater inflammatory environment when 
compared to the EGG group (which displayed decreases in plasma TNFα and SAA) [12]. 
Bosisio et al. [46] found that in human monocytes and macrophages, LPS induced TLR4 
mRNA expression, while reducing its surface protein expression. However, priming with 
interferon γ (IFNγ) increased the responsiveness of cells to LPS-induced NF-κB DNA 
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binding activity and production of TNFα and IL-12 [46]. Following our 12-week 
intervention, the SUB group did not display reductions in plasma TNFα and SAA as was 
observed in the EGG group [12], suggesting that the SUB cells could remain more primed for 
inflammatory responses following stimulation.   
 Given the changes in HDL composition and the cholesterol-accepting capacity of 
serum from egg intake described in the previous chapter, it is additionally plausible that the 
differences in PBMC inflammatory potential between the EGG and SUB groups could be 
due to changes in cellular cholesterol content and lipid raft formation. As described above, 
TLR4 signaling is dependent upon plasma membrane composition and lipid raft integrity to 
facilitate the convergence of LPS receptor complex components required for LPS/TLR4-
mediated inflammatory signaling [27, 43]. The inflammatory potential of leukocytes has 
further been shown to be regulated through modulation of the HDL-associated lipid 
transporter ABCA1, where greater expression of these membrane transporters is known to 
deplete lipid raft cholesterol and suppress TLR4-mediated inflammatory signaling [29, 30]. 
Therefore, it is possible that the effects of egg intake during carbohydrate restriction on 
PBMC inflammatory potential may be attributable to alterations in HDL-leukocyte 
dynamics.   
 Taken together, the data presented in this study highlights a novel perspective on the 
anti-inflammatory properties of egg intake during carbohydrate restriction. These findings 
further raise interesting questions regarding the role of HDL-mediated efflux in modulating 
PBMC inflammation, as well as implication for immunity.   
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Chapter 6 
Egg intake during carbohydrate restriction alters peripheral 
blood mononuclear cell cholesterol flux in  
metabolic syndrome  
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Abstract 
Leukocyte cholesterol flux has been linked to the regulation of cellular inflammatory 
potential. Therefore, we sought to determine whether peripheral blood mononuclear cell 
(PBMC) cholesterol content and distribution could be modulated through diet in metabolic 
syndrome (MetS) – a population associated with chronic low-grade inflammation and 
dyslipidemias. Thirty-seven men and women classified with MetS participated in a 12-week 
moderate carbohydrate-restricted diet (25-30% of energy), in addition to consuming either 3 
whole eggs per day (EGG group) or the equivalent amount of yolk-free egg substitute (SUB). 
Compared to baseline, there was a trend toward a reduction in PBMC cholesterol content in 
the EGG group, whereas no changes were observed in the SUB group. Although total PBMC 
lipid raft content was not altered in either group, changes in lipid raft content positively 
correlated with changes in total PBMC cholesterol. To determine the cellular pathways 
involved in the changes observed in cholesterol flux, expression of genes related to 
cholesterol efflux (ABCA1 and ABCG1) and cholesterol synthesis and uptake (HMG-CoA 
reductase and LDL-receptor (LDL-R)) were measured. While no changes in ABCG1 or 
LDL-R were observed in either group, ABCA1 and HMG-CoA Red mRNA expression 
increased from baseline to week 12 in the EGG group only. A trend toward an increase in 
ABCA1 protein was similarly observed in the EGG group. Together, these findings suggest 
that whole egg intake during carbohydrate-restriction reduces PBMC cholesterol content, 
most likely in part by efflux via ABCA1. Coupled with the changes in HDL lipid 
composition, the cholesterol-accepting capacity of serum, and PBMC inflammatory potential 
presented in previous chapters, these findings may serve as further evidence that whole egg 
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intake during carbohydrate restriction favorably modulates HDL-leukocyte dynamics in 
MetS.   
 
Introduction 
Regulation of leukocyte cholesterol flux has recently garnered significant attention due to its 
implications for inflammation, immunity, atherosclerosis, and metabolic disease [1-3]. 
Leukocytes with elevated levels of cholesterol have been shown to be more inflammatory 
and hyperproliferative [1, 4, 5], which may lead to inappropriate inflammatory hyper-
responsiveness to stimuli, impaired resolution of inflammation, or misguided immune 
responses.  
In line with this area of research, HDL-associated lipid transporters, including 
ABCA1 and ABCG1, have been shown to play significant roles in the modulation of 
leukocyte cholesterol content. While the anti-atherogenic properties of both ABCA1 and 
ABCG1 have been well documented due to their capacity to participate in the initiation of 
reverse cholesterol transport through efflux of macrophage foam cell lipids to HDL [6-8], 
these proteins additionally possess the capacity to reduce inflammatory responsiveness 
through depletion of lymphocyte cholesterol content and lipid raft formation [9, 10]. Cellular 
cholesterol depletion impairs the formation lipid rafts within the plasma membrane where 
transmembrane proteins and receptors such as TLR4 reside, thereby blunting the activation 
of inflammatory signaling [9-11]. ABCA1 expression in leukocytes has additionally been 
implicated in cellular recruitment and migration, as deletion of leukocyte-specific ABCA1 
results in more advanced atherosclerotic lesions, as well as increased leukocyte counts in the 
liver, spleen, and peripheral blood [12]. Further, ABCA1 is thought to efflux LPS to HDL as 
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a means of neutralizing it inflammatory effects, while also serving as a transports system for 
excretion of LPS from the body via the bile [13-15].  
In accordance with their role in atherosclerosis and leukocyte inflammation, 
expression of ABCA1, ABCG1, and SR-BI has been shown to be impaired in individuals 
with chronic metabolic disease, including coronary artery disease (CAD), hypertension, and 
T2DM [16-19]. Expression of these cellular transporters are also known to be impaired by 
specific serum components that are commonly found to be elevated in metabolic disease, 
including serum glucose, tumor necrosis factor α (TNFα), C-reactive protein (CRP), and 
oxidized LDL (oxLDL). Inhibition of HDL-associated transporters by these factors has been 
further linked to reductions in macrophage lipid efflux to HDL [20-24]. Dietary factors have 
also been demonstrated to differentially regulate ABCA1 expression in human PBMC [25], 
suggesting that therapeutic intervention aimed at treating metabolic dysfunction may have 
the capacity to alter leukocyte inflammatory potential through modulation of cellular 
cholesterol levels.  
 Given that 12 weeks of daily whole egg intake during moderate carbohydrate 
restriction has concomitantly modulated HDL composition, cholesterol efflux from 
macrophages to serum, and PBMC inflammatory potential in MetS, we further hypothesized 
that daily egg consumption alters cellular cholesterol content via expression of HDL-
associated transporters.  
 
Materials and Methods 
Study Design 
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Men and women (n = 37) classified with MetS according to the NCEP:ATP III criteria 
[26]were recruited to participate in a 12-wk moderate carbohydrate-restricted (25-30% of 
total energy) diet intervention. Subjects were randomly assigned to consume either 3 whole 
eggs per day (EGG group) or the equivalent amount of yolk-free egg substitute (SUB group). 
Details of this intervention are described in Chapter 3.   
 
Dietary analysis 
Dietary intake of was determined by analysis of 5-day food records collected at baseline, 
week 6, and week 12 of the intervention to ensure dietary compliance. Nutrient analysis was 
performed using Nutrition Data Systems for Research (NDSR). All subjects adhered to the 
experimental dietary regimen as described in previous chapters.   
 
Sample collection 
Fasting blood samples were collected at baseline and week 12 of the intervention for 
isolation of PBMC and plasma. PBMC samples were processed under sterile conditions. 
Plasma was obtained following blood collection into EDTA-coated tubes and centrifugation 
at 2200 x g for 20 minutes at 4°C. A preservative cocktail (1 ml/L sodium azide, 1 ml/L 
phenylmethylsulfonyl fluoride, and 5 mL/L aprotinin) was added to plasma prior to storage at 
-80°C.  
 
Peripheral blood mononuclear cell isolation 
Fasting blood (50ml) was collected into EDTA vacutainer tubes, diluted with PBS, and 
layered over Ficoll Paque (GE Healthcare) according to the manufacturer’s instructions. 
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Samples were centrifuged at 400 x g for 35 minutes using a Beckman Coulter centrifuge with 
swing bucket rotors allowing for separation of the buffy coat. The buffy coats were collected, 
washed twice with PBS, and resuspended in RPMI. Aliquots of freshly isolated PBMCs were 
taken for collection of nuclear extracts and RNA extraction as described below. Remaining 
cells were diluted 1:1 with cryopreservation media (RPMI containing 20% FBS, 10% 
DMSO) and frozen at a controlled rate in CoolCell Chambers (BioCision) at -80°C for at 
least 24 hrs. PBMC samples were then transferred to liquid nitrogen for long-term storage.  
 
Quantification of PBMC cholesterol content 
PBMC cholesterol content was measured by gas chromatography/mass spectrometry 
(GC/MS) using an Agilent 7890 GC/MS equipped with an Agilent HP-5MS capillary column 
with dimensions: 30 m x 0.25 mm (0.25 µm film thickness). PBMC cholesterol was extracted 
by isopropyl alcohol following the addition of 5α-cholestane as an internal standard. PBMC 
lipids were dissolved in hexane prior to injection. Run conditions were: Initial temperature = 
150 °C; Temp ramp = 15 °C/min to 225 °C (hold for 5 min); Temp ramp = 15 °C/min to 300 
°C (hold for 10 min); with a total run time of 25 min. Helium was used as the carrier gas. 
Cholesterol values were normalized to total cell protein as determined by BCA assay.  
 
Quantitative real-time RT-PCR  
PBMC mRNA expression of inflammatory genes was determined by quantitative real-time 
RT-PCR (qRT-PCR) as described in Chapter 5 [27, 28]. RNA from freshly isolated PBMCs 
was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. 1 µg of RNA was treated with DNase I (Promega, Madison, WI) 
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and reverse transcribed by MMLV reverse transcriptase (Promega, Madison, WI) using a 
Bio-Rad C1000 Thermal Cycler (Bio-Rad Laboratories). qRT-PCR analysis was performed 
using the Sybr Green procedure and a Bio-Rad CFX96 system (Bio-Rad Laboratories). 
Primer sequences were designed according to the GenBank database, and are presented in 
Table 6.1. Expression of mRNA values was calculated using the threshold cycle (Ct) value. 
Relative expression levels of each target gene were calculated using the comparative 2-∆∆Ct 
method following normalization to 18S rRNA expression [27-29].  
 
Table 6.1 Quantitative Real-time PCR primer sequences 
 
Gene Forward Primer Reverse Primer 
ABCA1 5’-TTTCTCAGACAACACTTGACCAAGTA-3’ 5’- GGTTTTTGTGTAATGAGAGGTCTTTTAA-3’ 
ABCG1 5’- CGGAGGGCAGCTGTGAAC-3’ 5’- GGGTCCTTCAGGAACCGAAT-3’ 
HMGR 5’- CCCAGTTGTGCGTCTTCCA-3’ 5’- TTCGAGCCAGGCTTTCACTT-3’ 
LDL-R 5’-ACTGGGTTGACTCCAAACTTCAC-3’ 5’- GGTTGCCCCCGTTGACA-3’ 
18S rRNA 5’- CGGCTACCACATCCAAGGAA-3’ 5’- GCTGGAATTACCGCGGCT-3’ 
 
 
ABCA1 protein 
Whole cell lysates were collected from freshly isolated PBMC as described by Rasmussen et 
al [27]. Briefly, following isolation, PBMCs were pelleted and resuspended in whole cell 
lysis buffer (150 mmol/L NaCl, 25 mmol/L Tris-HCL, pH 7.4, 1% Triton X-100) containing 
Protease Inhibitor Cocktail set III (Calbiochem) for 20 minutes on ice. Cells were repelleted 
to collect the supernatant for storage at -80°C until analysis. ABCA1 protein content was 
determined by ELISA (Biotang Inc). Data are presented as ng protein per 1 x 106 cells.  
 
Lipid raft staining and microscopy 
Lipid rafts were quantified using the Vybrant Alexa Fluor 488 Lipid Raft Labeling Kit 
(Molecular Probes, Eugene, OR) according to the manufacturer’s instructions. Briefly, 1 x 
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106 cryopreserved PBMCs were rapidly thawed at 37 °C, then labeled with a fluorescent 
cholera toxin subunit B (CT-B)-Alexa Fluor 488 conjugate, which binds to the 
pentasaccharide chain of plasma membrane ganglioside GM1 localized within lipid raft 
domains. An anti-CT-B antibody was then added to induce crosslinking of the fluorescent 
conjugate. PBMC were loaded onto chamber slides to visualize lipid raft fluorescence using a 
Leica TCS SP2 Laser Scanning Confocal microscope. Total lipid raft fluorescence was 
quantified using a fluorescence plate reader at excitation 488 and absorbance/emission 
495/519.  
 
Homeostatic model assessment-insulin resistance (HOMA-IR) 
 HOMA-IR was calculated as follows: fasting insulin (µIU/mL) × fasting glucose 
(mmol/mL)/22.5 [30]. Fasting glucose was measured enzymatically using a Cobas c 111 
analyzer (Roche Diagnostics, Indianapolis, IN). Insulin levels were determined by ELISA 
(Mercodia AB, Uppsala, Sweden) [31].  
 
Statistical analysis 
All statistical analyses were performed using SPSS version 18. Repeated measures ANOVA 
was used to test the overall effects of the intervention between EGG vs. SUB groups (the 
between-subjects factor) and over time (the within-subjects factor). Paired t tests were used 
to test differences between baseline vs. week 12 values within EGG or SUB groups. 
Independent t tests were used to compare the differences in absolute or percent change in 
variables between groups. Bivariate Pearson correlations were used to determine 
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relationships between parameters. Data are reported as mean ± SEM unless noted otherwise. 
P < 0.05 was considered significant.  
 
Results 
Egg intake induces a trend toward a reduction in PBMC cholesterol content  
Total PBMC cholesterol content was measured to determine whether egg consumption 
altered leukocyte cholesterol levels. Interestingly, there was a trend for a decrease in PBMC 
cholesterol content from baseline to week 12 in the EGG group, whereas no changes in 
cellular cholesterol levels were observed in the SUB group (Figure 6.1).  
 
Figure 6.1 Effects of egg intake and carbohydrate restriction on PBMC cholesterol 
content 
                                    
Relationship between PBMC cholesterol content and inflammatory gene expression from egg intake. 
A) Values are presented as mean ± SEM. #P = 0.057 for paired t test between baseline and week 12 in 
the EGG group. EGG: n = 15; SUB: n = 13.  
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Changes in PBMC cholesterol content correlate with changes in lipid raft content  
As we observed a trend toward a decrease in total PBMC cholesterol, we further sought to 
determine whether these changes corresponded to reductions in lipid raft formation. 
Potentially due to a lack of available samples, we failed to observe any changes in lipid raft 
formation from baseline to week 12 in either EGG or SUB group (Figure 6.2 A and B). 
However, changes in total PBMC cholesterol positively correlated with changes in lipid raft 
content (Figure 6.2 C). Although it is speculative, this relationship suggests that we may 
have seen a decrease in lipid raft fluorescence in the EGG group that would mimic the trend 
in cellular cholesterol levels if given a larger sample size. Interestingly, changes in PBMC 
lipid rafts were positively correlated with changes in HOMA-IR – an estimate of basal 
insulin resistance [32] (Figure 6.2 C), corresponding to the concept that inflammatory 
leukocytes promote insulin resistance [33].     
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 6.2 Effects of egg intake and carbohydrate restriction on PBMC lipid rafts 
 
PBMC lipid rafts were labeled with the Vybrant Alexa
PBMCs were visualized using a Leica TCS SP2 Laser Scanning Confocal microscope. B) Total lipid 
raft fluorescence was quantified using a
total fluorescence between EGG and SUB groups. C) The relationship between changes in total lipid 
raft fluorescence and PBMC cholesterol content
correlation.     
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 Fluor 488 Lipid Raft Labeling Kit. A) Labeled 
 fluorescence plate reader. P = 0.5 comparing the change in 
, and HOMA-IR as determined by Pearson 
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Cholesterol gene expression 
Given the trend toward a reduction in cellular cholesterol content observed in the EGG 
group, we further aimed to identify whether this change corresponded to alterations in the 
expression of genes related to cholesterol efflux (ABCA1 and ABCG1), synthesis (HMG 
CoA Red), and uptake (LDL-R). Interestingly, while no changes in ABCG1 mRNA 
expression were observed in either group (Figure 6.3 B), ABCA1 mRNA expression 
significantly increased from baseline to week 12 in the EGG group only (Figure 6.3 A). This 
change corresponded to a trend toward greater increases in ABCA1 protein from baseline 
when compared to the SUB group (Figure 6.3 E), as well as a trend toward significant 
change compared to the SUB group (Figure 6.3 F). Similar EGG group-specific increases in 
HMG CoA Red mRNA expression were observed from baseline to week 12 (Figure 6.3 C), 
whereas no changes in LDL-R mRNA expression were observed in either group (Figure 6.3 
D).   
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Figure 6.3 Egg intake during carbohydrate restriction alters PBMC cholesterol gene  
expression  
 
 
Effects of egg intake during carbohydrate restriction on PBMC cholesterol gene. Values are presented 
as mean ± SEM. mRNA expression was determined by real time PCR, with data normalized to 18S 
rRNA. ABCA1 protein was determined by ELISA.  
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Discussion 
Leukocyte cholesterol flux plays an important role in the regulation of cellular inflammatory 
potential, with important implications for metabolic disease and immunity. In this study, we 
have provided evidence that 12 weeks of daily whole egg consumption during moderate 
carbohydrate restriction alters leukocyte cholesterol flux, corresponding to the changes in 
HDL composition, cholesterol efflux, and PBMC inflammatory potential described in 
previous chapters. These findings highlight a novel and exciting role for diet in modulating 
the relationship between cellular inflammation and HDL metabolism.  
 In this study, we observed that egg consumption trended toward decreasing PBMC 
cholesterol content after 12 weeks. Previous studies have similarly reported changes in 
leukocyte cholesterol content through diet, although results have differed. In healthy men and 
women following an isolcaloric diet while maintaining dietary cholesterol < 250 mg/day, 
increasing dietary fat from an average of 17% of energy (“low-fat”) to 34% (“high-fat”) for 
10 days resulted in enrichment of leukocytes in cholesterol (3-fold) and phospholipids [34]. 
The cholesterol:phospholipid ratios further increased, as did leukocyte cholesterol ester 
synthase (CES) activity. Changes in leukocyte lipid fractions were evident within 5 days of 
consuming the 10-day “high-fat” diet, and lasted for an additional 40 days following a 
reversal to the “low-fat” dietary guidelines. Interestingly, changes in leukocyte cholesterol 
corresponded with reductions in cholesterol within CE-rich HDL2 particle fractions, and 
concomitant increases in cholesterol within smaller, denser HDL3 fractions [34]. While our 
intervention provided considerably more dietary fat as a percent of total energy (~45% on 
average), differences between the studies may be attributable to the fact that our subjects 
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were actively undergoing weight loss, restricting carbohydrates, and consuming greater daily 
doses of egg-derived cholesterol and bioactive phospholipids [35].  
 Although no changes over time were observed – potentially due to a lack of available 
samples – changes in PBMC cholesterol content positively correlated with PBMC lipid raft 
content. To date, this is the first study to our knowledge that has investigated the effects of 
diet on leukocyte lipid rafts within the context of human intervention trials. Cholesterol 
serves as an essential structural component of lipid rafts, which are dynamic cholesterol-rich 
microdomains within the exoplasmic leaflets of the phospholipid bilayer of plasma 
membranes where transmembrane proteins and receptors reside – including PRRs such TLR4 
[11]. Elevated levels of cellular cholesterol favor the formation of lipid rafts, and have been 
associated with increased pro-inflammatory responses in macrophages and T lymphocytes 
due to lowered cellular activation thresholds [1, 4, 5]. Given the significant role of leukocytes 
in immunity and chronic disease, regulation of cellular cholesterol flux and lipid raft 
formation may have important implications for the physiological consequences of obesity. 
Interestingly, changes in PBMC lipid rafts were positively correlated with changes in 
HOMA-IR – an estimate of basal insulin resistance [32]. This finding may be related to the 
role of inflammatory lymphocytes in the progression of T2DM [33], in addition to impaired 
ABCA1-mediated cholesterol flux and expression under conditions of insulin resistance [36], 
as discussed in further detail below.  
 In addition to changes in PBMC cholesterol content, we similarly observed changes 
in the expression of genes related to cholesterol flux, including ABCA1 and HMG CoA Red.   
Whereas expression of ABCA1 is traditionally regulated via LXR-mediated transcriptional 
activation under conditions of elevated cellular cholesterol levels, reduced cellular 
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cholesterol levels promote sterol regulatory element binding protein-2 (SREBP2)-mediated 
expression of HMG CoA Red – the rate-limiting enzyme for cholesterol synthesis. This 
pathway serves as a mechanism to replenish cellular cholesterol when it has become depleted 
[37]. Therefore, the increase in PBMC HMG CoA Red mRNA expression observed in our 
study corresponds to lower cellular cholesterol levels.   
 Conversely, the increased levels of ABCA1 expression observed in this study may be 
due to the improved metabolic and inflammatory milieu from egg intake during moderate 
carbohydrate restriction. As mentioned above, ABCA1 expression is reduced in patients with 
obesity-related metabolic disease [16-19], models of insulin resistance and diabetes [36], and 
by pro-inflammatory mediators such as TNFα and CRP [21, 22]. We have previously 
demonstrated the whole egg intake during moderate carbohydrate restriction reduces TNFα 
and SAA in this same MetS population [38], whereas no changes were observed in the group 
consuming egg substitute. Further, while HOMA-IR was reduced in all subjects over time, it 
was reduced to a greater extent in subjects consuming whole eggs [31]. Together, these 
findings suggest that whole egg intake during moderate carbohydrate restriction promotes 
global metabolic improvements that favors ABCA1 expression.   
 In line with previous findings within the literature, the findings from our study and 
previous chapters demonstrate the dynamic relationship between PBMC inflammatory 
potential, cholesterol flux, and ABCA1 expression. As mentioned above, ABCA1 has 
repeatedly been shown to serve as a link between cellular cholesterol flux and inflammatory 
potential. Landry et al. [39] demonstrated that ABCA1 expression leads to significant 
redistribution of cholesterol and sphingomyelin from lipid rafts to non-raft regions of cell 
membranes through its ATPase-related and efflux functions [39]. ABCA1-mediated 
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reductions in lipid raft content have been shown to increase ADAM17-mediated cleavage of 
TNF and TNF receptors, which may result in reduced TNFα signaling [40]. Lipid raft 
structure also affects TLR signaling, as TLR4 and MyD88/TRIF-mediated inflammatory 
gene expression was significantly increased in peritoneal macrophages isolated from 
ABCA1-/-, ABCG1-/-, and ABCA1-/-ABCG1-/- mice [2]. ApoA-I-ABCA1 interactions have 
also been shown to trigger JAK2-mediated activation of STAT3, which can suppress LPS-
induced pro-inflammatory gene expression of TNFα and IL-6 in macrophages [41, 42]. 
Together, these findings support our observation that egg intake concomitantly increases 
ABCA1 expression while blunting increases in LPS-induced cytokine secretion observed 
from carbohydrate restriction.  
  In conclusion, we have demonstrated that habitual whole egg intake during moderate 
carbohydrate restriction modulates PBMC cholesterol flux – a phenomenon that is most 
likely attributable to increased ABCA1 expression. These findings correspond to the changes 
observed in PBMC inflammatory potential, HDL lipid composition, and cholesterol-
accepting capacity of serum described in previous chapters. While future studies are needed 
to determine the functional consequences of these changes in relation to metabolic disease 
progression, these findings highlight a novel and powerful role for diet in the treatment of 
inflammation and dyslipidemia.  
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Chapter 7 
Significance and future directions 
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Summary of dissertation findings 
Obesity is associated with dysfunctional lipoproteins, low-grade inflammation, and an 
increased risk of chronic diseases such as CVD, T2DM, and cancer [1]. As outlined in this 
dissertation, HDL and leukocytes play well-documented independent roles in chronic disease 
development, whereas HDL-leukocyte interactions further modify cellular cholesterol flux 
and inflammatory potential [2, 3]. Therefore, therapeutic strategies that alter HDL-leukocyte 
dynamics may have profound effects on obesity-related disease progression.  
In line with this theory, the purpose of this dissertation was to evaluate the effects of 
dietary manipulation on the dynamics between leukocyte inflammation, cholesterol flux, and 
HDL function in MetS – a population at high risk for CVD and T2DM [4]. Given the 
capacity of dietary carbohydrate restriction and daily whole egg consumption to promote 
improvements in HDL profiles and inflammatory markers [5-8], we hypothesized that this 
dietary strategy was a potential therapeutic candidate to favorably modulate the relationship 
between HDL function and the inflammatory potential of leukocytes.  
Thirty-seven men and women classified with MetS consumed a moderate 
carbohydrate-restricted diet in addition to either 3 whole eggs per day (EGG) or the 
equivalent amount of egg substitute (SUB) for 12 weeks. In regard to HDL function, we 
discovered that carbohydrate restriction increased HDL-CE/TG ratios, whereas the addition 
of daily whole egg intake resulted in enrichment of HDL in phosphatidylethanolamine and 
egg yolk-derived sphingomyelin species. Whole egg feeding further increased the 
cholesterol-accepting capacity of subject serum from macrophage foam cells [9].  
We further assessed the effects of this intervention on PBMC inflammation. While no 
changes in IL-1β, IL-6, and TLR4 mRNA expression were observed throughout the 
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intervention, TLR4 mRNA expression was increased by whole egg intake, positively 
correlating with NF-κB p65 DNA binding activity. However, LPS-induced IL-1β and TNFα 
secretion was increased from baseline to week 12 in the egg substitute group only. To 
determine whether HDL-mediated cholesterol flux played a role in PBMC inflammation, we 
assessed parameters of cholesterol flux. Compared to baseline, there was a trend toward a 
reduction in PBMC cholesterol content in the whole egg group, whereas changes in PBMC 
cholesterol positively correlated with changes in lipid raft content. These observations 
corresponded to increases in ABCA1 and HMG-CoA Red mRNA expression from whole egg 
intake only, in addition to a trend toward increased ABCA1 protein. Together, these findings 
suggest that HDL-leukocyte dynamics can be favorable modulated through diet in MetS.   
 
Significance and novelty of dissertation work 
This dissertation has explored multiple novel areas of research within the context of human 
nutrition, with significant implications for obesity-related disease risk and treatment. In 
Chapter 4, we demonstrated the egg feeding during carbohydrate restriction modulates HDL 
lipid composition and increases the cholesterol-accepting capacity of human serum [9]. We 
have previously observed presumably favorable shifts in HDL particle sizes and increases in 
HDL-C from habitual egg feeding [5, 7, 10, 11]. However, as data presented in the literature 
suggests, the true atheroprotecive nature of HDL is best determined via measures of 
functional capacity – including its ability to serve as a cellular cholesterol acceptor [12]. 
Therefore, this study is significant and the first to our knowledge to demonstrate that 
increases in HDL-C and HDL particle size from egg consumption during carbohydrate 
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restriction corresponds to modulation of HDL lipid composition and increase in the overall 
lipid-accepting capacity of serum in MetS.  
 The findings from this first study not only have significant implications for the role of 
diet in atherosclerosis development and treatment, but, when coupled with findings presented 
in Chapters 5 and 6, also further support the role of HDL in mitigating leukocyte 
inflammation. To the best of our knowledge, this is the first comprehensive human 
intervention study to have examined the role of diet in modulating dynamics between 
leukocyte inflammation, cholesterol flux and lipid rafts, and HDL function. Overall, these 
findings may have profound implications for the capacity of diet to regulate metabolic 
disease progression and immunity.  
 
 
Future directions 
 
The findings presented throughout this dissertation have raised additional questions worthy 
of further research. While we have demonstrated that whole egg intake during carbohydrate 
restriction appears to increase the cholesterol-accepting capacity of HDL in serum [9], it 
could be beneficial to assess the effects of this intervention on additional atheroprotective 
functions of HDL – including antioxidant, anti-inflammatory, and vasodilatory activity. 
Given the known anti-thrombotic properties of PE, it may be reasonable to hypothesize that 
egg feeding may further promote anti-thrombotic HDL activity as it promotes HDL-PE 
enrichment [13].   
Given the capacity of egg feeding to promote incorporation of yolk-derived 
phospholipids into HDL [9], it may be further beneficial to assess the presence of oxidized 
phospholipid (OxPL) species in HDL. As mentioned in previous chapters, OxPL and 
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associated metabolites have been shown to inhibit LPS-induced inflammatory signaling in 
macrophages, endothelial cells, and smooth muscle cells through alteration of lipid raft and 
caveolar processing and through competitive interaction with TLR accessory proteins, such 
as MD-2, CD14, LPS-binding protein [14-16]. Together, the presence of OxPL inhibits LPS-
induced membrane translocation of LPS receptor complexes that are required for signaling 
and propagation of pro-inflammatory cytokine production [15, 16]. Compared to other 
dietary phospholipid sources, egg-derived phospholipids have been shown to more 
susceptible to copper- and pH-induced oxidation due to its relatively higher content of long-
chain PUFAs [17]. Generation of oxidized phospholipid metabolites by gut microflora has 
also been reported in response to egg feeding [18]. The presence of HDL-OxPL from our 
intervention may help explain the increases in LCAT activity from egg feeding [5, 7], as well 
as the decreased responsiveness of PBMC to LPS [14]. 
Future studies may also benefit from investigating the effects of this intervention on 
specific cell types and subsets within PBMC fractions. As mentioned in previous chapters, 
PBMCs consist of mixed leukocyte population containing approximately 60-70% T cells, 5-
15% B cells, 5-10% natural killer cells, 0.5-2% dendritic cells, 15-30% 
monocyte/macrophages, and 2% granulocytes [19-21]. Evidence suggests that the effects 
observed from this intervention may be variable across cell populations, and may have 
different implications for immunity and disease. For example, TLR4 protein is expressed 
intracellularly in naïve human CD4+ T cells, whereas cell surface TLR4 expression is found 
in activated CD4+ T cells [22]. Cell surface expression of TLR4 is associated with increased 
anti-inflammatory Treg cell activation, as well as an enhancement of Treg cell-mediated 
suppressive functions [23]. Further, certain subsets of “inflammatory” CD16+ monocytes 
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have been shown to be more likely to interact with activated endothelium, extratravasate into 
the arterial wall, and differentiate into macrophages [24, 25]. CD14+/CD16+ monocytes have 
been associated with hypercholesterolemia, as well as an increased incidence of CHD [26, 
27]. Therefore, it would be interesting to determine whether this intervention has differential 
effects on leukocyte subsets.  
Finally, given the observed effects on PBMC cholesterol flux and inflammatory 
potential in response to LPS, it is important to further investigate the effects of this 
intervention on immunity. Obesity has been associated with impaired immune responses to 
infection and influenza [28], in addition to increased risk of allergy and autoimmune disease 
[29, 30]. Calorie restriction and weight loss have been shown to enhance T cell-mediated 
immune responses in overweight adults, whereas dietary lutein – a carotenoid abundant in 
egg yolk – was shown to possess immunomodulatory activity in various animal models [31, 
32]. As highlighted in previous chapters, ABCA1-mediated cholesterol flux and expression, 
have been shown to possess immunomodulatory activity that alters an organism’s capacity to 
fight bacterial infection [33]. Therefore, it is plausible to hypothesize that future studies may 
uncover an effect of egg intake during carbohydrate restriction on immunity.  
Taken together, the work presented in this dissertation has highlighted a novel an 
exciting role for diet in the modulation of leukocyte inflammation, cholesterol flux, and HDL 
function in MetS. These findings have significant implications for the role of dietary 
intervention in the treatment of obesity-related metabolic disease and immunity.  
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